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Cover illustration: Fluorescence microscopy of tissue engineered bone formation
in a goat that received sequential fluorochrome labels.
After injection, fluorochromes are believed to adhere to free, unbound calcium,
which is present at physiologic concentrations in the body fluids. When the free
calcium is used for the mineralization of new bone, the label is irreversibly bound
and incorporated in the newly formed bone. The fluorochrome that is not
incorporated is excreted by the kidneys. Therefore, bone will only be labeled on the
day of fluorochrome admission. The goat received fluorochromes at 3 (green),
5 (yellow) and 7 (orange) weeks after implantation of the tissue engineered cell/
scaffold hybrids. Detailed observation of the image shows the green line very close
to the scaffold surface and the yellow and orange lines more towards the pore
center (away from the scaffold surface) with about equal distances between the
lines. This allows the interpretation that bone formation started before 3 weeks on
the scaffold surface and grew centripetally at a steady pace. At some locations,
bone formation started later (no green line) or stopped before 7 weeks (no orange
line).
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Abbreviations and definitions
List of Abbreviations
αMEM Alpha modified minimum essential 
medium
AG Autologous bone graft
ALP Alkaline phosphatase
ANOVA Analysis of variance
AS Autologous serum
ASAP Ascorbic acid-2-phosphate
BCP Biphasic calcium phosphate
BFGF Basic fibroblast growth factor
BGP β-glycerophosphate
BM Bone marrow
BMP Bone morphogenic protein
BMSC Bone marrow stromal cells
C Calcein green
CaP Calcium phosphate
CFU-F Colony forming unit fibroblast
CFU E CFUefficiency
CM-Dil Chloromethylbenzamido dialkylcar-
bocyanine
CP cells Cryopreserved cells
CSD Critical size defect
DAB 3’3diaminobenzidinetetra-hydrochlo-
ride/hydrogen peroxidase
DBM Demineralized bone matrix
DMEM Dulbecco’s modified eagle’s medium
DMSO Dimethylsulfoxide
DOPC Determined osteoprogenitor cell
ECM Extra cellular matrix
eGFP Enhanced green fluorescent protein
env Envelope protein (viral)
FACS Fluorescence activated cell sorting
FBS Fetal bovine serum
FITC Fluoroscein iso-thiocyanate
FTIR Fourier transformed infrared
G Gravity force (9.8 m/s2)
GALV Gibbon ape leukemia virus
  Gam-lgG1 Goat anti-mouse immunoglobulin G1
  HA Hydroxyapatite
  IOPC Inducible osteoprogenitor cell
  LacZ Bacterial β-galactosidase
  LNGFR Low affinity nerve growth factor 
receptor
  MoMuLV Moloney murine leukemia virus
  MRI Magnetic resonance imaging
  MTT Dimethylthiazol diphenyl tetrazoli-
umbromide
  n Sample size of statistical group
  OS OsSatura
  OTC Oxytetracycline
  p Probability of statistical finding
  P Power (1-β)
  PBS Phosphate buffered saline
  PDGF Platelet derived growth factor
  PE Phycoerythrine
  PHO Pathologic heterotopic ossification
  PLF Posterolateral fusion
  PLIF Posterolumbar interbody fusion
  PO Peroperative
  SEM Scanning electron microscopy
  SF Serum free
  SV40 Simian virus 40 promoter
  TCP Tri-calcium phosphate
  TE Tissue engineering
  TGFβ Transforming growth factor β
  TRITC Tetramethyl-rhodamine iso-thiocyan-
ate
  TPC Tissue progenitor cell
  US Ultroser
  USS Constructs kept in Ultroser for<24h
  X Xylenol orange
  XRD X-ray diffraction
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4Definitions as used in this thesis
Tissue engineering (TE)
1988, the National Science Foundation (USA): TE is the application of the principles
and methods of engineering and the life sciences toward the fundamental
understanding of structure/function relationships in normal and pathological
mammalian tissues and the development of biological substitutes to restore,
maintain or improve functions.
1993, referred to by Langer and Vacanti:[1,2] "TE is an interdisciplinary field that
applies the principles of engineering and life sciences toward the development of
biological substitutes that restore, maintain or improve tissue function". 
1999, Caplan[3] described this "interdisciplinary application of basic biological
principles" as biomimetics. "TE is the application of biomimetics toward the
development of biological substitutes that restore, maintain or improve tissue
function". 
Stem cell
Defined as quiescent ancestral cell capable of asymmetric cell division to allow both
self renewal (to prevent depletion of the stem cell pool) and the production of a
proliferating daughter cell, that becomes the progenitor cell for one or more tissue
types.[4-7]
The diversity of tissues that can be derived determines the potency of the stem cell:
Totipotent: capable of complete regeneration of an entire individual (blastocyst);
Multipotent: capable of regeneration of the tissues confined to one of the
embryological layers (endo, ecto and mesoderm);
Pluripotent: capable to regenerate cells of several lineages (haemaopoietic stem
cells);
Mono/unipotent: capable to generate only one type of progeny (spermatogonia).
Osteoconduction
The ability of a material/graft to allow ingrowth of vessels and osteoprogenitor cells
from the recipient bed,[8] or spreading of bone over the surface proceeded by
ordered migration of differentiating osteogenic cells.[9] An important aspect is the
direct bonding of bone to the material surface without fibrous tissue interposition,
so-called contact or bonding osteogenesis.[9]
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Osteoinduction
1967 Urist: The mechanism of cellular differentiation towards bone of one tissue
due to the physicochemical effect or contact with another tissue,[10] at that time only
tissues (like demineralized bone matrix and uroepithelium) were known to have this
ability. The last decades this ability is also recognized for some biomaterials.[11]
1968, Friedenstein: The induction of undifferentiated inducible osteoprogenitor cells
(IOPC's) that are not yet committed to the osteogenic lineage to form
osteoprogenitor cells.[12]
Osteogenesis
1966, Friedenstein: Osteogenesis is bone formation by determined osteoprogenitor
cells (DOPC's).[13]
The generation of bone by a certain tissue/cell by itself i.e. in the absence of host
cells e.g. in diffusion chambers.[14]
Autograft
Tissue transplanted within one genetic individual. 
Iso/syngeneic/homologous graft
Tissue transplanted between genetically similar individuals.
Allograft
Tissue transplanted between genetically different individuals of the same species.
Xenograft
Tissue transplanted between different species.
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6Biomaterial
Was described as a material that can be used for any period of time as a whole or
as part of a system that treats, augments or replaces any tissue, organ or function in
the body.[15] The interaction between biomaterials and bone has been classified
as[16] 
Biotolerant: characterized by a distant osteogenesis with the formation of a fibrous
tissue layer between implant and bone;
Bioinert: characterized by surrounding bone growing up to the material surface but
without a strong bonding;
Bioactive: characterized by bonding osteogenesis, meaning that bone formation
starts at the material surface and has a very tight and direct bond with the material.
This typically occurs when an apatite layer can precipitate on the material
surface.[17,18]
Hybrid construct
Combination of elements of different offspring. In this thesis: the combination of a
synthetic porous scaffold and (biological) cells.
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Chapter 1
INTRODUCTION AND AIMS
In orthopaedic surgery, the autologous bone graft is currently considered the golden
standard for many procedures that replace or reinforce bone. As is also the case
with many other empirically developed therapies, little is known about the
mechanism by which the autologous graft functions, especially regarding the
unknown role of the cells that are present inside these grafts. Disadvantages of the
autologous bone graft, which is often harvested from the pelvic bone, are many and
include donor site pain and a limited availability. Therefore, an alternative without
these disadvantages, that performs as well as the autologous graft is highly
desirable. Tissue engineering of bone has this potential. 
Tissue engineering is defined as a new, interdisciplinary research field that strives to
create (artificial) tissues or biologic stimuli to restore or reinforce existing tissue. The
cell-based method that combines cells that can generate certain tissues with
specifically developed scaffolds to create a so-called hybrid construct, is a
promising example. Such hybrid constructs can potentially function in a similar
manner as the tissue to be replaced and therefore obviate the need for using the
patient’s own tissue, such as bone, for grafting procedures.
The proof of the concept of cell-based tissue engineering has recently been shown
for tissues of all three embryological lineages (ectoderm, endoderm and
mesoderm). Especially the mesodermal i.e. mesenchymal lineage, that includes
bone, cartilage and tendons, has extensively been investigated. This may partially
be due to the enormous commercial potential, but crucial was the identification of
mesenchymal cells with stem-cell characteristics within the adult bone marrow.
Currently, bone tissue engineering has advanced so far that some investigators
already made the step towards clinical application. Although there is a great desire
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for the clinical application of tissue engineered bone, some fundamental questions
on cell performance have not yet been answered. 
At first: will the cells survive after transplantation? Actually, this is quite unlikely with
regard to the fact that vascularization of implants may take weeks, depending on
the graft volume that can exceed several cubic centimeters in the clinical situation.
Also for autologous bone grafts this is an unanswered question. 
At second: what tissue will the surviving cells produce? Until today, this cannot be
predicted, because the differentiation of the multipotent cells that are used cannot
be fully controlled. Again also in the autologous bone graft this is largely unknown.
It is not possible to entirely investigate these two issues in so-called "small animal"
models (mice and rats), where the survival potential is different, because implants
cannot be of clinically relevant size. Therefore, our research focused on "large
animal" models (goats) that allow clinically relevant sized implants to investigate
and optimize bone tissue engineering. We expected the potential role of the cells in
tissue engineered implants to be comparable to autologous bone grafts, from the
point of view that, although many other factors are involved, bone grafts may
resemble a 3D scaffold with osteoprogenitor cells. Therefore, we commenced with
an attempt to elucidate the role of cells in clinically relevant sized grafts (both bone
grafts and TE grafts). This was done by both an indirect method where control
implants were devitalized, and by a direct method that identified the cells after
transplantation. Furthermore, the method of tissue engineering was optimized and
the feasibility in a critical size bone defect was investigated. The aims of this thesis
were formulated as follows.
The aims of this thesis:
1 To investigate the role of cell viability in autologous bone grafts
2 To investigate the role of cell viability in TE constructs
3 To develop a labeling technique to trace cells used for TE
4 To investigate methods to optimize bone tissue engineering
5 To investigate the applicability of TE in clinically relevant models
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2Chapter 2
BACKGROUNDS ON TISSUE ENGINEERING OF BONE
Need for grafting material
Bone transplantation has been the solution for replacement or reinforcement of
bone defects for centuries. In a publication in the Netherlands Journal of Medicine,
Patka et al.[19] refer to a historical description (1668) by the Dutch surgeon Van
Meek’ren of such an orthopedic intervention. In this description, Russian priests ban
the duke Butterlijn that had received a piece of dog skull-bone to heal his skull
defect that was caused by a Tartar sword. The duke recovered well but the
combination of a Christian head with dog bone was unacceptable for the church.
Therefore, he finally decided to have it removed again. This anecdote is a typical
example of xenogenic transplantation (animal to human). With the current
knowledge of immunology, rejection by the host can be predicted and therefore
these grafts are no longer applied, unless thorough measurements to remove all
immunogenic proteins have been employed.[10,20] This also accounts for allografts,
that concern human donor bone.[10,21-23] By lyophilization or freezing at very low
temperature (–80ºC) and/or defatting the allograft, the immunogenicity decreases
and is considered acceptable.[24,25 ] Another alternative is the use of biomaterials
for grafting, these neither elicit an immune reaction, nor carry the risk of transmitting
infectious diseases. Many biomaterials have been developed the last decades,
ranging from free accessible materials like steel, coral, bamboo, plaster of Paris or
methyl methacrylate,[26-31] to sophisticated composites of copolymers and/or
ceramics.[32-35] However, in general these materials do not perform as good as the
autologous bone graft, because bone conduction over the material surface and the
replacement by bone are usually less and biomechanically most materials are
inferior to bone.[8,36-40] 
If the above had been the only grafting materials, orthopaedic surgery would never
have developed to what it is now. The great success of grafting procedures to solve
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problems related to congenital, traumatic, or infectious origin must be attributed to
the autologous bone graft, which is until today the golden standard for grafting in
many orthopaedic interventions.[41-44] Although the theory of evolution predicts a
highly efficient use of everything the body consists of, empirical knowledge dictates
quite some bone can be missed to use for grafting. Bone from the iliac crests and
the fibulae for example is often applied (Fig. 1). However, despite the fact that this
bone can be missed from a biomechanical point of view, harvesting is not without
complications, of which donor site pain is the most prominent.[45,46] Other
disadvantages include the still limited availability and the extended time of surgery.
Therefore, creating a substitute for the autologous bone graft with identical or better
performance has been a great challenge for decades.
Figure 1 X-ray radiograph of lumbar spinal fusion with autologous bone graft  (arrow) 
The image also clearly shows the defect in the iliac wing which was the source of the graft (*).
Autologous bone graft substitute
It is conceivable that a successful substitute of the autologous graft (AG) will need
those features that make it superior to the present alternatives (see also Chapter
3).[47] Unfortunately, these features cannot be identified easily, because little is
known about the exact mechanisms involved in AG functioning.[42,43] Nevertheless,
it is likely that the osteoconductive and osteoinductive properties together with the
presence of viable osteoprogenitor cells which are expected to be responsible for
osteogenesis, are crucial for the clinical success of AG. Bone tissue engineering
techniques therefore, aim at combining two or more of these features.
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Two important findings in the previous century have greatly propelled the
enthusiasm for bone tissue engineering.
First, the identification of bone morphogenic proteins (BMP’s) by Urist.[48,49] These
proteins can induce host cells to form bone in and around an appropriate scaffold. 
This led to a progressive research program, of which the first clinical studies have
recently been reported.[50-53] A disadvantage of this currently most successful
technique is the very high, unphysiologic BMP doses, that appeared to be
necessary for successful application in primates.[54,55] Despite many studies that
showed the technique to be safe,[55] the potential risk of uncontrolled bone
formation as a result of this unphysiologic stimulus should be considered with great
care.[56]
The second revolutionary finding was the identification of osteoprogenitor cells
within bone marrow aspirates of adults.[13,57-60] These cells appeared to have stem
cell characteristics and could be culture expanded.[61,62,63-65] Especially when
combined with an appropriate 3D scaffold, these so-called hybrid constructs
behaved like bone.[66-68] A potential advantage of the cell-based technique is the
possibility to engineer almost unlimited quantities of synthetic/autologous constructs
with theoretically, but not proven, less risk on uncontrolled bone growth, when
compared to the bone induction (BMP) strategy. In this thesis, bone tissue
engineering strategies based upon the combination of mesenchymal “stem” cells
with an appropriate synthetic scaffold to constitute hybrid constructs were
investigated.
Mesenchymal stem cells 
The existence of such a cell anywhere else than in early embryogenesis remains to
be proven formally, and therefore these cells need to be considered as putative
stem cells. The extensive work on identification of this putative mesenchymal stem
cell that was done by Alexander Friedenstein and colleagues at the Gamalaya
Institute in Moscow can hardly be over-estimated.[69-71] In a series of admirable
papers, they identified, characterized, and thoroughly investigated the cells they
referred to as colony forming unit fibroblast (CFU-F). The following summary of their
research delineates the fundamental concepts on which our research was based.
In 1966, they showed the bone forming capacity of fresh bone marrow.[13] The
bone that formed in host mice after transplantation of a certain minimum amount of
cells per surface area, was unequivocal of donor origin, because bone formed
inside so called diffusion chambers. Inside diffusion chambers the content was
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shielded from the host by a semi-permeable membrane that allowed fluid diffusion
but not cell passage.[60] 
In 1968, the osteogenic potential of the bone marrow was attributed to the
presence of determined osteoprogenitor cells (DOPC’s). Osteogenic bone
formation by these DOPC’s was considered different from osteoinductive bone
formation, that could only be accomplished with inducing substances (like
transitional epithelium or demineralized bone), together with so-called inducible
osteoprogenitor cells (IOPC’s).[12] In subsequent studies on bone induction, they
showed bone marrow contained both IOPC’s and DOPC’s.[61,70,72] Together with
observations of induction of lymphoid cells to form bone, Friedenstein concluded
that contrary to whole bone marrow, haematologous cells contained only IOPC’s .
These observations were actually in conflict with Urist’s hypothesis of inductor cells
and inducible cells that, according to him, were both not blood born.[10,48,73]
In a series of sophisticated studies using guinea pigs, rabbits and different strains of
mice with specific (sex) karyotypes, semi-syngeneic F1-hybrids of these strains,
and radiochimeras (bone marrow transplantation of one strain into the another after
sublethal irradiation), the donor origin of the bone that formed was again shown.
The donor cells were also shown to be subject to immunologic rejection when
allogeneically transplanted.[74] Interestingly, the haematopoietic marrow (without the
osteoprogenitors therein) that populated the newly formed ossicles was always
derived from the recipient. This finding clearly demonstrated the presence of two
separate cell lineages within the bone marrow organ. 
In 1971, they showed in a remarkable experiment, that the newly formed bone
marrow inside the ectopic tissue engineered ossicles could be retrieved and was
again capable of ectopic bone formation. This could be repeated for four passages,
always showing the original (initial) donor origin of the bone forming cells.[74-76]
In the consecutive period, they reported the presence of colony forming unit
fibroblasts (CFU-F’s) within the bone marrow at 1-10 per 100.000 nucleated
cells.[61] For the first time, they showed that these CFU-F’s were responsible for
bone formation, even after 20 population doublings. CFU-F’s adhered to plastic
within 90 minutes and transferred from their resting (G0) phase to a proliferating
state within 24 hours after adherence. Monoclonal colonies of the CFU-F’s
emerged, that could be culture expanded. These CFU-F’s constitute a large
proportion of the cells that most researchers are currently using and refer to as
Bone Marrow Stromal Cell (BMSC), Mesenchymal Stem Cell (MSC) Tissue
Progenitor Cell (TPC) and many other descriptions.
In 1974, the efficiency of colony formation was shown to depend on several
characteristics, i.e. species (guinea pig BM yielded more colonies than mice BM);
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location (from the guinea pig iliac wing more colonies than from the femur); marrow
disruption, or blood loss 2 hours before aspiration (this resulted in increased CFU
efficiency as a result of a haematopoietic stimulus).[70,77] In-vitro, the presence of
feeder cells or the natural non-adherent bone marrow cells at an optimal density of
2x105 nucleated human BM cells per cm2 was determined.[78] 
In 1982, they reported successful ectopic bone formation in hybrid constructs of
CFU-F’s and gel foam sponges, if these “scaffolds” did not resorb too fast.[66] They
found a linear relationship between seeded cell number and bone formation.
In 1987, rabbit CFU-F’s from single colonies were transplanted into diffusion
chambers, 20% formed bone, cartilage and reticular (fibrous) tissue, 20% formed
bone only and 27% formed only reticular tissue, indicating the pluripotency but also
the heterogeneity of these cells.[70,79] By weighing the dry weight of constructs that
formed bone in diffusion chambers, they calculated that bone marrow derived from
0.5mg pelvic rabbit bone could generate 30 kg of bone.[79] The single cell origin of
the colonies that formed and the potential of these single colonies to generate both
cartilage and bone was shown by mixing male and female bone marrow aspirates
prior to culture. The colonies that formed from this mix were always only XX or XY,
this cannot be explained if the colonies were derived from cell aggregates, that
should at least in a proportion, contain both XX and XY cells. [79] 
In 1992, they optimized the culture conditions; by trypsinizing instead of
mechanically disaggregation, the colony forming efficiency could be increased a
tenfold. The presence of haematologic (non-adherent) cells appeared to stimulate
colony formation from the adherent single cells dramatically, in their experiments
with mice CFU-F’s. This suggests the haematologic cells have a “feeder” function
and indicates the importance of plating the whole BM aspirate, including the
naturally haematologic feeder cells.[80]
In 1995, experiments with human CFU-F’s that showed colony formation requires
participation of at least four growth factors: PDGF, BFGF, TGF-beta and EGF.[81] 
This CFU-F assay as it was developed by Friedenstein, to select and identify the
BMSC’s, remained standard until today. To facilitate the selection, others developed
BM purification methods by either selection on density gradient (by centrifugation
over a ficoll gradient),[63] or immunologically with antibodies that select the cells
from the haematopoietic cells (SH2, SH3 and SH4[82]), or to select the primitive cell
phenotype (e.g. HOP26[83] and STRO1[84,85]). Although the CFU-F populations
definitely show stem cell characteristics, i.e. self-renewal, clonogenicity and the
potential to form many mesenchymal tissues, they are not homogeneous (of one
single cell type). This is reflected by the differences in growth potential (colony size)
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and spontaneous differentiation pathways.[5,7,60,86-88] Another deviation from the
definition of mesenchymal stem cell is that not all types of mesenchymal tissues can
be generated from (all) the CFU-F’s. Finally, the cells appear not to be committed to
one lineage, because they can shift to other phenotypes during and even after their
differentiation (plasticity).[5,7,89]
Therefore, an important issue is to identify markers that can distinguish the different
cell types, e.g. bone forming from fibrous tissue forming cells or multipotent stem
cells. Several markers have been developed to identify the cells in the various
stages of osteogenic differentiation.[4,62] An important marker for early osteogenic
differentiation appears to be CBFA1, which is linked to the osteocalcin promotor.[90]
However, to my knowledge neither the existence of the ultimate multipotent
mesenchymal stem cell, nor a specific marker for such a cell has been shown, and
many researchers refer to progenitor cells instead.[6,91,92]
Development of hybrid constructs
No less than 20 years after Friedenstein’s first publication, many research groups,
of which Caplan and co-workers are well known, realized the mesenchymal “stem”
cell could be utilized to engineer bone, cartilage and other mesenchymal tissues for
grafting and patented several related technologies to obtain and apply these
cells.[93] The concept of Caplan’s group was to combine the “stem” cells with an
appropriate porous scaffold and rely on paracrine and host derived factors after
transplantation, to stimulate differentiation and subsequent bone formation. As a
scaffold material they preferred porous biphasic ceramics,[68,94] which are well
known for their bioactivity i.e. the capacity for bonding osteogenesis.[17,18,95,96]
After implantation of calcium phosphate ceramics such as BCP, but also pure
hydroxyapatite (HA), some physicochemical dissolution of the surface occurs,
which is followed by reprecipitation of a biological carbonated apatite layer. In
addition, organic compounds are incorporated in this layer that may be responsible
for selective adhesion and stimulation of osteoprogenitor cells.[97-101] Other groups,
including our group, applied somewhat different strategies for bone tissue
engineering, especially with regard to the scaffold material (we initially used only
pure HA) and preparation of the hybrid construct.[102-105] By culturing the construct
for one or more weeks, the cells can already differentiate into the osteogenic
lineage and generate extracellular matrix.[106,107] The proof of the concept of
Caplan’s approach was convincingly shown in ectopic rodent models.[63,67,68,94,108-
116] Also orthotopic application proved to be feasible in small animals,[108,117] even
with human MSC’s in a segmental femur defect in athymic rats.[118] In 1998 they
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showed an effect of bone tissue engineering in the healing of a segmental femur
defect in the dog.[119] This success was repeated with allogeneic cells in the same
model.[120] The cells were labeled with the fluorescent membrane marker CM-Dil
and could be traced in the newly formed bone. This outstanding result however, can
be interpreted in two ways:
1) The concept of tissue engineering is feasible, even with allogeneic cells in a
clinically sized defect.
2) The contribution of the cells in terms of participation in tissue engineered bone
formation is limited, because the allogeneic cells will be destroyed by the immune
system.[74] The presence of labeled cells does not proof the survival of these cells,
as it was shown later that the CM-Dil label is subject to transfer to neighboring
cells[121] (see Chapter 6). Further progress of bone tissue engineering in terms of
clinical trials or at least a comparison with the autologous bone graft have not yet
been reported and only a limited number of other groups also reported on the
feasibility of this procedure in critically sized defects in large animals.[35,47,122-126]
Interestingly, these groups have a relatively short history of research on bone tissue
engineering and they do not show the osteogenicity of their constructs (ectopically)
in the animal where the orthotopic functioning is investigated. In fact, the group of
Cancedda implanted constructs ectopically, but did not observe osteogenicity of
these implants.[127] It is surprising that since the early work of Urist and Friedenstein
in the seventies of the last century, ectopic implantations in rodents are considered
as proof of the concept of osteogenicity and osteoinductivity,[48,49,67,116,128,129]
whereas only a few groups showed this proof of osteogenicity for cell-based TE
constructs in larger mammals.[130,131] As long as the mechanism of functioning of
the technique is unclear and the survival of the cells is questionable, such an
ectopic control seems to be desirable. Based upon the literature that is available
and our own experience, bone TE appears to be unexpectedly challenging with
regard to clinical application where large grafts are required.
Potential pitfalls of bone tissue engineering
Upscaling cell-based bone tissue engineering from rodent models to the clinical
situation involves many pitfalls that can be related to the size of the construct, to the
location of application and to species related characteristics like the tendency for
bone formation and age.
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Size 
Increasing the size from the cubic mm-range (in mice) to the clinical, cubic cm-
range (1000 fold) has dramatic repercussions on both the implant and the wound
bed. It is generally accepted that in order to stay alive, organisms that exceed the
volume of several mm3 need vascularization for oxygen and nutritional supply (e.g.
osteoblasts die within two hours when deprived of oxygen).[132] This axioma exists
in many disciplines of life sciences. Typical examples are the limited size of
nonvascularized animals such as insects and the ingenious mechanisms that
evolved to compensate for this lack of vascularization. The early development of
active perfusion in the human embryo already during the fifth week of gestation,
when it is about 3mm long, is another example.[133] Finally, a promising strategy to
prevent tumor growth is by inhibiting neo-angiogenesis. Without vascularization,
tumors will not grow larger than several mm3.[134-136] 
When regarding the scarce literature on the relationship between the size of tissue
engineered constructs and the survival of the cells, it can be concluded that the
unvascularized volume that cells can survive in is limited. The acceptable distance
from nutrition by diffusion ranges from 100µm to 5mm.[137,138] By improving
vascularization of tissue engineered constructs an advantage of in-vivo
performance has been found.[139,140] Therefore, methods to improve diffusion in
scaffolds are promising and may be essential for further progress.[1,141,142] 
Another disadvantage of an increased implant size is that the injury to tissues will be
extensive, which will result in a profound wound healing reaction. Inside the wound
haematoma, cell survival will be compromised, due to the high potassium
concentration.[143] This was also the explanation by Takushima et al for their
observation that in a rabbit segmental defect model, bone formation by injected
progenitor cells was only possible when the defect was created by distraction, to
prevent the occurrence of a haematoma.[144] The physiologic mechanism of wound
repair actually does not rely on the presence of cells inside the wound bed before
any vascularization, as can be deduced from the description of normal wound
healing by Dvorak[145] and Anderson[146] (Fig. 2). This implicates that the concept of
tissue engineering deviates from mother nature’s strategy of wound repair and may
not be supported, or may even interfere with this mechanism. Whether, despite of
this, the TE strategy has a chance in the clinical situation remains to be proven, but
it may be a solution when mother nature’s strategy alone is inadequate. 
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Figure 2 Steps in wound repair
1) The excudative phase (immediately after injury, minutes to hours): fluid, proteins and cells
escape from the damaged vessels and a haematoma forms. A provisional matrix is made of
fibrin. Components within or released from this matrix initiate the resolution (of the clot) and
repair processes such as cell recruitment and neovascularization;
2) Acute inflammatory phase (minutes to days): more excudation (edema) and organized
leukocyte influx;
3) Chronic inflammation phase (granulation, initiates after 3 to 5 days): blood vessel and
fibroblast (tissue) proliferation in the fibrin clot.
Location
In the bony environment, the wound healing response has a specific appearance
known as the fracture repair mechanism. The cascade of histological events leading
to the regeneration of the normal osseous anatomy was described in detail by
Bolander and Jingushi (Fig. 3).[147,148] 
Figure 3 Steps in fracture repair
1) Immediate injury response: haematoma, proliferation of surrounding mesenchymal cells
and influx of inflammatory cells. The fibrous clot is organized into a reparative granuloma,
called external callus.
2) Intramembranous ossification (first days): differentiation of precursor cells from the periost
adjacent to the fracture. Membranous trabecular bone formation called hard callus.
3) Chondrogenesis (days to weeks): Mesenchymal cells inside the granulation tissue are
induced to chondrogenesis called soft callus.
4) Endochondral ossification: Capillaries from surrounding bone invade into the cartilage,
followed by osteoblasts that synthesize osteoid on the calcified cartilage. 
According to the description of fracture healing, it can be concluded that two
mechanisms of new bone formation are present: intramembranous bone formation
from the periosteal “stem” cells and endochondral bone formation preceded by
chondrogenesis from mesenchymal “stem” cells that migrated into the
haematoma.[148] This phenomenon of osteogenic cell influx was elegantly
demonstrated by Mizuno et al,[149] who showed that only 4-days-old fracture
haematoma’s were osteogenic ectopically in rats whereas 2-days-old fracture
haematoma’s were not (indicating the absence of progenitor cells in the 2-day
haematoma’s). Again, progenitor cells are initially not playing a role inside the
wound bed, but play their role from the surrounding tissue after the start of
revascularization, which may be a limitation for the tissue engineering approach. 
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Species
The osteogenicity of BMSC’s of human origin in diffusion chambers, or seeded on
constructs, has often been reported to be inferior to BMSC’s of other species origin,
e.g. mouse.[128] Regardless of the reason for this, species differences for bone
formation/reparation are common, as also reflected by the differences in tendency
for pathologic heterotopic ossification (PHA),[150,151] the differences in the ability to
generate bone upon inductive stimuli,[152-155] and the various success rates of
spinal fusion surgeries between different species (Chapter 3).[156] Usually primates
are found to be less prone for bone formation, although Ripamonti showed bone
formation inside ectopically implanted ceramic scaffolds to occur more frequently in
baboons.[152,157] An inevitable factor in humans is the relatively high age at which
the treatment will be performed. There is an age related decrease in the osteogenic
potential of marrow aspirates that is normally not considered in the animal
experiments.[7,158,159] This may be due to the decreased yield of BMSC’s in fresh
bone marrow, from 100 at birth down to 1 per million in elderly people,[93,160,161]
although theoretically culture expansion (of the adherent BMSC’s) would
compensate for this matter.[65] Another factor is the bone forming potential of the
BMSC’s per se.[162] This might be diminished as a result of the replicative
senescence (the total number of potential cell divisions is restricted as a result of
breaking down of the telomeres that cap the chromosomes).[7] As an experimental
approach to overcome this problem, two research groups showed that transducing
BMSC’s with telomerase which partially restores the telomeres, inhibited
senescence of the BMSC’s and allowed up to 10 times more population doublings
(from 20 to 200) Indeed, in-vivo bone formation was significantly higher in the
constructs with transduced cells.[163,164]
In conclusion, the many pitfalls are challenging and may need a radical change in
the strategy for cell-based tissue engineering, for example, to seed cells on
prevascularized scaffolds or to implant the cells in a temporary dormant state with
minimal metabolic demands. However, as a first step, more insight in the
possibilities of the transplanted cells to survive and function will be needed.
Eventually, the pitfalls should be considered in clinically relevant animal models.
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Comparison of tissue engineered bone to the autologous bone graft
As already mentioned, the approach of bone TE may partially resemble the cellular
processes in the autologous bone graft. Besides other important factors such as
inductivity and an ultimate template, the cancellous bone graft may be considered
as a porous calcium phosphate scaffold loaded with cells that are related to bone
formation i.e. (lining) osteoblasts and progenitor cells. Therefore, biological
restrictions to autologous graft functioning probably also will account for the tissue
engineered graft. Unfortunately, little is known about these restrictions and in fact
the biological performance of the autologous bone graft is largely unknown.[42,43]
Especially whether in clinically relevant sized AG the cells at first survive the
transplantation, and secondly participate in new bone formation (osteogenesis) is
controversial.[42,43,165-168] Because this fundamental question could not be
answered from the current literature, the following (indirect) sub-questions were
formulated and investigated in the available literature.
• Do cells survive inside the autograft after transplantation?
• Does vitality of the graft influence bone formation?
• Are the transplanted cells present in the newly formed bone?
Do cells survive inside the autograft after transplantation?
Direct observations of the cells in bone grafts range from all cells being death, as
was shown in studies on autologous grafts of dogs, rabbits and human,[49,57,151,169]
to limited cell survival up to a diffusion depth of 300µm.[41,42,170-173] Even
substantial survival around 50% of the cells in child rib grafts, that were stored in the
back muscles for two weeks during a multi-stage spinal fusion procedure, was
reported[174] In posterior intertransverse spinal fusion, where donor bone is laid
between the transverse processes, a typical lag in new bone formation was shown
in the central part of the bone mass, whereas close to the transverse processes
(and blood supply) an early osteogenic response was shown, which is expected to
be partially the result of surviving cells.[175-177] It can be concluded that cells can
survive inside autografts of yet undetermined size.
Does vitality of the graft influence bone formation?
An indirect method to investigate cell survival is to study the influence of graft
viability at transplantation. This has been studied by several authors in small animal
models ectopically and orthotopically [49,57,178-180] and occasionally orthotopically in
large animals.[23,181]
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Although some effect of graft viability was reported by all authors, many authors
ascribe this not to osteogenesis, but to other mechanisms such as the release of
bone stimulating factors prior to death.[57] Therefore, we conclude that based on
indirect evidence even in large bone grafts, cells survive at least the first period after
transplantation to release stimulating agents, or maybe longer to participate in new
bone formation (osteogenesis).
Are the transplanted cells present in the newly formed bone?
By using 3H labeling, Ray[182] showed in mice that cells inside ectopically
transplanted AG survived and were present in the newly formed bone. Boynton[183]
showed the survival and subsequent new bone formation in human bone grafts,
when implanted ectopically in immune-compromised mice. Observations in rats and
rabbits though, made others to conclude that viable graft cells were only responsible
for stimulating the host tissue to form bone.[57,172] However, in larger animal models
this has never been investigated. 
In conclusion, cell functioning in autologous bone grafts will be indicative for the
feasibility of cell-based tissue engineering. However, cell survival and participation
in bone formation has as yet only been shown in small sized implants (mm3) in
rodents, although some indirect evidence suggest transplanted cells do play a role
in large sized grafts.
Tracing the implanted cells by labeling 
In order to answer many of the uncertainties discussed above, the ability to trace
the transplanted cells in clinically relevant sized models is required. This may sound
easy, but the prerequisites for an accurate label are difficult to fulfil. The label should
neither effect, nor select the cells in any way, it should not fade and must be
compatible with (large) bone histology and naturally, the label should be specific
and not transfer to neighboring cells. Currently there are only a few labels available,
which are still far from ideal.
Labeling cells of TE constructs is relatively easy, because the BMSC’s are in culture
and therefore easy to handle before transplantation. Most well known labels are
fluorescent dyes that can be incorporated inside the membrane bilayer,[184-186] or
inside the cytosol.[187,188] These labels are divided equally at each division over the
daughter cells, which allows tracing of the cell progeny, but results in a decrease in
label intensity until the label becomes undetectable. Another disadvantage is the
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incompatibility with histology procedures like dehydration, which make hard tissue
histology impossible.[189] In recent years, genetic marking, by using for instance
(retro)viruses has become available and has shown to be compatible with bone
histology.[116,190-193] This technique applies the ability of (retro)viridae to introduce
(marker) genes into the cells without apparently disturbing these cells[194,195]
Contrary to adenoviral labels, which stay outside the nucleus, retroviral markers
integrate in the cell genome and are copied at each cell doubling. Therefore the
retroviral labels maintain relatively stable in proliferating cells. By using
sophisticated methods to generate the infectious particles, replication of the original
virus in the infected target cells is prevented and therefore infection of the host is
prevented.[196,197] This approach is promising, although tracing the label in large
bone grafts remains difficult with regard to the histological procedures. An exciting
potential of retroviral cell marking is to integrate functional genes that are traceable
in-vivo. These can be genes that produce substances that can be measured in the
blood e.g. interleukin 3,[116,198] or even more exiting, genes derived from the firefly
that are responsible for bioluminescence. Because of the long wavelength of the
light (>500nm) the light can penetrate through tissues and bone.[199-201]
It will be more difficult to label cells in autologous bone grafts, because the cells are
incorporated inside the tissue, not easily accessible for labeling procedures. In this
situation, retroviral transfection also appeared to be successful to label cells in
cruciate ligament auto-transplants.[193] Because retroviral transduction is restricted
to dividing cells, alternative transductions with lentivirus or adeno-associated virus
can be considered in that situation.[195,197, 202] 
Because no adequate labeling methods were available at the moment that we
started our research, an important aim of this thesis was to develop a label to trace
the cells in tissue engineered constructs in clinically relevant models. 
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Chapters of this thesis
In Chapter 3, in addition to the general backgrounds, a review on the investigation
of bone tissue engineering in spinal fusion models is presented;
In Chapter 4, we investigated the role of viability of autologous bone grafts both
ectopically and orthotopically in the goat;
In Chapter 5, we addressed the role of cell viability in tissue engineered constructs
ectopically in the goat;
In Chapter 6, the off-the-shelf fluorescent intramembranous CM-Dil label was
investigated as a potential marker for tracing cells in bone tissue engineering;
In Chapter 7, the more sophisticated retroviral labeling technique with a cell surface
marker gene was addressed; 
In Chapter 8, a study on optimization of tissue engineered bone formation with
respect to scaffold material and culture period of the constructs is reported;
In Chapter 9, another study on optimization with a new scaffold material and a
peroperative seeding method is addressed;
In Chapter 10, we investigated the feasibility of bone tissue engineering
orthotopically in critically sized iliac wing defects;
In Chapter 11, the results of all studies are discussed;
In Chapter 12, we make an effort to draw some general conclusions.
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Chapter 3
BONE TISSUE ENGINEERING AND SPINAL FUSION: 
THE POTENTIAL OF HYBRID CONSTRUCTS BY COMBINING 
OSTEOPROGENITOR CELLS AND SCAFFOLDS: A REVIEW
Summary
In this review paper we discuss the current knowledge and achievements on bone
tissue engineering with regard to spinal fusion and highlight the technique that
employs hybrid constructs of porous scaffolds with bone marrow stromal cells
(BMSC’s). These hybrid constructs potentially function in a way comparable to the
present golden standard, the autologous bone graft, which comprises besides many
other factors, a construct of an optimal biological scaffold with osteoprogenitor cells.
However, little is known about the role of the cells in autologous grafts, and
especially survival of these cells is questionable. Therefore, more research will be
needed to establish a level of functioning of hybrid constructs to equal the
autologous bone graft. Spinal fusion models are relevant because of the increasing
demand for graft material related to this procedure. Furthermore, they offer a very
challenging environment to further investigate the technique. Anterior and
posterolateral animal models of spinal fusion are discussed together with
recommendations on design and assessment of outcome parameters.
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The need for graft material in spinal fusion 
Spinal surgery is performed with increasing frequency for many orthopaedic and
neurosurgical indications. It is estimated that more than 200.000 spinal fusions are
performed each year in the United States.[44,203] The standard technique of recent
years combines pedicle screw instrumentation or intervertebral joint screw-fixation
with bone grafting between transverse processes and laminae if available
(PosteroLateral Fusion – PLF, Fig. 1).[204] Another technique, with stabilization and
(some) distraction of the disc space, performs an anterior arthrodesis between the
vertebral bodies (Anterior Interbody Fusion – AIF, Fig. 1). A third technique,
applying smaller cages from a posterior approach, is the so-called Posterior-Lumbar
Interbody Fusion (PLIF, Fig. 1). Anterior constructs, alone or in combination with
posterior instrumentation in the case of PLIF’s are thought to be mechanically more
stable, as in humans the majority of the compressive loads are conducted through
the anterior column. 
The increasing frequency of anterior spinal fusion can partially be attributed to the
invention and commercial promotion of the so-called ‘cages’ for inter-body spinal
fusion.[203,205] These cages were originally developed to distract and stabilize the
cervical spine of horses suffering from the “wobbler syndrome”.[206,207] Additional
advantages of cages are a reduction of the required graft volume, the potential
improvement in fusion rate, and the possibilities to insert cages using less invasive
surgery. None of the current procedures is perfect, as reflected by the nonunion
rates ranging from between 7-30%.[208] Furthermore, the use of cages has not
obviated the need for graft material, although a reduction was achieved from ±15cc
for PLF to 4-6cc for AIF.[204]
As a graft material, the golden standard for most orthopaedic applications is the
autologous bone graft, which is however inherent to a limited availability and an
additional surgical procedure with potential complications.[45,46] Therefore, many
substitutes have been developed which all have specific disadvantages, like
immunogenecity for allogeneic bone grafts and unfavorable biomechanical
properties for most synthetic biomaterials. To be more successful, it is conceivable
that these substitutes will need one or more of the features that determine the
superior functioning of the autologous bone graft. Although little is known about the
exact mechanisms involved in the use of autologous bone graft,[43] the
osteoconductive and osteoinductive properties, in addition to viable osteoprogenitor
cells are likely to be such features, and crucial for their clinical success. Therefore,
substitutes using tissue-engineering techniques aim at combining two or more of
these features. 
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Two important findings have propelled the enthusiasm for bone tissue-engineering
research: (1) The identification of bone morphogenic proteins (BMP’s) by Urist et
al.[48,49] which led to a progressive research program of which the first clinical
studies have recently been reported,[50-53] and (2) the presence of osteoprogenitor
cells in bone marrow aspirates, and the development of techniques to culture and
expand these cells.[58,59,61,63] In the present paper, we will further address the bone
tissue-engineering strategies based upon the combination of these osteoprogenitor
cells with synthetic scaffolds to constitute the so-called “hybrid constructs”.
Figure 1 Spinal fusion techniques
a): Posterior view of posterolateral fusion (PLF). Graft material is bilaterally applied between
the transverse processes and on the facet joints.
b): Lateral view of anterior interbody fusion (AIF). The perforated cage is inserted between
the vertebral bodies to distract and stabilize. The cage is filled with graft material to stimulate
bony fusion through the cage.
c): Lateral view of posterior lumbar interbody fusion (PLIF). Two cages are inserted bilaterally
from a posterior approach. To create space the facet joints need to be removed.
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Bone Tissue engineering with Hybrid constructs
History
The osteogenic capacity of viable fresh bone marrow was already demonstrated in
1955 by de Bruyn et al., and confirmed during subsequent years by others.[57,58,209]
However, this bone formation appeared to be limited in larger animals.[38,130,131,210]
Probably this was related to the more challenging environment combined with a
very low density of osteoprogenitor cells in fresh bone marrow (1-30 per 100.000
nucleated cells).[5,123,211] Friedenstein and co-workers identified in bone marrow
aspirates the colony forming unit fibroblast (CFU-F), with bone forming
capacity.[61,76,79] These cells, having bone forming capacity, were easily culture-
expanded to increase the yield of tissue-engineered bone.[105,114,123,211] Since the
early nineties, many investigations concerning identification and purification of the
CFU-F’s or mesenchymal “stem” cells have been performed.[4,63,66,105,212-215]
These cells will be further referred to as Bone Marrow derived Stromal Cells
(BMSC’s). At present, several studies demonstrated the feasibility of hybrid
constructs in rodent and large animal models.[119,122-125,130,131] However, studies
comparing tissue-engineered bone to autologous bone grafts in a clinically relevant
model, or in controlled studies in primates, have not yet been reported. This
relatively slow progression towards clinical application may be due to the absence
of a clear understanding of how tissue-engineered bone should function, especially
when considering the impaired vascularization after transplantation. 
Potential mechanism of bone formation in hybrid constructs
In studies where fluorochrome markers were used[105,110,131] (see also Fig. 2), it
was demonstrated in porous, ceramic based hybrid constructs that ectopic bone
formation starts at the material surface, a mechanism similar to bonding
osteogenesis.[9] This observation however, does not explain the exact mechanism
by which the bone is formed. To answer this question, first the well-known
mechanisms of enchondral (with cartilage intermediate) and intramembranous
(without cartilage intermediate) bone formation[216,217] have to be distinguished.
The occurrence of these two mechanisms, together with other contributing factors,
may indicate the similarity of bone formation in hybrid constructs with aspects of the
following empirically known processes of “spontaneous” post-embryonic bone
formation:
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• Fracture repair
• Osteoinduction
• Medullar bone formation
• Bone formation in autografts
In hybrid constructs, the cartilage intermediate has never been described
convincingly, although chondrogenesis from BMSC’s without replacement by bone
has been consistently observed, especially in less perfused areas, such as central
regions in diffusion chambers, or inside relatively large implants in animal
models.[63,79,125,158,191] Therefore, intramembranous bone formation is expected to
be the predominate mechanism.
Fracture repair is unique when compared to other post-embryonic repair
mechanisms that result in scar formation, instead of tissue regeneration. The
osteogenic process, that commences after the inflammatory phase, under the
influence of bone-derived bioactive factors,[147] is initiated by precursor cells from
the periosteum adjacent to the fracture, that generate the hard callus by
intramembranous bone formation. The majority of bone formation however, is by
enchondral ossification of the soft callus that appears after infiltrated mesenchymal
cells are induced to chondrogenesis.[147,148,216,218] Therefore, fracture repair is
probably not a predominate process in TE bone formation. 
Osteoinduction is most apparent as bone formation in a non-bony environment,
described for pathologic heterotopic ossification (PHO)[150] and artherosclerous
plaques.[219,220] This phenomenon was consistently observed in ectopically
implanted demineralized bone matrix (DBM) and investigated extensively by Urist et
al.[48,49,129] They identified bone morphogenetic proteins (BMP’s) that induce
undifferentiated mesenchymal cells to form bone. Depending on the BMP
concentration, both enchondral and intramembranous bone formation mechanisms
are considered to be involved in this process.[221,222] An interesting and less clearly
understood observation is that porous ceramics alone, which are often applied as a
scaffold for TE, can induce bone formation, without a cartilage
intermediate.[98,152,223] Theoretically this material based osteoinduction, or the
presence of additional inductive factors in the extracellular matrix, could be the
responsible mechanism of bone formation in hybrid constructs. However, this is
unlikely as in many studies bone was absent in the control ceramics,[110,224] even
when cell matrix without viable cells was present.[131]
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Medullar bone formation is an intriguing phenomenon of intramembranous bone
formation that was observed inside rodent femora, after disruption of the bone
marrow stromal cavity. Amsel and others described in detail how the femoral cavity
was entirely filled with bone that constituted a preliminary scaffold for bone marrow
restoration.[225,226] Even when the femora were transplanted ectopically, the origin
of the bone was typically from the (stromal) donor cells while the haematopoietic
cells appeared to be host derived.[225-227] This resembles bone formation described
for hybrid constructs in many ways. Especially the stromal origin of the bone
forming cells and the tendency to create a haematopoietic
environment.[66,67,75,113,228] However, medullar bone formation depends on
precursor cells that are capable of extensive proliferation, as was determined by
irradiation studies.[226,229,230] This implicates that a well-vascularized environment
is obligatory, which is definitively not the situation during the first period after
implantation of clinically relevant sized grafts.[172,173,231]
Bone formation in autologous bone grafts was shown in ectopically transplanted
grafts in rodents. The necessity for viable cells in the graft (no bone formation when
devitalized grafts were implanted), but also the relative contribution of these cells to
the newly formed bone were demonstrated.[57,172,178,179,182,183] We demonstrated
in goats a similar necessity of implant viability for ectopic, membranous
osteogenesis in clinically sized autologous bone grafts.[232] This observation, that
viable cells are required initially, does not necessarily implicate the presence of
these cells in the newly formed bone. In fact, a mechanism where donor cells do not
survive, but release prior to death a bone inducing substance that activates invading
mesenchymal cells, has been proposed by many authors.[42,57,170,172] 
In conclusion of this section we assume that (the initiation of) bone formation in
hybrid constructs is dependent on, or at least enhanced by viable cells, and
progresses with appositional bone formation without a cartilage intermediate.
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Figure 2 Micrographs of hybrid constructs implanted intramuscularly in goats (☞ p. 179)
a): Low magnification micrograph of 7x7x7mm hybrid construct. New bone is clearly present
as bright red on the biphasic calcium phosphate (BCP) ceramic scaffold surface. Note the
typical distribution of bone that is present only in the interior of the scaffold (bar=1.3mm).
b): High magnification micrograph showing newly formed bone lined by osteblasts (arrows),
on the surface of the BCP scaffold (bar=100µm).
c): High magnification with fluorescent microscopy showing the sequential fluorochrome
labels in newly formed bone: C=calcein green at 4 weeks; X=xylenol orange at 6 weeks;
T=tetracyclin at 8 weeks. Mineralization initiated around four weeks and was directed
centripetally (bar=200µm). 
Towards spinal fusion
Spinal fusion is considered to be one of the most challenging applications for bone
graft substitutes, since even autologous bone, the golden standard, has a relatively
high rate of failure. For research purposes, this can be advantageous as it allows for
critical examination of both positive and negative effects. Recently, the necessary
burden of proof was discussed to decide for clinical use of osteoinductive (BMP
based) bone graft substitutes.[44,56] For spinal fusion, it was recommended by
Boden et al. to follow an extensive establishment of efficacy. This starts with the
proof of the concept, normally in small animal models, followed by feasibility studies
in larger animals and efficacy studies in non-human primates. In principle, this
thorough pathway of pre-clinical evaluation should also be applicable for the use of
hybrid constructs. Particularly for spinal fusion, where the use of an
osteoconductive scaffold material alone is not regarded as an acceptable
alternative for the autologous bone graft[38,40,44] and thus the surplus value of
osteoprogenitor cell addition becomes essential. In the following sections we will
discuss our view on the sequential steps needed in the development of a cell-based
tissue-engineering technique for spinal fusion.
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Proof of the concept
The diffusion chamber assay, where cells are shielded from invading host cells by a
semi-permeable membrane, can be considered as proof of cell
osteogenicity.[79,128,158] The subcutaneous nude-mouse model that allows
implantation of hybrid constructs of other species’ cells, due to the immune-
compromised status of these mice, is a scientifically well-established test for
construct osteogenicity.[67,116,128] 
Rodents however, do not fully represent the situation in larger mammals. For
example, we observed that hybrid constructs of goat BMSC’s with a certain type of
hydroxyapatite ceramic scaffold yielded always bone in nude mice, but almost never
when implanted autologously in the goat muscles. Another scaffold type showed
comparable osteogenicity in both species.[131] To investigate osteogenicity in larger
mammals, and to optimize the characteristics of a construct, ectopic implantation
models are of great value, as these allow paired comparisons of many parameters
without the disturbing influence of surrounding bone.[129,233] However, successful
ectopic performance does not guarantee adequate orthotopic activity. For instance,
we found consistent TE bone formation ectopically in 12 out of 12 goats, whereas
identical constructs showed no bone formation when implanted in a femoral
segmental defect.[131] On the other hand, other investigators claimed the opposite
experience in sheep (orthotopic functioning without ectopic bone formation).[122,127]
Feasibility studies
To investigate the feasibility of tissue-engineered grafts, models in larger animals,
where both donor cell survival and host response are more comparable to the
human situation are required. Critical-size defect studies with hybrid constructs
have been promising, and there are indications of an enhancing effect of cell-based
bone TE compared to the scaffolds only for spinal fusion.[35,119,123,124,234] However,
as long as the mechanism of TE bone formation is largely unknown, and therefore
the functioning cannot be predicted, the comparison with the autologous bone graft
seems more than relevant. In the paragraph below, considerations and
prerequisites for spinal fusion models are discussed. 
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Spinal fusion models
Since the investigations of Albee[235] on canine spinal fusion almost a century ago,
many animal models for spinal fusion have been developed and used. This has
resulted in increased knowledge of the healing process and the role of surrounding
tissue. For example, Hurley et al. showed, by interposing permeable and
impermeable sheets between the host and grafted bone, the essential role of the
surrounding tissue in the provision of nutrients through diffusion.[236] It was
demonstrated in rabbit posterolateral fusion studies, that the vascular supply of the
fusion mass originated from the decorticated transverse processes.[176,237]
Furthermore, histology revealed that bone formation in the fusion mass was mainly
intramembranous, but with a central “lag effect”, meaning that maturation of the
fusion was most advanced near the transverse processes and delayed
centrally.[175,238] Largely unknown, but crucial for cell-based TE, is the mechanism
of bone formation in autologous bone grafts, especially with regard to osteogenicity
as a function of residing osteoprogenitor cells.
Bone tissue engineering is primarily a biologic process, in which various other
aspects such as biomechanics play an important role. Therefore, to study the
feasibility of this technique in spinal fusion, biologic similarity and non-union rates
analogous to the human situation are considered to be of utmost
importance.[44,239,240] Furthermore, understanding of the many factors that
influence spinal fusion is essential to optimize and identify the effect of TE. In Table
1a and 1b we summarize some potential posterior and anterior spine fusion models. 
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Table 1 A Selected animal models for posterolateral spinal fusions
* AG is Autograft derived from iliac crest, rib or proc.spinosus
** DBM is Demineralized bone matrix
*** BMP is Bone morphogenetic protein 2,7 or extract
# PLA is Polylactic acid 
Species
(Surg. Model)
Author 
year ref
Segment Follow uptime (weeks) Conditions
Rabbit
(Decort. non instr.)
Boden 1995175 L5-L6 2-10 Sham+/- decort, AG*
1995238 1-10 AG
1995250 5 AG, DBM**, Ceramics, +/-BMP*** 
Mini Pig
(Decort. instr.)
Christensen 2000251 L3-L4 12 AG, screw materials
Dog-Mongrel
(Decort. non instr.)
Frenkel 1993252 T1-8 6 AG, DBM
Lovell 1989253 T6-13 3,6,12 AG, PLA# +/-BMP
Cook 1994254 T13-L7 6,12,26 AG, Collagen +/-BMP, No graft
Dog-Beagle
(Decort. non instr.)
Sandhu 1997255 L4-5 12 AG, PLA+/-BMPs
David 1999256 4,8,12 AG, Collagen, PLA +/-BMP
Goat
(Decort. instr.)
Johnston 1990244 10 
Consecutive
T Levels
6,12 AG, instr. stiffness
Johnston 1995257 L3-5 12 AG, instr. stiffness
Sheep
(Decort. +/- instr.)
Kotani 1996245 L2-3 3-4 4-5
5-6
16 Sham(- instr.), AG (+instr.)
Kanayama 1999168 8,16 AG (+/- instr.)
Kanayama 1998258 16 Sham(+/- instr.), AG (+instr.)
(Decort. + instr.) Kanayama 1997259 4,8,12,16 AG, No graft
Baramki 2000260 20 AG, Ceramics, No graft
Walsh 2000210 24 AG, Collagen/ceramic mix
+/- Bone marrow
Steffen 2000261 12,20,36,72 AG, Ceramics, No graft
Non-human 
primate
Boden 1995250 L4-5 12 DBM+/- BMP
(Decort. non instr.) Boden 1999262 24 AG, Ceramics+/-BMP
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Table 1 B Selected animal models for anterior spinal fusions
* AG is Autograft derived from iliac crest or proc.spinosus
** Allo is Allograft material
*** BMP is Bone morphogenetic protein 2,7 or extract
Species
Author 
year ref
Segment Follow uptime (weeks) Conditions
Dog Cook 1986263 C2-3 5-6 1-24 Stand alone Ceramics
1994264 6,12,26 Stand alone AG*, Ceramics
Goat Zdeblick 1992265 C2-3 3-4 4-5 12 Sham, AG, Allo**
199440 AG, Allo, Ceramics +/- plate
1998266 Cyl. cage with AG or BMP***
Toth 1995267 C2-3 5-6 12,24 Stand alone AG, Ceramic
Pintar 1994243 2x separate 
cervical 
2x separate 
lumbar
6,12,24 Stand alone AG, Ceramics
Brantigan 199434 L4-L5 24,48, 96 Stand alone Allo, Flex. box cage
Van Dijk 2002268 L3-4 12,24 Flex. and Titanium box cage
Sheep Cunningham 1998269 T5-6 7-8 9-10 16 AG+/- plate, Cyl. cage with AG 
1999270 Cyl. cage with AG or BMP
Steffen 2000261 L2-3 4-5 8,32 Box cage with Ceramics
2001271 8,16,32 Box cage, empty 
with AG or Ceramics
Sandhu 1996272 L4-5 24 Sham, AG dowel,
Cyl. Cage with AG
Non-human
primate
Hecht 1999155 L7-S1 12,24 Allo dowel with AG or BMP
Boden 199854 L6-S1 12,24 Cyl. cage with Coll+/-BMP
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Factors that influence experimental spinal fusion 
There are numerous factors that influence the success rate of experimental spinal
fusion. These can be divided into animal related and surgery related factors. Animal
related factors are the variations between different species, as a result of
evolutionary complexity and the varying pace and degree of skeletal maturity. For
example, in rats the fusion rate is much higher than in mature non-rodent mammals,
including humans, where spontaneous fusion after decortication of the facet joints
and lamina is exceptional.[241] Surgery related factors include the location and
number of fused segments,[236,242,243] and the use and rigidity of
instrumentation.[168,244,245] For instance, the lumbosacral junction is exceptionally
prone to non-union, potentially as a result of excessive motion.[242] Vascularization
is critical for the osteogenic process and is greatly influenced by the regime of
decortication. In the case of PLF, the pars inter articularis preferentially is not
decorticated,[237] contrary to the facet joints and transverse processes, where
decortication facilitates vascular ingrowth into the fusion mass.[176] Medication is
another important issue, for example non-steroidal anti inflammatory drugs
(NSAID’s), that are normally used for post-operative pain relief, have shown to
negatively affect osteogenesis.[246-248] Finally, postoperative handling also
appeared to influence the outcome, as was shown by the negative effect of regularly
lifting rabbits that underwent non-instrumented PLF from their cages in comparison
to a non disturbed group.[249] 
Posterolateral fusion (Table 1a)
Spine surgeons are aware of the difficulties of achieving successful fusion, therefore
they meticulously decorticate the facet joints, transverse processes and laminae,
and commonly use rigid instrumentation to keep the segments fixed during the
critical period during which the fusion mass forms. The animal models simulating
this challenging surgical practice, however, have not consistently reproduced these
surgical techniques. In the frequently used rabbit model, decortication is restricted
to the intertransverse processes and no instrumentation is applied. In most sheep
models, extensive decortication, facetectomy and rigid instrumentation (although
not always[168]) have been reported. One general advantage of the PLF model for
tissue engineering research is that it can be regarded as both orthotopic and
ectopic.[241] This allows to some extent the evaluation of a potential osteogenic
process per se, with limited confusion by osteoconductive bone formation. Although
dogs and sheep approximate the human size and anatomy better, they do not
simulate the graft-healing environment of humans any better than rabbits.[238,240]
This was one of the reasons why Boden et al. chose to validate a non-instrumented
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posterolateral intertransverse model in rabbits (see table 1a). In dogs and sheep no
such validated models exist. 
Anterior interbody fusion (Table 1b)
Most AIF study models are reported for larger mammals, like dogs and goats. The
erected goat cervical spine is popular for its analogy with the human cervical spine.
Zdeblick and others developed a three level goat cervical AIF model and
investigated the effect of plate-instrumentation on stand-alone grafts and the use of
interbody cages. When ceramics were used as stand alone grafts, fragmentation
was shown for porous and even dense blocks.[40,243,263] Cages offer a unique, well-
nourished, relatively small and shielded area, which is especially interesting for the
application of hybrid constructs. Considering the much larger graft volumes applied
for other spinal fusion techniques, cell survival inside the TE constructs in cages is
more likely and little restrictions on scaffold biomechanical properties exist. 
Study design
The design can vary from multilevel left-right comparisons to a single condition per
animal. In pilot experiments, left/right comparisons can be performed. However,
especially when no instrumentation is used, the left/right comparison can be
misleading, because fusion on one side will influence the mobility and thus the
fusion rate on the contralateral side.[240] Potential biomechanical differences
between segmental levels should also be carefully balanced in the design.[242] Most
authors leave one segment intact between two operated levels. As with all
experiments, a conservative power analysis should be made. Based on
histomorphometry results that were published on TE bone, the coefficient of
variance (SD/average) was about 0.2 in the experimental groups compared to
about 0.5 in the scaffold-only groups.[118,119,123,273] Precise power calculations
therefore cannot be made, but unpaired studies exceeding twenty animals per
treatment group are not overdone.
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Outcome parameters
Radiographs, CT and MRI can provide relevant information on fusion mass and
progression. However, determining spinal fusion is complicated and
controversial.[274] Particularly when ceramics or hardware are used, current
imaging techniques become unreliable and other techniques such as manual
palpation or more sophisticated biomechanical testing become
necessary.[44,238,260,265,266,274] Brantigan et al. demonstrated that post mortem
radiographs and CT scans correlate well with histology, when radiolucent cages
were used.[34] This supports the opinion that histology is of great importance as an
outcome tool to evaluate the quality and quantity of bone formation in spinal
fusion.[56,274] Additionally, other tissues like cartilage can be identified and a
detailed examination of the host response and scaffold behavior can be made.
Finally fluorochrome labels can be applied which indicate the direction and rate of
mineralizing bone (Fig. 2).[131,275,276] 
Prerequisites for research on TE hybrid constructs
To investigate bone tissue engineering in any spinal fusion model, a reproducible
osteogenic construct should be selected. Although the well established rabbit spinal
fusion model is highly preferable, our experience with rabbit BMSC’s is that the
criterion of reproducibility could not be fulfilled. Rabbit BMSC’s are extremely
variable both in-vitro and in-vivo, as was also shown by others.[277] In addition,
animal losses exceeding 10% are not exceptional. Sheep and goat BMSC’s are
increasingly popular in the literature.[103,122-125,131] In our own experiments using
goat bone marrow aspirates, we found these cells to be easily selected and culture-
expanded. When seeded on appropriate scaffolds and implanted ectopically, the
hybrid constructs were almost 100% osteogenic.[131,278] 
From a clinical perspective, it is debatable whether the TE construct needs to proof
osteogenicity ectopically in the animal of investigation. It can be argumented that
the local conditions are so different between the ectopic and orthotopic implant
location that this influences local osteogenicity. Furthermore it should be realized
that not all constructs allow ectopic evaluation, such may be the case with fast
degrading scaffolds like hydroxy carbonate.[123]
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Discussion
In the present paper we reviewed the current knowledge and achievements on cell-
based bone tissue engineering with regard to spinal fusion. Because cell survival in
large graft applications is questionable, and therefore a simple cell derived bone
formation is unlikely, emphasis was put on the potential mechanisms by which the
technique should function. Although the exact mechanism is not elucidated, there
are indications that TE bone formation resembles the appositional osteogenesis
described to occur in ectopic autologous bone grafts[178,232] and in disrupted bone
marrow cavities.[225-227] In both processes, viable cells were shown to be crucial.
This might be a serious limitation for the TE technique, because in many studies
substantial loss of viability has been reported in the weeks after transplantation of
autologous bone grafts that, with respect to cell survival, can be considered as cell-
constructs.[42,169,231] Furthermore, in studies where autografts were implanted
orthotopically for several months, the added value of viable cells in the grafts was
considered insignificant. In these studies, viable autografts were compared to
autografts that were devitalized by freezing in liquid nitrogen, before
transplantation.[23,181,231,279] On the other hand, the functioning of hybrid
constructs might be possible with relatively few surviving cells, as an increasing
number of reports of successful critical-size defect studies in large animals has
appeared.[119,122-125] These findings are promising and make spinal fusion studies
a logical next step in research on feasibility of the technique.
Although anterior interbody fusion with the application of cages has many
advantages, researchers should realize that the ability to discriminate between the
long-term effects of TE and simple osteoconduction may diminish. Therefore, the
more challenging posterolateral model seems initially more appropriate. Besides
construct osteogenicity, successful spinal fusion will also rely on functionality of the
newly formed bone and integration in the surrounding bone. This is a concern,
because hybrid constructs have the tendency to form individual
ossicles[66,67,75,113,228] with mainly central bone formation and only occasional
bridging of individually implanted granules (Fig. 2).[131] Therefore not only the
percentage of bone, but also these aspects of functional behavior should be
studied.
As soon as the feasibility of the technique has been established, the question will
arise whether safety and efficacy studies in non-human primates are necessary, as
was done extensively for BMP’s.[54,155] According to our opinion, the need for
primate models is defendable for BMP studies, where the risks of (uncontrolled)
bone formation may be higher as compared to cell-based TE. Especially when non-
stimulated cells are applied, this risk seems reasonably low and from this
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perspective, does not necessarily legitimate primate models. On the other hand, the
risk of inadequate bone formation in human applications of hybrid constructs cannot
be ignored, as the differentiation of the cells cannot be predicted. This is reflected
by the finding that only half of the constructs from patients above 50 years showed
to be osteogenic in the nude mice model.[159]
In conclusion, since the potentials of cell-based (bone) TE are only emerging
recently, a humble research attitude to primarily gain insight in the technique should
be applied. Then, the challenge is to establish a level of functioning at least as good
as the autologous bone graft in a feasibility model of spinal fusion.
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Chapter 4
THE OSTEOGENICITY OF AUTOLOGOUS BONE TRANSPLANTS IN 
THE GOAT
Summary
Introduction: Little is known about the specific mechanisms that make autologous
graft bone (AG) superior to the current alternatives. A potential mechanism is the
active bone formation by the osteoprogenitor cells within the AG. However, whether
these cells survive the transplantation is questionable, especially in non-
vascularized clinically sized grafts. In the present study we investigated the role of
viability in AG, implanted ectopically and orthotopically in the goat.
Methods: Eight goats were operated on twice. At the first operation, pieces of vital
or devitalized autologous cortical bone were implanted in the paraspinal muscles.
Eight weeks later, corticocancellous plugs were taken from the femoral condyles,
morselized and re-implanted as either vital or devitalized orthotopic grafts. The
goats received fluorochrome labels at 5, 7 and 9 weeks after the first operation. At
twelve weeks the goats were killed and the samples were examined histologically. 
Results: Ectopically, new bone had formed in both the vital and devitalized grafts.
In the vital grafts, all three fluorochrome labels were present, indicating an early
osteogenic mechanism. Within the devitalized grafts, only the 9 weeks label was
observed. Histomorphometry indicated significantly more new bone in the vital
grafts, 10.3 vs. 1.7% in the devitalized grafts. Orthotopically, both vital and
devitalized grafts showed new bone. Again, graft viability was advantageous in
terms of new bone formation (14.5 vs. 9.3%). 
Conclusion: The cells inside the autologous bone transplants most likely survived
transplantation and were capable of initiating and sustaining new bone formation.
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Introduction 
Currently, bone is one of the most frequently transplanted tissues and applied in
many orthopedic, neurosurgical and maxillofacial interventions. The non-
vascularized autologous bone graft (AG), as a structural graft or morselized, is the
gold standard for most applications. However, many disadvantages, such as donor
site pain and limited availability, are inherent to this graft.[45] A fundamental
difference with alternative graft materials, such as allograft bone, is the presence of
a viable osteoprogenitor cell pool in the autograft at implantation. Besides many
other important factors, subsequent bone formation by these cells may be
responsible for the superiority of the AG. However, contrary to vascularized bone
grafts,[280] cell survival and participation in bone formation in non-vascularized
grafts is largely unknown and highly controversial.[42,43,49,166] After transplantation,
the cells are exposed to the harsh environment of a haematoma[143] and may be
deprived of vascular supply for weeks.[173] Some authors report an almost total loss
of vital cells in the AG,[49,57,169] others report substantial survival, although limited
to a diffusion depth of 300µm.[170,172,173] Elves and Gray[178,179] reported the
osteogenicity of ectopically implanted AG in rats. The implants were not osteogenic
if devitalized by freezing before transplantation. As direct proof of osteogenicity,
Boynton et al.[183] used immunohistology to identify human cells within new bone
appositions on human bone chips implanted ectopically in immune-compromised
mice. These studies indicated that the cells inside small (cubic mm’s) grafts have
the potential to survive and form new bone ectopically. To our knowledge, this has
never been shown in larger mammals with transplants of clinically relevant size
(cubic cm’s), where cell survival is expected to be more difficult because of the
1000-fold increased volume and subsequently delayed re-vascularization.[173] 
Considering orthotopic bone transplants, only a few experiments are reported that
compared vital and devitalized autografts in large mammals.[23,181] In these
experiments, the contribution of viable cells in the autografts was considered
insignificant, however, these grafts were analyzed after incorporation in the host
bone. We did not find studies that analyzed grafts early after orthotopic
transplantation, before incorporation, when bone formation as a function of
transplanted progenitor cells is more likely to be determined.
At present, much research is focussed on cell-based tissue engineered bone as an
alternative for autologous bone.[123,131,281] The concept of this technique is to form
a hybrid construct from an osteoconductive scaffold and cells that have bone
forming capacity. In rodent studies, bone that formed in these hybrid constructs
contained the implanted cells.[116] Therefore, the success of tissue engineering is
likely to rely on survival and subsequent functioning of these cells. As for the
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autologous bone graft, this is questionable when clinically sized constructs are
applied. Therefore, as a first step to obtain a better understanding regarding the
importance of cell survival for bone grafting, we performed a study on autologous
bone grafts in a large animal model. The aim of this study was to investigate
whether the viability of autologous bone grafts influenced new bone formation,
ectopically and orthotopically in the goat, which would be an indication for cell
survival and functioning in these grafts.
Materials and Methods
Experimental design and groups
A total of 8 adult Dutch milk goats were operated on twice during the experiment, for
which the local animal care committee gave approval. At the first operation,
autologous cortical bone grafts, obtained from a femoral diaphyseal segment, were
implanted in the paraspinal muscles after one of the following treatments: 
1 Vital cortex – no specific treatment; 
2 Devitalized cortex – by freezing in liquid nitrogen; 
3 Morselized vital cortex and 
4 Morselized devitalized cortex. 
This resulted in a sample-size of eight for each treatment group. Fluorochrome
labels were administered at 5, 7, and 9 weeks. 
Eight weeks after the first operation the goats were operated on again. A
corticocancellous plug was taken from both the medial and lateral aspects of the left
femoral condyle. Both plugs were morselized and implanted in the trephine shaft
opposite the location of origin after one of the following treatments:
1 Vital corticocancellous chips – no specific treatment; 
2 Devitalized corticocancellous chips – by freezing in liquid nitrogen. 
The animals were killed 4 weeks later (12 weeks after the first operation). Ectopic
and orthotopic bone formation was investigated by normal histology, fluorescence
microscopy, and histomorphometry of nondecalcified sections. 
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General procedures
Goats (19-26 months) were obtained from a professional stockbreeder, at least four
weeks prior to surgery. Surgery was performed under general inhalation anesthesia,
preceded by i.v. detomidine sedation (Domosedan®, Pfizer, The Netherlands).
Thiopental 10mg/kg (Rhone-Merieux, The Netherlands) was introduced i.v. and
anesthesia was maintained by a halothane gas mixture (Sanofi, The Netherlands).
Postoperatively, pain relief was provided by buprenorfine hydrochloride (Shering-
Plough, The Netherlands). Three fluorochrome labels (Sigma-Aldrich,
The Netherlands) were administered intravenously: Alizarin Red (30mg/kg) at 5
weeks, Calceine green (10mg/kg) at 7 weeks and Xylenol orange (100mg/kg) at 9
weeks.[131] After twelve weeks the animals were killed by an overdose of
pentobarbital (Euthesate®, Organon, The Netherlands). 
Ectopic grafts
Autologous cortical bone was derived from a femoral segment that was excised as
part of a segmental defect model studied in the same goats. The 2.3cm, diaphyseal
segment was excised by sawing under constant saline cooling and cleaned of
periosteum and medullary contents. It was then sectioned in the sagittal and frontal
planes to provide four grafts with a volume of approximately 1cm3 each. Two grafts
were morselized with a mortar and pestle into bone chips (approximately
2x2x2mm). One intact and one morselized grafts was then devitalized by freezing
twice for 5 minutes in liquid nitrogen.[282] The grafts were implanted according to a
randomized scheme into separate pockets, created by blunt dissection, in the
paraspinal muscles.[131] The intact grafts were cut into two 1.1cm pieces before
implantation. The fascia was closed with a non-resorbable suture to facilitate
implant localization at explantation and the skin was closed in two layers. 
Orthotopic grafts
At the second operation, eight weeks after the first operation, both condyles of the
left femur were exposed. Corticocancellous bone plugs of 10mm length were
taken[283] with a Ø9.5mm hand trephine and extractor (Mathys, Bettlach,
Switzerland) and stored in warm saline. A 12mm Ø1.2mm Kirschner wire was
placed centrally in the trephine shaft to serve as a reference during explantation and
histology. Per goat, one of the plugs was devitalized in liquid nitrogen. Both plugs
were then morselized (approximately 2x2x2mm) and implanted press-fit in the
opposing location. The origin of the devitalized plugs and the operative order of the
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condyles were randomized. The periosteum was closed carefully before closing the
skin in two layers. 
Validation of osteogenicity
To determine the osteogenicity of the applied bone grafts in an established model of
osteogenicity,[49,121,183] vital and devitalized pieces (1-5mm3) of both the cortical
and corticocancellous grafts of each goat were implanted subcutaneously in nude
mice for four weeks. 
Validation of devitalization
Cortical (n=8) and corticocancellous (n=6) grafts, as used for ectopic and orthotopic
transplantation, were morselized and cultured under standard conditions for goat
bone marrow stromal cells (BMSC’s)[131] in 10cm2 culture dishes (Nalge Nunc,
Denmark) for 30 days to detect for surviving adherent cells. Another eight vital and
devitalized corticocancellous grafts were cultured for one week to expand the
number of any surviving cells. A 48h alamarBlue™ (AB. Biosource, Camarillo, US)
assay was then done to detect metabolic activity.[284] 
Post-mortem sample acquisition, histology and histomorphometry
At explantation, the ectopic implants were localized and excised together with
surrounding muscle. The orthotopic implants were sawed en-bloc from the
condyles. Explants were fixated in a 4%paroformaldehyde-5%glutaraldehyde
mixture, then dehydrated by alcohol series and embedded in
polymethylmethacrylate. Semi-thin sections (10µm) were obtained with a sawing
microtome (Leica, Nussloch, Germany) and analyzed with fluorescent microscopy
using a fluorescence/light microscope (E600 Nikon, Japan) with double filter block
(dichroic mirror 505nm and 590nm). Other sections were stained with methylene
blue and basic fuchsin for routine histology and histomorphometry. The bright red,
highly cellular, newly formed bone was identified and distinguished from the pale,
mainly acellular grafted bone. The mid-section through the implants was used for
histomorphometry. For the ectopic implants, this was the section providing the
largest sample area. For the orthotopic implants, the explanted condyle blocks were
ground in the sagittal plane until the outer (circular) margin of the grafted defect
appeared. Then the block was cut 5mm below and parallel to the ground surface
through the middle of the 10mm defect. Image analysis was done by a blinded
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observer using a VIDAS system (KS400, Zeiss, Munich, Germany) coupled to a
light microscope. For the ectopic implants, the area of interest was defined by
outlining the graft. Within this area the percentage of newly formed bone was
measured. In the orthotopic implants, the area of newly formed bone was measured
within four quadrants of the Ø9.5mm outlined defect at 25x magnification. The area
percentage newly formed bone was then calculated.
Statistics
Results are given as mean±standard deviation (SD). Two-tailed paired student t-
tests were performed after the data were analyzed for normal distribution with
SPSS10 software (p<0.05 was considered significant).
Results
Efficiency of devitalization and osteogenicity of the cells
The devitalized grafts did not show remaining viable cells during one month of
culture. The vital grafts, however, showed outgrowing fibroblastic cells within one
week. When these cells were detached, seeded onto 70% porous hydroxyapatite
scaffolds (Cam Implants, The Netherlands) and implanted in nude mice, these
constructs were shown to be osteogenic.[121] The 48 hour alamarBlue™ assay also
did not indicate any vitality in the devitalized grafts, whereas, in the viable control
grafts, metabolic activity could be measured within 1 hour of incubation. The
subcutaneous implants of cortical and corticocancellous grafts in mice showed new
bone formation only in the vital implants, indicating a cell-dependent osteogenicity
of these small grafts (Table 1).
General
Two of the goats developed a painful hoof disease for which they were terminated
after 10 weeks instead of 12 weeks. Autopsy and cultures of blood and tissue did
not indicate a cause related to the procedure. The ectopic implants of these two
goats were used for qualitative measurements and for paired comparisons within
the animal. The orthotopic grafts were excluded from quantitative analysis because
these had been implanted for only half the planned evaluation time.
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Table 1 Bone formation in the study groups
The fraction of samples showing new bone and the area percentage new bone (Mean±SD)
are shown. The time points at which the observed fluorochrome labels were administered to
the goats are shown in the right column. 
Ectopic grafts (Table1)
At retrieval, all devitalized morselized cortex chips had been resorbed. All other
implants were surrounded by well-vascularized muscle tissue without signs of
inflammation. Histology showed new bone formation in all retrieved implants
ranging from minute spots on the devitalized implants to abundant trabecular bone
formation in the morselized vital implants (Fig. 1). 
The vital morselized cortex typically formed rigid ossicles (Fig. 1) as a result of
extensive new bone bridging between the implanted chips. The interior of these
ossicles was filled with fat cells (Fig. 2a). 
Within the vital intact cortex, new bone had formed between the two implanted
pieces, however, bone apposition on the walls of resorbed haversian channels was
responsible for most of the newly formed bone (Fig. 2c). 
The devitalized intact cortex had decreased in size substantially when compared to
the vital intact implants. Inside these implants, minimal resorption was found. On the
periphery, however, extensive resorption was present and small amounts of bone
had formed on the bottom of resorbed cavities in all samples (Fig. 2e). 
Fluorochrome analysis of the vital morselized cortex indicated that mineralization
was present within the newly formed bone at 5, 7 and 9 weeks after transplantation
(Fig. 2b). In the vital intact cortex, the 7 and 9 weeks labels were typically present in
the remodeled bone within the osteons (Fig. 2d). Within the bone that had formed
on the devitalized implants only the 9 weeks label was detectable (Fig. 2f). 
Group New bone 
ectopically in mice
New bone 
ectopically in goats 
(area%)
Fluorochrome 
labels (weeks)
Vital morselized cortex N.A. 8/8 (18.9±8.7%) 5,7,9
Vital intact cortex 8/8 8/8 (10.3±5.0%) 5,7,9
Devitalized intact cortex 0/8 8/8 (1.7±1.2%) 9
Devitalized morselized cortex N.A. Resorbed Resorbed
Vital corticocancellous chip 8/8 N.A. N.A.
Devitalized corticocan. chip 0/8 N.A. N.A.
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Figure 1 Micrographs of ectopic autologous implants in goats. (☞ p. 180) 
a): Vital morselized cortical implants had formed ossicles as a result of new bone (NB)
bridging the grafted chips (bar=250µm).
b): Vital intact cortical implants showed new bone bridging the two implanted pieces and
appositioned in the resorbed haversian channels (bar=250µm).
c): Devitalized intact cortical implants showed minute spots of new bone on the periphery
(triangles). Note the absence of resorption around the haversian channels (bar=250µm)
Histomorphometry of the samples that were retrieved from the goat, indicated an
area% of 18.9±8.7% (Mean±SD) new bone within the vital morselized cortex
sample and 10.3±5.0% within the intact vital cortex. The devitalized intact cortex
showed only 1.7±1.2% new bone, which was significantly less when compared to
the vital intact cortex (p<0.01 Fig.3a). The histomorphometry data of the morselized
cortex indicated that morselization resulted in a higher yield of new bone. However,
statistical comparison with the intact cortex would be difficult, because in the intact
cortical grafts the available area for bone formation was different and restricted to
the framework that this structural graft provided. Meaningful histomorphometrical
comparisons with respect to the influence of viability of morselized grafts could not
be made, because the morselized devitalized cortex was completely resorbed. 
Figure 2 Detailed histology of ectopic autologous implants in goats (☞ p. 180)
a): Vital morselized graft. Detail of new bone (NB) bridging the chips that were implanted vital.
The interior of the ossicles was filled with fat cells (F) (bar=400µm).
b): Fluorescent image of morselized vital implant showing all labels A=Alizarine red (5 weeks)
C= Calcein green (7 weeks) X= Xylenol orange (9 weeks) (bar=400µm) .
c): Vital intact implant at high magnification. Bone resorption by osteoclasts (OC) and new
bone apposition by osteoblasts (OB) is visible. The distinction between pale grafted (G) and
red new bone (NB) is obvious (bar=100µm). 
d): Fluorescent image of the vital intact implant showing the 7 and 9 weeks labels in the
remodelled bone around haversian channels (bar=200µm).
e): Devitalized intact graft (G) with a thin layer of new bone present on the periphery
(bar=400µm). 
f): Fluorescent image of the devitalized implant showing only the 9 weeks label (bar=400µm).
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Figure 2
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Orthotopic grafts
Histology of the orthotopic implants showed good integration of both the vital and
devitalized grafts in the surrounding bone without an apparent difference between
the two groups at first observation (Fig. 4a-b). A distinct layer of new bone covered
most surfaces of the grafted bone (Fig. 4c), occasionally reaching the center of the
defect. The variance between goats was considerable, however, detailed
microscopic and histomorphometric analyses of the paired samples indicated more
new bone inside the defects grafted with vital bone, (14.5±3.5 vs. 9.3±4.9% p<0.02).
(Fig. 3b). The fluorochrome label given one week after implantation was
occasionally present, both in the vital and devitalized grafts, without an obvious
difference between the groups. 
Figure 3 Area% new bone in vital and devitalized grafts implanted in goats
Statistical analysis with paired t-tests, error bars indicate the standard deviation. 
a): The area% newly formed bone within the vital and devitalized ectopic cortical implants
(n=8, p<0.01).
b): The area% newly formed bone covering the vital and devitalized orthotopically grafted
corticocancellous bone chips (n=6, p=0.02).
Figure 4 Histology of orthotopic autologous grafts implanted for 4 weeks. 
a): Overview of the outlined Ø9.5mm defect showing the grafted devitalized chips embedded
in soft tissue and surrounded by host bone.
b): Overview of the defect showing the vital graft. 
c): High magnification micrograph of the rectangle in b. At this magnification newly formed
bone can be distinguished from the grafted bone. Triangles point to osteoblast linings (white
bar=200µm)
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Discussion and conclusions
In a study on transplants of human bone pieces (0.5mm3) ectopically in nude mice,
Urist et al. observed that graft cell survival was exceptional and limited to bone-
tumor transplants.[49] Whether cell death was due to insufficient oxygen and
nutrition or the result of a residual humoral immunologic response was not clear. In
the present study, we investigated new bone formation in ectopically and
orthotopically transplanted autologous bone grafts. After implantation of these
grafts, with a volume of about 1cm3, poor oxygen and nutrition conditions can also
be expected. To study the role of vital cells present in the graft, we devitalized the
control grafts by freezing in liquid nitrogen.[282] We chose this method as other
methods, such as lysing, gamma irradiation or heating, might be insufficient or
interfere with osteoinduction by devitalized bone matrix.[42,48,285,286] Although
freezing has minimal effect on bone morphogenetic protein (BMP) related
osteoinductivity,[48] we cannot rule out that freezing interfered with new bone
formation in any other way. Oklund et al. postulated that freezing could result in
calciolysis of bone grafts, thereby promoting ECM exposure and resorption.[181] In
our study, new bone formation in the frozen grafts was typically found on the
periphery where mineralized bone had been partially resorbed, indicating a positive
effect of organic matrix exposure. This is in agreement with the finding of Ripamonti
that bone induction occurred on the resorbed surface of partially demineralized
allografts in baboons.[11] For these reasons, freezing probably did not negatively
influence the osteoinductive capacity of the grafts in our study.
In pilot studies, we found that corticocancellous bone (as used for the orthotopic
investigations) could not be used in the ectopic model. Although abundant new
bone formed in viable corticocancellous grafts, all devitalized grafts were completely
resorbed. We cannot exclude the possibility that the devitalized grafts resorb faster
as a result of freezing.[181] It is therefore possible that bone formation in the viable
grafts may be the result of bone induction that initiated after the frozen samples had
resorbed. Consequently, we chose cortical bone, which was more resistant to
resorption, for ectopic investigations in the current study.
Increased bone formation was found in the viable ectopic implants, which showed
the early fluorochrome label. This suggests an early, osteogenic mechanism,[287]
which indicates that cells do survive after transplantation and are involved in new
bone formation. However, we cannot be sure how long cells survive or if they only
initiated host derived bone formation by unknown or not fully understood
mechanisms.[57,172] 
Another interesting finding was the absence of bone resorption around the
haversian channels in the devitalized cortical grafts. In the vital cortical grafts,
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resorption and subsequent new bone formation were abundant after 5 weeks of
implantation, based on the presence of the fluorochrome labels (Figs. 1 and 2).
Apparently, bone resorption for remodeling, according the principles of so-called
“creeping substitution”,[166,287] requires an environment of vital bone, as was also
postulated by others,[57] or the residence of vital osteoclasts within the transplant. 
The aim of studying the orthotopic model was not for comparison to the ectopic
model but to investigate whether the findings on cell survival and function in the
ectopic location were of any relevance orthotopically. Irrespective of cell
osteogenicity, we expected progressive bone formation in the orthotopic grafts as a
result of osteoconduction and induction. Therefore, we chose an evaluation time
that would be most distinctive for cell related osteogenesis. In rat studies, consistent
osteogenic bone formation was shown two weeks after subcutaneous implantation
of an autologous bone graft.[179] In the goats, we expected new bone formation to
occur later due to a longer re-vascularization period.[173] We therefore estimated
that an implantation period of 4 weeks would allow us to easily detect bone
formation. After this period, new bone was indeed present in both conditions, even
centrally in the defects. Apparently, host initiated bone formation is the predominant
mode of repair in this model. However, histomorphometry indicated a significantly
higher percentage of new bone in the defects grafted with vital bone. We therefore
conclude that at least a proportion of the grafted cells survived to promote bone
formation, leading to an acceleration of this process. However, in agreement with
observations by others,[23,181] no advantage of graft viability should be expected for
such a model in the longer term. 
In conclusion, the cells present in autografts in our ectopic and orthotopic models
most likely survived transplantation and were capable of initiating new bone
formation. With respect to tissue engineering of bone, these observations suggest
that the combination of vital osteogenic cells with an appropriate scaffold may be
advantageous to non-vital graft materials. This may be especially important in
applications where host bone formation is limited, such as spinal fusion.
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Chapter 5
VIABLE OSTEOGENIC CELLS ARE OBLIGATORY FOR TISSUE 
ENGINEERED ECTOPIC BONE FORMATION IN THE GOAT
Summary
Introduction: Cell survival in tissue engineered (TE) implants is questionable in
large animal models, therefore we investigated the significance of vitality, and thus
whether living cells instead of only the potentially osteoinductive extracellular matrix
are required to achieve bone formation.
Methods: Vital TE constructs of porous hydroxyapatite (HA) with bone marrow
stromal cells (BMSC’s) within an extracellular matrix (ECM), that resulted from one
week in-vitro culture, were compared with identical constructs that were devitalized
before implantation. Furthermore, we evaluated HA impregnated with fresh bone
marrow and HA only. Two types of HA granules were investigated: HA70/800, a
microporous HA with 70% interconnected macroporosity and an average pore size
of 800µm and HA60/400, a smooth HA. Two granules of both types were combined
and then treated as single units. To devitalize, TE constructs were frozen in liquid
nitrogen according to a validated protocol. Fresh bone marrow (BM) impregnation
was performed peroperatively. All study groups were implanted in the bilateral
paraspinal muscles. After 12 weeks, the units were explanted and analyzed by
histology. 
Results: Bone was present in all vital TE implants. None of the other groups
showed any bone. Histomorphometry indicated the microporous HA70/800 yielded
more bone than the HA60/400. 
Conclusion: Tissue engineered bone formation in the goat can be achieved only
with viable constructs of an appropriate scaffold and sufficient BMSC’s.
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Introduction
Bone tissue engineering (TE) has the potential to provide us with a promising
substitute for the autologous bone graft. To be successful, sufficient numbers of
potential bone forming cells, an appropriate scaffold to seed the cells, a vasculary
supply, and factors to stimulate the cells in-vivo are prerequisites.[63,105,288] Bone
Marrow Derived Stromal cells (BMSC’s) are the cells most frequently applied, and
these have been characterized and investigated extensively by Friedenstein et
al.[75,76] To date, many studies have been performed to optimize the selection,
culturing, and seeding of the BMSC’s to increase the bone forming
capacity.[68,115,130,214] It has now been demonstrated that combining BMSC’s with a
porous ceramic scaffold is a feasible concept to generate bone ectopically, or in
critical sized defects in rodents.[67,103,109,118,128,224] However, upscaling this
knowledge to larger mammals is challenging, and only few reports have actually
demonstrated bone formation orthotopically[119,122,123] or ectopically in rabbits and
dogs,[130,289] with limited control observations. In general, such implants will be
larger, and after implantation the cells will be inside the harsh environment of a
heamatoma.[143] This, in combination with the expected lack of vascularization until
the first week after implantation may compromise cell survival.[173,290] With our
method of bone tissue engineering, the hybrid construct consists of (1) living
osteoprogenitor cells, (2) non mineralized extracellular matrix (ECM) that already
has been produced by these cells during the culturing process,[103,105,291] (3) a
biocompatible porous scaffold and (4) media and supplements that have been used
during culturing and seeding. We think that a better understanding of the potential
separate roles of these parameters is essential in the upscaling of bone tissue
engineering to a larger animal, where cell survival is a major concern. To investigate
these parameters, it should be considered that osteoinduction is a potential
mechanism for bone formation, in addition to the osteogenicity of the BMSC’s.
Osteoinduction has been described for ECM,[292] that is also produced by the
BMSC’s after seeding on our scaffolds, and for porous ceramics that were
implanted ectopically, either with or without the addition of bone marrow.[98,293,294] 
The purpose of the present study was to determine the osteogenicity of tissue
engineered constructs in goats, taking into consideration the individual contributions
of the parameters mentioned above. Therefore we compared for two different
ceramics the bone forming capacity of vital hybrid constructs
(scaffold+ECM+BMSC’s), devitalized hybrid constructs (scaffold+ECM), scaffolds
only and scaffolds loaded with fresh bone marrow in a large animal model (goat). To
rule out osteoconduction or periosteal bone formation[119,122,295] as disturbing
mechanisms in this fundamental approach, we chose ectopic implantation sites. 
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Materials and Methods
Experimental design
Eight adult Dutch milk goats were used for the experiment, for which approval was
given by the local animal care committee. Two scaffolds types, HA70/800 and
HA60/400, were investigated. First, 32 treatment-units were made by combining two
granules of each material type. Each of these units was then subjected to one of the
following four treatments: (1) TE-vital: seeding of culture expanded BMSC’s
followed by in-vitro culturing of the constructs in the presence of differentiation
supplements; (2) TE-devitalized: like treatment 1, but followed by devitalization; (3)
BM: loaded with fresh bone marrow; and (4) Control: scaffold treated as in treatment
1 but without cells. One unit of each treatment was randomly allocated to one of four
implantation positions in the paraspinal muscles of the goat from which the BMSC’s
were derived (autologous implantation). This resulted in a sample-size of eight for
each treatment group. Fluorochrome labels were administered after 5, 7, and 9
weeks and the animals were killed after 12 weeks. Ectopic bone formation was
investigated by histology and histomorphometry of nondecalcified sections.
Harvesting and culture of the cells
BMSC’s were derived from the iliac wing and culture expanded as described in
detail previously.[103] In brief, 30ml aspirates were plated in culture flasks (5x105
nucleated cells per cm2) and cultured in a standard culture medium[103]
supplemented with 1ng/ml basic fibroblast growth factor (Instruchemie,
The Netherlands). When colonies of adherent cells had formed, these were replated
at 5000 cells/cm2. After another passage, the cells were resuspended at 5x105
cells/ml in seeding medium containing 2% Ultroser (US. Life Technologies, Grand
Island, US) as a replacement for the calf serum in the standard medium.
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Scaffolds
Two different scaffolds were used in the current experiment (Fig. 1): HA70/800, a
70% porous hydroxyapatite with an average pore size of 800µm was provided by
CAM Implants (Leiden, The Netherlands). According to the manufacturer, these
scaffolds were produced with spray-dried HA powder. The lamellar interconnected
pores were created using a H2O2 foaming method and the ceramic was sintered at
a temperature above 1100°C. This resulted in a marked microporosity as shown in
Fig. 1d. HA60/400, a 60% porous hydroxyapatite with an average poresize of
400µm was provided by IsoTis (Bilthoven, The Netherlands). This scaffold was
produced with commercial HA powder (Merck, Darmstadt, Germany) using wax
bead incorporation in addition to a MMA foaming method to create a porous
structure with interconnections in all three dimensions.[296] The sintering
temperature was 1200ºC. Microporosity was much less remarkable in this scaffold
(Fig. 1b). The chemical composition of the materials was analyzed by X-ray
diffraction (XRD) and Fourier Transformed Infrared (FTIR) spectroscopy. Both
scaffold types were sieved until granules of about 40mm3 (3x3x4mm) remained.
These were cleaned in an ultrasonic bath and then autoclaved. Two granules of
each scaffold type (total four granules) were combined and processed as one unit
for all further treatments.
Seeding and differatiation
The units were seeded with a load of 107 cells per cm3 scaffold (1.6x106 cells per
unit), overnight (14h) in 10ml tubes on a roller bank. To estimate the seeding
efficiency, eight constructs of each scaffold type were digested overnight in 500µl of
buffered proteinase K solution (Sigma, St. Louis, MO) at 56ºC. The DNA content
was quantified after RNA’se treatment with a CyQUANT® kit (Molecular Probes,
Eugene, OR).[297] The same assay was done with six-well plates seeded with
known cell numbers to provide the calibration curve. After seeding, the units were
cultured for another 6 days in medium supplemented with 10-8M dexamethasone
and 0,5mg/ml β-glycerophosphate (both from Sigma) to promote osteogenic
differentiation.[106] Control units (scaffold only) were maintained under the same
conditions. Cell increase during the culture period was assayed by a second DNA
quantification of eight, 6-day cultured constructs. Scanning electron microscopy
(SEM) of the constructs was performed to visualize the ECM and related cells. To
provide bone marrow impregnated units, fresh aspirate (4ml) without anti-coagulant
was loaded on the units for one hour at 37ºC during the operation.
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Figure 1 SEM micrographs of HA 60/400 and HA70/800 
a and c): At low magnification the interconnected porosity of HA60/400 (a) and HA70/800 (c)
is visualized. Note the more lamellar pore orientation and interconnections of the HA70/800.
b and d): At higher magnification the smooth microstructure of the HA60/400 (c) is clearly
different from the microporous structure of the HA70/800 (d).
Devitalized samples 
Tissue engineered constructs with living cells were devitalized by freezing in liquid
nitrogen.[59,282,298] The constructs were frozen for 5 minutes and then thawed in
saline. This was done twice, to increase the efficiency.[282] To demonstrate this
efficiency, we performed the following procedures after devitalization: Eight units
were morselized and cultured to detect adhering cells.[299] Another eight units were
cultured for one week to expand the potentially surviving cells, and then a 48h
alamarBlue™ (AB. Biosource, Camarillo, CA) assay was done to demonstrate
possible metabolic activity of cells.[284] Finally SEM of frozen and non-frozen
constructs was done to detect for intact cells and to investigate the appearance of
the ECM.
a
dc
b
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Animals and surgical procedure
Goats (19-26 months) were obtained from a professional stock-breeder, at least
four weeks prior to surgery. The surgical procedures were performed under general
inhalation anesthesia, preceded by intravenous detomidine sedation (Domosedan;
Pfizer, New York, NY). Thiopental 10mg/kg (Nesdonal; Rhone-Merieux, Athens,
GA) was introduced intravenously and anesthesia was maintained by a halothane
gas mixture (Sanofi; Paris, France). After shaving the lumbar area and disinfection
with iodine, 3cm skin incisions were made at the four implant locations. The muscle
fascia was exposed and cut. Using blunt dissection, an intramuscular pocket was
created which was filled with one of the four treatment units (autologous
implantations). Subsequently, the fascia was closed with a non-resorbable suture to
facilitate implant localization at explantation. The skin was closed in two layers.
During the postoperative period, pain relief was given by buprenofine (Temgesic;
Shering-Plough, Kenilworth, NJ). Fluorochromes (all from Sigma) were
administered intravenously: at 5 weeks, Alizarin Red (30mg/kg), at 7 weeks
Calceine green (10mg/kg) and at 9 weeks Xylenol orange (100mg/kg).[275,300] After
12 weeks, the animals were killed by an overdose of pentobarbital (Euthesate;
Organon, Oss, The Netherlands) and potassium chloride. Besides the
intramuscular implantations the goats were subjected to a femur defect
operation[301] that is not discussed in this article.
Post-mortem sample acquisition, histology and histomorphometry
At explantation, the units were localized, excised and then fixated in 1.5%
glutaraldehyde. The units were dehydrated by alcohol series and embedded in
polymethylmethacrylate. Semi-thin sections (10µm, made with a sawing
microtome[302]; Leica, Nussloch, Germany) stained with methylene blue and basic
fuchsin for routine histology and histomorphometry, or left unstained for
epifluorescence microscopy. As the units consisted of four separate granules,
several sections were made to provide sections through the center of each granule.
The sections were evaluated for general tissue response, bone formation and the
fluorochrome labels, using a fluorescence/light microscope (E600 Nikon, Tokyo
Japan) with a double filter block (dichroic mirror 505nm and 590nm). The mid-
section through the single granules was chosen for histomorphometry. The
percentage bone occupying available pore space within the two granules of one
scaffold type was measured using a VIDAS image analysis system (KS400, Zeiss,
Munich, Germany) coupled to a light microscope. First, the area of interest was
defined by outlining the specific granule. Pores that interrupted the exterior scaffold
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contour were crossed with straight lines. Next the pore area and the bone area were
identified and measured.
Figure 2 SEM micrographs of HA70/800 granules seeded with 107cells/cm3 material 
(HA60/400 constructs were comparable in appearance)
a): After seeding overnight, cells attached to the HA surface were distributed homogeneously
over the scaffold.
b): After culturing the constructs for another 6 days, a multilayer of cells within an ECM had
formed on the HA surface.
c): After culturing 6 days, SEM at low magnification showed the granules were fully covered
with ECM and cells. Only the contour of the peripheral pores remained.
d): After devitalizing the constructs, the ECM covering the HA surface remained visually
unaffected.
Statistics
Paired two-tailed student t-test were done to analyze differences in DNA contents
between the scaffold materials. The Wilcoxon signed rank test was used to analyze
the difference of bone formation between the two scaffold materials (significance
level, p=0.05).
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Results
In-vitro results (Scaffolds, TE-vital and TE-devitalized samples)
XRD and FTIR analyses were comparable for the two scaffold materials. No
additional phases or impurities were detected and both materials were comparable
to HA standards (Ca/P ratio of 1.67).[303] The bone marrow aspirates yielded
(1.65±0.4)x108 (mean±SD) nucleated cells that were plated with 5.8±1.6x105 cells
per cm2. After 11±2 days, colonies had formed. After the cells were replated, the
population doubling time was 24±2 hours. Cells were seeded on the scaffolds 21
days after the aspirate. Dynamic seeding resulted in an equal distribution of the
cells inside the scaffolds as shown by SEM (Fig. 2a). The average seeding
efficiency according to the CyQUANT® assay was about 60%, without a significant
difference between the two scaffold materials (Fig. 3). After the 6-day postseeding
culture period, the total DNA had doubled once on average, with significantly more
DNA in the HA60/400 scaffolds as compared with the HA70/800 scaffolds (p=0.02).
By then the scaffolds were fully covered with a multilayer of cells within an
extracellular matrix, as visible with SEM (Fig. 2b). Examination of the devitalized
units with the alamarBlue assay and by culturing the morselized granules did not
indicate any vitality. SEM imaging showed the granules were covered with ECM,
without the presence of intact cells in these constructs. 
Figure 3 DNA quantify of the HA70/800 and HA60/400 scaffolds seeded overnight with
4x105 cells/granule and after culturing the constructs for 6 days (n=8).
The seeding efficiency was approximately 60% and not significantly material dependent.
After 6 days, cell amounts had once doubled on average and the HA60/400 contained
significantly more DNA (p=0.02).
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In-vivo histology and histomorphometry
There were no surgical complications, however, two goats developed a painful hoof
disease for which they were terminated after 10 weeks instead of 12 weeks.
Autopsy and cultures of blood and tissue did not indicate a cause related to the
procedure. The data of these to goats was applied for qualitative analysis and for
paired comparisons within each animal.
At retrieval, all samples were surrounded by well vascularized muscle tissue.
Microscopy showed no signs of an inflammatory tissue response related to the
implants. The different appearance of the HA70/800 and HA60/400 was clearly
visible under the microscope as a result of the different microporosity (Fig. 4a). In all
of the TE-vital implantation units, ectopic bone was present distributed unevenly
throughout the granule close to the HA surface with a strong preference for the
interior. This was characterized both as woven bone and bone of lamellar
appearance, with osteocytes inside the matrix and osteoblast linings. In addition,
bone marrow was often present within small voids in the newly formed bone.
Occasionally, bone bridging between the separate granules was found (Fig. 4b).
Fluorescence microscopy of the newly formed bone showed the five weeks’ Alizarine
red label closest to the implant surface, while the 7 and 9 weeks labels were present
more distant from the surface, indicating centripetal bone formation (Fig. 4c).
Histomorphometry of the bone inside the pores revealed an average 13.2±15.9%
(±SD) for the HA70/800 scaffolds and 3.4±4.0% (±SD) for the HA60/400 scaffolds
(Table 1). Despite the high variation between goats, paired comparisons
demonstrated this difference to be significant (p=0.03). In none of the TE-devitalized
samples, neither the BM nor the control samples of both scaffold materials, was any
sign of bone formation detected. In these samples the pores were occupied with well
vascularized, fibrous tissue without signs of adverse tissue response. 
Table 1 Ectopic bone formation in goats
Incidence of bone formation and percentage of bone area (mean±SD) in the two scaffold
materials for each of the four treatment groups after twelve weeks implantation.
Group Bone formation HA70/800 HA60/400
Vital TE 8/8 13.2 (15.9) 3.4 (4.0)
Devitalized TE 0/8 - -
Bone marrow 0/8 - -
HA only 0/8 - -
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Figure 4 Histology of tissue engineered constructs implanted for 12 weeks (☞ p. 181)
a): Overview showing the distribution of bone on the HA surface of the granules implanted as
one unit. Both scaffold types can be distinguished (bar = 1mm).
b): Detail of bone (B) bridging between two granules of HA70/800. The triangles point at
osteoblast zones (bar = 100µm).
c): Fluorescent microscopy showing the fluorochromes in the bone that formed: Alizarin red
(given at 5 weeks) directly on the HA surface, Calcein green (7 weeks) in the middle and
Xylenol orange (9 weeks) on the pore side (bar = 50µm ).
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Discussion and Conclusions
In the present fundamental study, we clearly demonstrate that the presence of
living, culture expanded osteoprogenitor cells inside our porous calcium phosphate
scaffolds is a prerequisite for in-vivo ectopic bone formation in the goat. The
scaffolds alone or when combined with either devitalized ECM or undifferentiated/
non-expanded bone marrow were never successful with respect to bone formation
in the current setting. The potential synergistic influence of ECM with cells and the
differentiation state of the cells was studied separate and are reported
elsewhere.[233] On the basis of our own experience and on the scarcity of
comparative literature on the subject, bone tissue engineering appears to be much
more challenging in larger mammals. This might be due to impaired cell survival, as
the metabolic rate of these animals is lower and/or larger implants that are required.
This potential reason is supported by previous studies that report negligible cell
survival and delayed revascularization of bone grafts, after autotransplan-
tation.[43,169,173,180,290,304] To study if cell vitality is crucial for bone formation, we
compared our TE-vital implants with identical implants that were devitalized by a
freezing protocol. Other methods for devitalization such as lysing, gamma
irradiation or heating might be insufficient or interfere with the expected
osteoinduction.[42,73,220,285,286,305] According to literature, freezing has a minimal
effect on osteoinductivity.[48,292] We demonstrated by scanning electron microscopy
the presence of intact ECM on the scaffold surfaces after freezing, however, we
cannot completely rule out that freezing did not interfere with new bone formation in
another way. Oklund et al. postulated that freezing resulted in calciolysis of bone
grafts, thereby exposing the ECM and promoting matrix resorption.[181] In our study
this is not likely to be important, as the ECM is exposed at implantation of the TE
samples. Furthermore, the presence of the 5 week label in the newly formed bone
suggests an early osteogenic mechanism.[287] Therefore, our findings strongly
indicate that vitality is crucial for bone generation, and imply that cells do survive, at
least the first period after implantation in which they might secrete osteoinductive
factors or longer to finally form bone. It has not been proven yet whether the
implanted cells are indeed present in the bone that formed, this will be difficult as a
proper label for tracing these cells remains to be found.[306] The bone that formed
typically initiated at the HA surface and extended towards the center of the pores as
shown with the fluorochrome labels. This finding is in agreement with other reports
regarding osteoblast differentiation and bonding osteogenesis,[114,291] and
emphasizes the importance of an appropriate scaffold[68] allowing cell attachment,
proliferation and differentiation. The difference in bone formation we found between
the different scaffolds can not, however, be easily explained by these
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characteristics. FTIR and XRD did not indicate differences between the chemical
compositions of the bulk materials. The pore sizes were different but as a result of
different manufacturing techniques are difficult to compare. However, the pores
were interconnected in both materials and >100µm which is regarded as a minimal
size.[307] Furthermore, quantitative DNA analysis did not show differences in
seeding efficiency and in fact showed a DNA amount in favor of the HA60/400 after
the 6-day culture period. The most prominent difference between the scaffolds was
the microporosity, as shown in Fig. 1. As postulated by others, the larger surface
area might result in increased ion exchange and bone like apatite surface formation
by the dissolution and re-precipitation process. Furthermore, more proteins and
inducing factors could be adsorbed.[98] From that perspective, it should be noted
that the scaffold alone did not show any bone induction. As the scaffold type
appears to be of major importance, more specific material research is needed that
is beyond the scope of this article.
The addition of bone marrow to scaffolds in order to reach ectopic bone formation
has been the topic of many investigations in the past, with various levels of success.
A limited number of studies that demonstrated bone formation, applied high
amounts of bone marrow,[109,209,273] and it should be realized that the presence of
osteoprogenitor cells in fresh bone marrow is limited.[211] We attempted to mimic
the clinical situation where the amount of BM is limited by using only 1ml of BM per
40mm3 granule. That could explain why no bone formation occurred in our implants.
In agreement with earlier publications,[105,114,211] this finding emphasizes the value
of cell-expansion or at least the necessity for a larger number of precursor cells in
the scaffolds. 
It is concluded from the current investigation that consistent tissue engineered bone
formation in the goat can be achieved with vital constructs of an appropriate scaffold
and sufficient BMSC’s.
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Chapter 6
APPLICATION AND LIMITATIONS OF CM-DIL FOR TRACING CELLS 
IN BONE TISSUE ENGINEERING
Summary
Introduction: Despite extensive research on bone tissue engineering (TE), little is
known about the survival and function of the cells after implantation. To monitor the
cells in-vivo, labeling is the method of choice. In this study we investigated the use
of the fluorescent membrane marker Chloromethyl-benzamidodialkylcarbocyanine
(CM-Dil) to label cells used in bone tissue engineering. 
Methods: Different label protocols were evaluated and concentrations up to 50µM
appeared without negative effects on cell vitality, proliferation or bone forming
capacity. Porous hydroxyapatite scaffolds were seeded with labeled cells, and
traced up to 6 weeks after implantation in nude mice. To determine transfer of the
label in-vivo, devitalized, labeled constructs were implanted for different time
periods. The presence of vital labeled cells inside these constructs would indicate
transfer of the label. 
Results: Cells could be traced at all time points, also inside tissue engineered
bone. However, contrary to other reports concerning intramembranous labels,
transfer of the label from labeled to unlabeled cells was found. Transfer occurred
both in-vitro and in-vivo between vital cells and from dead to living cells. Transfer
was found at 7 days when 40µM label was applied while 10µM labeled constructs
showed transfer 10 days after implantation. 
Conclusion: The CM-Dil label is useful for in-vivo tracing of cells for follow-up
periods up to 10 days. This makes the label particularly useful for cell-survival
studies in tissue engineered implants.
Proefschrift_Moyo_Kruyt.book  Page 65  Wednesday, September 10, 2003  1:03 PM
Chapter 6
66
Introduction
Despite its drawbacks, autologous bone is the graft material of choice for many
orthopaedic and maxillofacial reconstructions. It is hypothesized that the superiority
of autologous bone is partially derived from the osteogenic potential from the cells
inside the graft. However, their role - if present - is controversial.[42,43] Some
authors report an almost total loss of cells in the autologous graft material after
implantation,[169] whereas others report substantial survival and function of these
cells.[174] There is no doubt, however, that inside large sized grafts the survival of
cells will be compromised, as the cells will be inside the harsh environment of a
heamatoma,[143] without vascularization during the first week after
implantation.[173,290]
Bone tissue engineering potentially provides us with an autologous bone substitute.
The concept studied most extensively is the combination of bone marrow derived
mesenchymal cells with a biocompatible porous scaffold. Since the early nineties,
many reports have been published on bone formation ectopically or in critical sized
defects, using this concept.[113,119,122,123,130,137] However, only a few reports
address the question whether the implanted cells survive and are functional.[120,144]
As for autologous bone transplants, cell survival is also questionable in tissue
engineered constructs of clinically relevant size. To address this question,
monitoring the cells in-vivo by labeling is the method of choice.
Elegant labeling methods that have been reported include the application of quail
cells which have a specific nucleolar marker, or the use of transgenic cells. Both
methods showed the donor origin of tissue engineered bone.[67,128] These
approaches, however, are limited to xenografts and allografts and cannot be used
for autologous cells. Recently, genetic markers have shown to be compatible with
the process of bone histology.[116,190] Genetic labeling though, requires special
facilities and precautions, and a substantial amount of cells is lost during the
procedure.[116] Another drawback is a possible immune reaction of the host towards
the viral products,[308,309] thus interfering with the intended feasibility of the graft. As
yet, the ideal label for labeling cells effectively, does not exist.
A promising alternative is the use of intramembranous fluorescent labels. This
technique has already been applied for tracing cells in soft tissues.[184,310-314] Once
incorporated within the membrane bilayer, the label becomes trapped due to its
water insolubility. At cell division it is distributed equally between daughter cells. A
drawback of this method could be the transfer of label to neighboring cells. For
application in soft tissue, several authors reported the absence of this transfer to
cocultured cells.[185,312]
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As compared to soft tissue, tracking cells with fluorescent membrane label in tissue
engineered bone introduces two problems: First, bone and the commonly used
calcium phosphate scaffold hydroxyapatite have a relatively high auto fluorescence,
which means the label has to be specific and intense to allow adequate
discrimination. Second, the label must be maintained during (un)decalcified
histology processing. Andrade et al. showed the CM-Dil label (chloromethyl-
dialkylcarbocyanine) is maintained within the cell membrane after dehydration for
paraffin embedding, therefore this label is potentially suitable for bone histology.[315]
Recently, Ferrari et al. introduced CM-Dil as a label for tracing cells in bone tissue
engineering. They did not find label transfer when labeled cells inside a scaffold
were cultured next to unlabeled fibroblasts for 10 days.[316] Unfortunately this study
did not investigate transfer from dead to living cells or label transfer in-vivo.
In our research on bone tissue engineering we chose to study CM-Dil as a label for
investigation of cell survival and differentiation. As we expected some of the
implanted cells to loose vitality and disintegrate after implantation, the transfer of
label both in-vitro and in-vivo from dead labeled cells to neighboring cells as well as
the transfer between living cells was examined thoroughly. The purpose of the
present study was to determine an optimal label protocol for bone marrow derived
goat cells. We defined optimal as the highest label intensity without noticeable effect
on cell vitality, proliferation and bone forming capacity. Furthermore we investigated
the limitations of the label with respect to label transfer to host cells in-vitro and in-
vivo. 
Materials and Methods
Design
Culture-expanded bone marrow cells were divided into 11 groups (one control, eight
groups that were treated with different labeling procedures and two groups that
were treated with high concentrations of DMSO). All groups were analyzed for cell
vitality, label intensity and label efficiency. Fluorescence activated cell sorting
(FACS) analysis of label maintenance was done for all groups at every passage.
Groups labeled with 10, 50 and 60µM CM-Dil and the controls were analyzed for
cell proliferation. Groups labeled with 10, 30, 40, 50 and 60µM CM-Dil and the
controls were seeded on porous hydroxyapatite (HA) scaffolds and implanted in
nude mice. The implants were evaluated at ten different time points to determine
survival and differentiation of the cells, and the maintenance of the label. To
investigate label transfer, cells labeled with 10 and 40µM CM-Dil were cocultured
with unlabeled cells. To assess in-vivo label transfer from dead to living cells,
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constructs of cells labeled with 10 and 40µM CM-Dil were devitalized before
implantation. Analysis of these implants was done after various periods to
determine when transfer occurred.
Harvesting of cells
Goat bone marrow cells were obtained from an iliac wing bone marrow aspirate.
The cells were cultured in a standard culture medium[106] supplemented with 1ng/ml
basic fibroblast growth factor (BFGF; Instruchemie, Hilversum, The Netherlands).
Cells were cryopreserved at the end of the first passage (p=1). Within 6 months, the
cryopreserved cells were thawed and replated. When confluent, the cells were
trypsinized and a trypan blue exclusion was performed to identify dead cells. The
cells were distributed over eleven 10ml tubes, each containing 10 million cells, and
centrifuged. The pellets were treated as indicated in Table 1.
Table 1 CM-Dil labeling procedure
Cells were labeled with various concentrations of CM-Dil (column 1) by the following
procedure: 50µg CM-Dil was diluted in different volumes of DMSO (column 2), these
solutions were diluted further in HBSS (column 3) and then added to cell pellets resuspended
in HBSS (column 4) to yield final DMSO (column 5) and CM-Dil (column 1) concentrations.
The incubation time was either 2 or 4 minutes at 37ºC plus 15 minutes on ice.
Group
Vol. of DMSO to 
solute 50µg 
CM-Dil
Vol. of CM-Dil 
solution per vol. 
HBSS
Vol. of HBSS to 
resuspended cell 
Pellet
% DMSO Incubation time
Control - - 1.0ml - 4+15
5µM 50µl 10µl/1.0ml 1.0ml 0.5% 4+15
10µM 50µl 10µl/0.5ml 0.5ml 1.0% 4+15
20µM 25µl 10µl/0.5ml 0.5ml 1.0% 4+15
30µM 25µl 15µl/0.5ml 0.5ml 1.5% 4+15
40µM 25µl 20µl/0.5ml 0.5ml 2.0% 4+15
40µM 25µl 20µl/0.5ml 0.5ml 2.0% 2+15
50µM 25µl 25µl/0.5ml 0.5ml 2.5% 2+15
60µM 25µl 30µl/0.5ml 0.5ml 3.0% 2+15
4% DMSO DMSO only 40µl/0.5ml 0.5ml 4.0% 2+15
6% DMSO DMSO only 60µl/0.5ml 0.5ml 6.0% 2+15
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Labeling procedure (Table1)
The pellets were resuspended in Hanks’ buffered salt solution (HBSS; Gibco,
Paisley, Scotland). Chloromethyl-benzamidodialkylcarbocyanine (CM-Dil, mol. wt.
1051.5; Molecular Probes, Eugene, US) was used as labeling agent. This long-
chain carbocyanine membrane probe has a peak excitation at 553nm and emits at
570nm. First, 50µg of CM-Dil was reconstituted in 25 or 50µl dimethylsulfoxide
(DMSO; Sigma, St. Louis, MO) to make a stock solution. Subsequently, the CM-Dil
stock solution was added in varying amounts to 0.5 or 1ml HBSS and immediately
combined with the cell suspension. This final suspension was pipetted thoroughly to
obtain equal mixing and incubated in a 37ºC water bath. We used incubation times
of 2 minutes for label concentrations above 40µM and 4 minutes for lower
concentrations, which we determined did not effect cell vitality negatively. However,
during this study we found that labeling for 4 minutes negatively influenced cell
proliferation, therefore later experiments used a maximum incubation time of 3
minutes. The cells were then incubated for another 15 minutes on ice. According to
the manufacturer, incubating at this lower temperature allows the dye to label the
membrane, but slows down endocytosis. After incubation, the reaction was stopped
by adding 9ml of phosphate buffered saline (PBS, Gibco), and the cells were
washed and centrifuged. After centrifugation, the cells were counted and a trypan
blue exclusion was done. To study the effect of DMSO only on cell vitality, 2x10
million cells were incubated with high concentrations of DMSO. 
Label efficiency and maintenance
All groups were analyzed by FACS (FACScalibur; Becton & Dickinson, San Jose
CA). Fluorescent intensity was analyzed on 10.000 gated events of every group in
the Fl2 channel (585±21nm). The cells with an intensity higher than 97.5% of
control cells were considered to be labeled. The mean fluorescent intensity and the
percentage of these labeled cells were registered. All groups were kept in culture
and were plated on chamber slides at every new passage (Nalge Nunc, Naperville,
IL.) for analysis with an epifluorescence microscope (E600, Nikon, Tokyo, Japan)
using the TRITC filter set (excitation 540nm dichroic mirror 565nm). To study the in-
vivo implants we made use of a double filter block (dichroic mirror 505nm and
590nm) to allow good discrimination between labeled and unlabeled cells.
Micrographs were taken with a digital camera system.
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Cell proliferation
To monitor cell proliferation of the control, 10, 50 and 60µM labeled groups, each
group was plated in two six-well plates. At 3 and 5 days, the cells were counted
(n=6). The cells obtained after 5 days were again plated in three six-well plates and
counted after another 3, 5 and 6 days. Cells were counted twice in duplicate with a
Coulter® counter Z2 (Coulter, Miami FL). The proliferation was expressed as the
amount of population doublings [2Log(increase)]. 
In-vitro label transfer
From the cells labeled with 10µM for 3 minutes and 40µM for 2 minutes, 6 aliquots
of 100.000 cells were frozen in liquid nitrogen and thawed in PBS at room
temperature.[59,282] This was done twice, to effectively devitalize the cells. Another
6 aliquots of each label concentration were frozen and then lysed in demineralized
water to obtain the actual label content of these cells in suspension. A final group of
six aliquots from each label concentration was left untreated. Three of the untreated
(vital) aliquots were cultured single, the remaining three were mixed with an equal
amount of vital unlabeled cells and cocultured to determine transfer between vital
cells. The frozen and the lysed aliquots were also mixed with unlabeled cells, to
determine label transfer from devitalized to vital cells. At 4 days, cultures were
replated. All cultures were analyzed at 1, 2, 4, 7, 8 and 11 days by FACS analysis
after washing the cells. To assess the percentage of labeled cells, at each time
point, we defined regions for labeled and unlabeled cells in the dot plot of the
unlabeled cells that were applied to the other dot plots. As labeled cells were mixed
with an equal amount of unlabeled cells, the expected percentage of labeled cells in
the cocultures was half the percentage found in the labeled cultures at the same
time point. Higher than expected percentages indicated transfer of the label to
unlabeled cells. When labeled cells were detected in the cocultures of vital
unlabeled and devitalized labeled cells, transfer was assumed. These cells were
then plated in chambers slides for evaluation by fluorescent microscopy. To ensure
the efficiency of devitalization, the remaining frozen and lysed aliquots were
cultured for two weeks and checked for vital adhering cells. 
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In-vivo traceability
We selected the control, 10, 30, 40, 50 and the 60µM groups as representatives for
in-vivo tracing. Per group, one million cells were dynamically seeded on ten
hydroxyapatite granules of 3x3x4mm with a 70% interconnected porosity. (HA; CAM
Implants, Leiden, The Netherlands). The constructs were cultured for one week in
medium containing 10-8M dexamethasone and 0,5mg/ml β−glycerophosphate (both
from Sigma) to promote osteogenic differentiation.[106] The granules were implanted
subcutaneously in nude mice (per mouse one granule of each group), and
explanted after 2, 3, 4, 5, 7, 10 days and 2, 3, 4 and 6 weeks. Another five granules
were implanted for decalcified histology at 10 days. All samples were fixated in
1.5% buffered glutaraldehyde and dehydrated in alcohol. For the undecalcified
procedure samples were embedded in methyl-metacrylate (MMA; Merck,
Darmstadt, Germany) and sectioned (10µm with a sawing microtome; Leica,
Nussloch, Germany). After epifluorescence microscopy, the sections were
counterstained with methylene blue and basic fuchsin for routine light microscopy.
For decalcified histology the samples were decalcified in a 10% EDTA solution,
embedded in glycol methacrylate (GMA; Merck) and sectioned at 10µm on a
standard microtome. 
In-vivo label transfer
Constructs of cells labeled with 10 and 40µM were devitalized by freezing in liquid
nitrogen. To evaluate the devitalization, three frozen constructs of each condition
were morselized and cultured for 30 days to determine the appearance of adhering
cells (when vital constructs were cultured this way, adhering cells appeared within 7
days). Devitalized samples were implanted in duplo into six nude mice. As a control,
vital labeled constructs were implanted in the same mice. At 3, 5, 7 and 10 days,
and at 2 and 4 weeks, the samples were explanted and analyzed as described
before. When labeled vital cells (as judged by morphology) were detected in the
devitalized samples, label transfer was assumed.
Statistics
Statistical calculations were done with the SPSS 9.0 software package. The type 1
error was set at 5%. Cell count data per group at different time points were analyzed
by multiple factor analysis of variance (ANOVA). In case of significant interaction
between time and group, multiple comparisons per time-point were done using
Bonferroni-corrected t-tests.
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Results
Labeling procedure (Table 2). 
Before labeling, 11% of the cells obtained after trypsinization were indicated non-
viable by the trypan blue exclusion method. After labeling this was on average 9%,
without large differences between the groups. This indicated that cell vitality was not
influenced by the procedure itself, the concentration of CM-Dil, or higher
concentrations of DMSO (Table 2). Cell counting after the whole procedure revealed
that 20±6% of the cells was lost in all groups; no relation with label intensity was
found. FACS analysis after labeling and at each cell passage indicated the
difference in intensity and efficiency. This was visualized with epifluorescent
microscopy of the plated cells (Fig. 1).
Table 2 Analysis label maintenance and cell growth results
1 Cell mortality is expressed as the percent difference of dead cells before and after the
procedure as measured by trypan blue exclusion. 
2 Percentage of cells lost is calculated on the basis of cell count data taken before and after
the procedure. 
3 Proliferation is expressed as the number of population doublings = 2Log(increase) in 11
days. 
*Cells labeled with 60µM had proliferated significantly less as shown in Fig. 2. 
Group Cell
Mort.1
Cells
Lost2
Results of FACS analysis on CM-Dil labeled cells
percentage labeled and mean intensity
Proliferation3
t=0 t=1 t=3 t=4
Labeled Mean Labeled Mean Labeled Mean Labeled Mean
Control -1.5% 28% 2.5% 11 2.5% 12 2.5% 19 2.5% 30 8.4
5µM 0.4% 18% 65% 53 61% 58 14% 34 1.1% 43
10µM -4.9% 13% 62% 55 57% 54 9% 33 3.2% 41
20µM -3.1% 11% 80% 87 84% 133 30% 58 2.6% 52 8.7
30µM 2.4% 14% 75% 60 76% 92 19% 40 1.8% 60
40µM (2min) -1.3% 27% 62% 64 70% 92 19% 45 2.3% 43
40µM (4min) -4.2% 21% 84% 162 81% 132 27% 66 4.0% 56
50µm -1.3% 27% 84% 213 87% 151 28% 65 2.1% 49 8.6
60µM -2.5% 22% 88% 329 90% 171 37% 83 3.1% 60 7.1*
DMSO 4% -3.8%
DMSO 6% -4.0%
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Label maintenance (Table 2)
FACS analysis after the first trypsinization showed no loss of label intensity. At the
second trypsinization, after more than seven population doublings, the label
intensity had decreased. At the third trypsinization only few labeled cells were
detected. The population had by then doubled about 10 times. In the chamber
slides individual cells could be detected by fluorescent microscopy even after 10
population doublings. Cells that we identified as labeled had typically many
fluorescent spots. According to the manufacturer, the label spontaneously
aggregates at concentrations above 5µM, which could explain this phenomenon.
No fading of the label was seen when exposed to the excitation light of the
fluorescence microscope. 
Figure 1 Epifluorescent images of cells labeled with varying concentrations of CM-Dil
Higher label concentrations resulted in higher intensities and efficiencies of the label. All
micrographs were taken after 5 days culture on microslides at the same magnification (200x).
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30PM 60PM
10PM
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Proliferation (Fig. 2)
Statistical analysis of the six-well counts showed a weak, though significant
interaction between group and time (data not shown). Therefore, multiple
comparisons were done to examine all relevant group and time combinations.
Analysis indicated a significantly lower rate of proliferation at all time points of the
cells labeled with 60µM, compared with the control. The group labeled with 50µM
was never significantly different from the control group. Cells labeled with 10µM
(incubated for 4 minutes) had proliferated significantly less than the control group at
10 days.
Figure 2 Cell proliferation 
Expressed as the amount of population doublings (2Log increase) ± SD, n=6 for each time
point. At all time points the 60µM group had proliferated significantly less than the control
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In-vitro label transfer (Figs. 3 and 4)
Devitalization was efficient as no vital, adherent cells were detected in the control
cultures. Fig. 3 shows the combined histograms of the unlabeled cells, the labeled
cells and the coculture of unlabeled cells with devitalized 10µM labeled cells at 2
and 4 days. The fluorescence intensity in the coculture was progressively higher
than the control group. At 2 and 4 days, 20% and 43% of these cells, respectively,
had label intensities higher than 97.5% of the control cells. These findings indicate
transfer of the label between dead and vital cells. When the devitalized cells were
labeled with 40µM CM-Dil, the amount of transfer was higher, 47% and 79%
respectively (data not shown). The method of devitalizing by itself (freeze thaw
freeze or lysing) did not appear to influence the amount of transfer. Transfer of the
label was confirmed by fluorescence microscopy of the cells when cultured on
chamber slides.
Fig. 4 shows the result of region-statistics on the FACS dot plots. Vital cells labeled
with 10µM CM-Dil did not show any transfer to the unlabeled cells during the 11-day
period during which they could be detected. In the coculture with 40µM labeled vital
cells, the percentage of labeled cells exceeded the expected percentage, indicating
transfer of the label. However, the percentage of false positive cells [(actual-
expected)/actual x 100%)] did not increase between 1 and 8 days. This suggests
transfer had mainly occurred after plating the cells and before analysis on day 1.
Figure 3 Combined histograms of FACS results from the in-vitro transfer experiment 
a) After two days of coculturing with devitalized 10mm labeled cells, 20% of the initially
unlabelled cells had label intensities higher than 97.5% of the control (within M1).
b) After 4 days this percentage had increased to 43% indicating progressive label transfer.
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Figure 4 Percentages of labeled cells at different time points
Assessed by statistical analysis of regions of FACS dot plots. Data are from labeled cell
cultures and 50/50 cocultures of labeled and unlabeled cells.
a) 10µM label concentration. Expected values were calculated from data of labeled cells.
Coculture percentages were in agreement with expected values, indicating no transfer.
b) 40µM label concentration. Coculture percentages exceeded expected values, indicating
transfer of label. The relationship between actual (coculture) and expected values, indicated
by the false positive line, did not change during the first 8 days indicating that no additional
label transfer occurred in this time period.
In-vivo label transfer
During the first 5 days after implantation, no label transfer from the dead labeled
cells to host cells could be determined. At 7 days, labeled fibroblastic cells could be
detected in the 40µM devitalized implants, indicating label transfer. This was not
found for the implants that contained 10µM devitalized cells. However, by 10 days,
the 10µM devitalized implants also contained occasionally labeled fibroblastic cells.
After two weeks label had almost disappeared from the 10µM samples, by then, in
vital and devitalized 40µM samples fluorescent cells could be found in equal
numbers (Fig. 5e). This was also seen at 4 weeks.
Histology (Figs. 5a-d)
Fluorescence microscopy of the samples implanted for 2 days showed invasive
host tissue on the periphery of the scaffold that could be distinguished from the
labeled cells (Fig. 5a). At 3 days, the first small blood vessels had invaded in the
periphery of the implants. By 4 days, blood vessels were visible throughout the
scaffolds adjacent to vital labeled cells (Fig. 5b). After 10 days, the pores were filled
with loose connective tissue containing abundant blood vessels. Cells within this
reticular tissue were labeled, however, their origin remains uncertain. On the
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periphery of all scaffolds (five of five), osteoid formation could be identified with light
microscopy. After 2 weeks bone was present at the periphery of all scaffolds. After
three weeks bone was present mainly inside the scaffolds (five of five). In some
pores, cartilage was found. Counterstaining of the slides, demonstrated the double-
filter fluorescent image corresponded well with normal histology (Figs. 5c and d).
The four and six weeks’ samples demonstrated lamellar bone in all vital samples
(24 of 24), occasionally containing bone marrow. Inside the bone, labeled
osteocytes were visible (Fig. 5f). Histological evaluation of decalcified samples after
10 days implantation, showed labeled cells, though less bright and in lower
frequency. 
Proefschrift_Moyo_Kruyt.book  Page 77  Wednesday, September 10, 2003  1:03 PM
Chapter 6
78
Figure 5 Micrographs of samples after various implantation periods (☞ p. 182)
a) 2 days after implantation: Invading host tissue (HT) next to 40µM labeled cells on the HA
surface (original magn. x200).
b) 4 days after implantation: 40µM Labeled cells were found next to small bloodvessels (V)
within the fibrin network inside the pores (original magn. x100).
c) 3 weeks after implantation: New bone formation was visible (B) and appeared as light
green, more mature bone appeared brown when compared with (d) (original magn. x100).
d) sample shown in (c), counterstained with methylene blue and basic fuchsin. 
e) 2 weeks after implantation sample with devitalized 40µM labeled cells: labeled fibroblastic
cells were abundant indicating label transfer by this time  (original magn. x200).
f) 6 weeks after implantation: 50µM labeled cells within the newly formed bone (green) were
clearly visible. (original magn. x400).
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Discussion and Conclusions
In the present study, we evaluated a method for labeling and subsequently,
histological identification of cells used for bone tissue engineering. The labeling
procedure took approximately 30 minutes, cell loss was approximately 20%, and no
effect on cell vitality was observed. With label concentrations above 20µM, more
than 75% of cells maintained the label for at least 4 population doublings. In-vivo,
the label could be traced with undecalcified histology at all follow-up periods.
Labeled cells were detectable in the newly formed bone and surrounding fibrous
tissue. No effect on bone forming capacity was observed. According to these
findings, labeling with 50µM for 2 minutes, could be considered optimal. However,
the in-vitro transfer experiments demonstrated label transfer between vital cells
when the label concentration was increased from 10µM to 40µM. Furthermore, we
found label uptake when cells were cocultured with devitalized cells labeled with
both 10 and 40µM CM-Dil. These findings are in contrast to reports where no
transfer was found.[184,312,316] Ferrari et al. did not detect label transfer from cells
labeled with 20µM CM-Dil. They mention, however, that they could not rule out label
transfer from dead labeled cells or via direct membrane contact, as we found in our
study. Although transfer between vital cells might be controlled, since this occurred
only within the first day after coculturing with unlabeled cells (Fig. 4) and only with
high label concentrations, the transfer from dead cells cannot. In tissue engineered
constructs, where cell death and subsequent release of the label can be expected,
the question apparently is not whether transfer occurs, but rather when this occurs.
To determine when the label transfer from dead cells became visible, we analyzed
samples after different implantation periods. We found label transfer after 7 days in
the samples labeled with 40µM, and after 10 days in those labeled with 10µM CM-
Dil. These findings imply that the label is applicable for discrimination between
implanted and host cells only during the first week after implantation. Therefore, a
satisfactory method for tracking cells for longer periods to determine autologous cell
differentiation and survival in large immunocompetend animals still must be found. 
From the current investigation it can be concluded that fluorescent labeling with
CM-Dil has many advantages and is compatible with bone histology. At
concentrations that should be defined for specific cells populations, the CM-Dil label
is stable in vital cells and useful for tracing these cells. However, transfer does occur
from dead labeled cells to host cells at all concentrations. In-vivo this was found one
week after implantation of dead labeled cells. Therefore, studies for cell survival
using the CM-Dil label are only considered feasible during the first days after
implantation.
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Chapter 7
GENETIC MARKING WITH THE ∆LNGFR-GENE FOR TRACING 
GOAT CELLS IN BONE TISSUE ENGINEERING
Summary
Introduction: Little is known about the survival and differentiation of cells used for
bone tissue engineering (TE). The aim of this study was to develop a method to
trace goat BMSC’s in-vivo by retroviral genetic marking. 
Methods: Goat BMSC’s were subjected to an amphotropic envelope containing a
MoMuLV-based vector expressing the human low affinity nerve growth factor
receptor (∆LNGFR). Labeling efficiency and effect on the cells were analyzed.
Furthermore, transduced cells were seeded onto porous ceramic scaffolds,
implanted subcutaneously in nude mice and examined after successive
implantation periods.
Results: Flow cytometry indicated a transduction efficiency of 40-60%.
Immunohistochemistry showed survival and subsequent bone formation of the gene
marked cells in-vivo. Besides, marked cells were also found in cartilage and fibrous
tissue. These findings indicate the maintenance of the precursor phenotype
following gene transfer as well as the ability of the gene to be expressed following
differentiation.
Conclusion: Retroviral gene marking with ∆LNGFR is applicable to trace goat
BMSC’s in bone tissue engineering research.
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Introduction
Tissue engineering (TE) by combining specific cells with an appropriate scaffold has
gained much attention during the last decades. The proof of the concept has been
shown for many tissues types.[1] Especially the mesenchymal lineage has been
investigated extensively, since the identification of putative stem cells in the adult
bone marrow.[63,75,79] These Bone Marrow Stromal Cells (BMSC’s) can be cultured
and directed towards several lineages of differentiation[7,63,79,317] e.g. bone,[123,131]
cartilage,[79,188] and tendon.[318] Furthermore, these cells have been investigated
as a delivery vehicle for gene therapy.[116,198,319] The application of BMSC’s in
tissue engineering of bone has progressed fast and some investigators already
made the step towards clinical application.[320,321]
However, with regard to the clinical application of bone TE, there are two important
gaps in the current knowledge of cell performance. First, the differentiation of
BMSC’s cannot be predicted, because they constitute a heterogeneous
population.[7,79,317] At second, little is known about cell survival. Although survival
was shown convincingly in implants of the mm3-volume range in
rodents,[67,75,116,128] this will be compromised in the clinical situation, due to the
dramatically increased volume (several cm3), and delayed vascularization.[322]
To investigate these two issues, monitoring of BMSC’s in an established “large
animal” model for bone TE is the method of choice. Recently, we developed such a
model for ectopic bone TE in the goat.[131,278] Together with a more challenging,
critical sized defect model in the same animal,[36] this gives the opportunity to
extensively evaluate both differentiation and survival of the BMSC’s.
To trace cells efficiently, a variety of labeling methods has been developed. The use
of fluorescent membrane markers is relatively simple,[121,184,188] but inherent to
dilution with cell division and the risk of label transfer to neighboring cells.[121] More
reliable methods are the use of transgenic cells,[128] x-y mismatches[75] or
xenogenic transplantation.[67] These approaches however, are not compatible with
autologous transplantation. Recently, genetic marking has become a standard tool
and it was shown to be compatible with bone histology.[116,191-193,323] Although an
immune response cannot be excluded, this approach seems to be most
optimal.[193,323]
To trace cells after long implantation periods in large bone samples, the label must
be compatible with histologic procedures, such as dehydration and decalcification,
and not depend on the diffusion of a substrate into the sample for enzymatic
conversion. Therefore, a retroviral label (which integrates stable in the cell genome)
that can be traced with routine immunohistochemistry is most appropriate. The
truncated human nerve growth factor receptor (∆NGFR) has been applied
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successfully for tracing many cell types with both flow cytometry and
immunohistochemistry.[323-326] The purpose of the present study was to develop a
method to retrovirally label goat BMSC’s with the NGFR label without noticeable
effect on cell viability and bone forming capacity. Furthermore, the process of tissue
engineered bone formation by implanted goat BMSC’s in the ectopic nude mice
model was investigated.
Materials and Methods
Study design
A key consideration in retroviral transduction is the choice of the viral surface
envelope - pseudotype -, which determines the vector tropism. In a first experiment
we therefore compared Amphotropic, GALV, RD114 and VSV-G vector
pseudotyped virus, expressing the EGFP gene for the transduction efficiency of
goat BMSC’s, and selected the best for further studies with the NGFR marker gene.
The transduction efficiency, i.e. the percentage of NGFR positive goat BMSC’s was
determined using flow cytometry. Long-term stability of NGFR expression in-vitro
was determined by weekly analysis for up to 6 weeks. In addition, a population of
transduced cells was co-cultured with mock-transduced cells to determine relative
differences in cell proliferation. 
To analyze in-vivo traceability, transduced and mock-transduced cells were seeded
on porous ceramic scaffolds and implanted subcutaneously in nude mice. The
implants were evaluated at different time points.
Cell cultures
Cryopreserved goat BMSC’s that had shown to be osteogenic in a previous
study[131] were thawed and replated in culture medium containing 30% Fetal Bovine
Serum (FBS, Gibco, Paisly, Scotland, lot# 3030960S).[131] When confluent, the cells
were detached and replated at 5000 cells/cm2 in standard culture medium
containing 15% FBS.
Phoenix-ampho retrovirus packaging cells were cultured in DMEM (Gibco),
supplemented with 10% FBS, penicillin (100U/ml) streptomycin (100µg/ml) and 2
mM L-glutamine (Gibco). Cultures were passaged twice a week and selected for
gag, pol, env expression every 8 weeks using Hygromycin B (300µg/ml) (Roche
Diagnostics, Mannheim Germany) and Diphtheria Toxin A (1µg/ml) (Sigma-Aldrich,
Zwijndrecht, The Netherlands).
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Construction and packaging of retroviral vector containing NGFR
The construction of the retroviral vector, pLZRS-TK, (Fig. 1) has been described
previously.[325] The ∆LNGFR marker gene is under the control of Simian Virus 40
early promoter (SV40), flanked by the Moloney Murine Leukaemia Virus (MoMuLV)
long-terminal repeats. All experiments for evaluation of the NGFR label were done
with amphotropic pseudotyped viral particles, generated in Phoenix-Ampho
packaging cell line as follows: 20µg DNA of a retroviral plasmid construct was
transfected into Phoenix-Ampho packaging cells that had grown to 70% confluence
by using calcium phosphate precipitation.[327] Twenty-four hours after transfection,
medium was replaced with fresh culture medium. The following day, retroviral
supernatant was collected, filtered through a 0.45µm filter and stored at –80ºC. For
an additional harvest of retroviral supernatant, transfected Phoenix-ampho cells
were cultured for 3 days in the presence of puromycin (1µg/ml, Sigma) followed by
2 days in culture medium without puromycin.
Selection of vector pseudotype 
To select an optimal vector pseudotype, we used the pSFFV-EGFP- vector created
and characterized by Baum et al,[328] containing the Enhanced Green Fluorescent
Protein (EGFP) under the control of a hybrid promoter of Spleen Focus Forming
virus and Stem Cell Virus. EGFP was chosen as the transgene because of the ease
of detection and quantification of expression by flow cytometry. Two goat BMSC
batches were transduced with vectors from four different retrovirus producing cell
lines (see also Fig. 2): 1) The Phoenix-Ampho packaging cell line expressed the
amphotropic envelope;[327] 2) The PG 13 packaging cell line expressed the Gibbon-
Ape Leukemia Virus envelope (GALV);[329] 3) The 293 GPG expressed the
vesicular stomatitis virus G envelope (VSVG)[196] and 4) The FLYRD18 packaging
cell line expressed the Feline Endogenous Virus envelope (RD114).[330] Viral
supernatant containing the different pseudotyped vector particles was generated
according to standard procedures. The viral titers were determined on 293T cells,
calculated from the linear part of the curve in which the percentage of fluorescent
cells (transduction efficiency) was plotted against the dilution of supernatant. The
viral titer was adjusted to 1.0x105 Transduction Units (TU) per ml.
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Fig. 1 The  retroviral construct
The retroviral vector LZRS-TK as described by Weijtens et al.[325] contains the HSV-tk
suicide gene under the transcriptional control of the 5’LTR and the truncated nerve growth
factor receptor gene (∆LNGFR) under the control of the SV40 early promotor that is
constitutively switched on. The puromycin resistance gene which is driven by the PGK-1
promoter is present in the nonretroviral portions of the plasmid to allow selection of packaging
cells.
Retroviral transduction of goat BMSC’s 
For comparative goat BMSC transduction studies, the BMSC’s were plated in six-
well plates (Nalge Nunc, Roskilde, Denmark) at 105 cells per well the day before
transduction. Transduction was performed by replacing the standard culture
medium with a 3-fold dilution of the retroviral supernatant in culture medium
supplemented with 6µg/ml polybrene (Sigma). Culture medium supplemented with
polybrene was used for mock-transductions. The plates were cultured for another
24 hours, after which the medium was refreshed. Two days later the cells were
harvested and analyzed.
 
Flow cytometry
After transduction, aliquots of cells were withheld for flow cytometry to determine
the transduction efficiency. The cells were labeled with primary mouse αNGFR
monoclonal antibody (20.4 culture supernatant) for 20 minutes at 4ºC, washed and
then incubated with goat anti-mouse Phycoerythrine (PE) conjugated IgG1
(Southern Biotechnologies, Birmingham, US). Cells were washed in PBS-1%FBS
and resuspended in standard culture medium, immediately before analysis of
10.000 events on a flow cytometer (FACS Calibur, Becton and Dickinson, San Jose,
US). 
5’LTR HSV-TK 3’LTRSV40e 'NGFR
Puromycin 
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Immunomagnetic purification of the NGFR positive BMSC’s
The presence of NGFR on the cell surface allows in-vitro selection of transduced
cells by the use of immunomagnetic microbeads. Transduced goat BMSC’s were
incubated with diluted αNGFR Mab 20.4 (20µl/1x106 cells) and subsequently
incubated with goat anti-mouse IgG microbeads (20 µl/107 cells) for 10 minutes at
4ºC. Then, cells were washed and separated using a miniMACS separation column
according to the manufacturers protocol (Miltenyi Biotec, Bergisch Gladbach,
Germany).
Long-term evaluation and co-culture assay
To investigate long-term label expression, two populations of transduced cells were
plated in 25cm2 flasks, cultured for six weeks and analyzed by FACS at each
passage. Mock-transduced populations were analyzed parallel. To determine a
potential difference in proliferation between transduced and mock-transduced cells,
a 50/50% mixture was also investigated.
In-vivo traceability of gene-marked BMSC’s 
Tissue engineered constructs with transduced (n=14) and mock-transduced (n=14)
cells were prepared as described before.[121] Briefly, 105 cells were seeded on
50%-porous, 4x4x3mm ceramic scaffolds (OsSaturaBCP, IsoTis, Bilthoven, The
Netherlands). The hybrid constructs were cultured for one week before implantation
in separate subcutaneous pockets on the back of fourteen NMRI nude mice[121]
(two mice per evaluation period). Additional constructs with transduced cells (n=7)
were devitalized by freezing in liquid nitrogen before implantation, (one mouse per
evaluation period) to investigate the specificity of the label for viable cells.[121] The
implants were retrieved after 2, 4, 7 and 10 days, and 2, 4 and 6 weeks. All animal
experiments were according to the regulations of the local committee for animal
research.
Immunohistochemistry 
Samples were fixated in a 4% formaldehyde solution and decalcified for 1-2 days in
50% formic acid. Dehydration to allow paraffin embedding, was performed by
graded alcohol series. The decalcification procedure was based on series of
experiments with increasing concentrations of formic acid or EDTA (data not
shown). Sections of 5µm were dewaxed, rehydrated and endogenous peroxidase
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activity was blocked with 1.5% H202 in phosphate-citrate buffer. To prevent
nonspecific staining due to reactivity of the secondary anti-mouse IgG antibodies
with the surrounding murine tissue, the DAKO ARK kit was applied according to
manufacturers’ recommendations (DAKO Corporation, Carpinteria, USA). For
counterstaining we used hematoxylin and Giemsa (Merck, Darmstadt, Germany)
which specifically colors the bone bright pink.[331] Samples were analyzed with light
microscopy (E600 Nikon eclipse, Japan).
Results
Selection of vector envelope (Fig. 2)
Fluorescence microscopy showed effective EGFP transduction of both goat BMSC
batches with all vector pseudotypes. Although these different pseudotyped viruses
were used at identical MOI’s, transduction with retroviral particles derived from the
Phoenix-Ampho packaging cell line resulted in the highest transduction efficiency
i.e. nearly eighty percent when using a 3-fold dilution of the virus. While the GALV
and VSV-G pseudotyped viral vectors gave only slightly lower values, the efficiency
with RD114 was substantially lower. Because of the ample experience with the
Phoenix-Ampho system and the intention to transduce human BMSC’s in future
studies, the Phoenix-Ampho line was chosen for further experiments. 
Figure 2 Selection of optimal envelope pseudotype
The transduction efficiency of the four different envelope pseudotypes as a function of the
dilution of viral supernatant. With a three fold diluted supernatant about 80% of the goat
BMSC's was transduced successful with the EGFP gene packaged with the amphotrope
packaging cell line.
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In-vitro analysis of transduced goat BMSC’s (Fig. 3) 
A single round of transduction of various batches of goat BMSC’s with a 3-fold
dilution of retroviral supernatant expressing NGFR, resulted in 40-60% transduction
efficiency. In subsequent weeks, this percentage dropped to 30-40%. The long-term
culture experiment also showed this decrease during the first period after the
transduction, but thereafter stabilized around 35% for up to 6 weeks. The co-culture
experiment showed the percentage of labeled cells to be less than expected the first
week after transduction, indicating a relative decreased proliferation compared to
the non transduced cell fraction. During the subsequent weeks, the percent NGFR+
cells in the co-culture reached the expected percentage, indicating a minimal
influence on cell proliferation at the long term. A single round of sorting with
immunobeads yielded a stable 70-80% NGFR positive cells that were cultured for 4
weeks (Fig. 3). 
Figure 3 Long term label expression
The transduction efficiency of this batch of BMSC's was 50% (squares). After an initial
decrease and moderate increase, the percentage stabilizes around 35% for up to 6 weeks.
The interrupted line (circles) shows the expected percentage labeled cells in the 50/50%
mixture. The actual percentage labeled cells in the co-culture (triangles) showed to be initially
lower, but finally close matched the expected percentage. One week after MACS sorting
(X-X), the population remained 70-80% positive for four weeks.
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Analysis of the retrieved in-vivo samples (Fig. 4) 
All mice survived the planned implantation periods and all samples were retrieved
without signs of infection. Immunistochemistry did not show aspecific binding of the
20.4 antibody (control samples with mock-tranduced cells and secondary antibody
stainings were always negative). Analysis of devitalized constructs indicated some
residual NGFR label, not associated with viable cells, up to 4 days after
transplantation.
The samples implanted for 2 days showed NGFR positive cells on the scaffold that
could be well distinguished from surrounding host tissue (Fig. 4a). At 4 and 7 days,
small blood vessels were visible inside the scaffolds, NGFR positive cells were
distributed evenly throughout the pores without a preference for the ceramic
surface. Ten days after implantation, condensations of fibroblast-like cells on the
scaffold surface appeared partially consisting of gene marked cells (Fig. 4b). By
then, the samples were well vascularized (Fig. 4c). Comparable observations were
made for the two weeks implanted samples. After four weeks, bone that harbored
labeled cells was present inside all scaffolds that contained transduced cells. In
some pores, also cartilage that contained NGFR positive cells was found (Fig.
4d,e). Six weeks’ samples demonstrated lamellar bone in all vital samples. Besides
inside the bone, labeled cells were also found within the osteoblast zones (Fig. 4f).
No difference in bone forming capacity was observed between transduced and
mock-transduced cell constructs (all samples gave bone).
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Figure 4
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Figure 4 Samples of in-vivo hybrid constructs with NGFR labeled cells (☞ p. 183)
4a): Low magnification immunohistochemistry of 2 days implanted sample. The pores
surrounded by the ghost of the scaffold (S) were filled with brown (labeled) goat BMSC's,
distinctive from the surrounding host tissue (HT). 
4b) High magnification immunohistochemistry of 10 days implanted sample. Condensations
of fibroblast-like cells on the scaffold surface were found including labeled cells.
4c): Macroscopic image of sample in-situ at 10 days. Considerable neo vascularization of the
hybrid construct was seen.
4d): Low magnification immunohistochemistry of 4 weeks implanted sample. New bone was
lining the scaffold ghost. Many osteocyte lacunae were labeled (arrows).
4e): High magnification immunohistochemistry of 4 weeks implanted sample. Inside cartilage
that occasionally formed, labeled cells were present (arrow).
4f): High magnification immunohistochemistry of 6 weeks implanted sample. Labeled cells
were present within the osteoblast zone (arrow). 
Discussion and Conclusions
The aim of the present study was to retrovirally label goat BMSC’s, and apply these
for experimentation in bone tissue engineering. We found that 40-60% of the cells
were labeled with the NGFR marker gene by means of a relatively simple retroviral
transduction protocol, after a single round of transduction. When using retroviruses,
the transduction is confined to replicating cells, and therefore a 100% transduction
efficiency, was not expected.[197] In a large study, Mosca et al. investigated optimal
parameters required to transduce BMSC’s from eight different species, including the
goat.[319] For goat BMSC’s they reported a relatively low transduction efficiency with
the amphotropic receptor binding envelope (<10%) compared to 50% when using
their xenotropic (ProPak-X) packaging cell line. In our study the amphotropic
envelope showed the best results. It is difficult to find an explanation for the
discrepancy because different procedures of transduction were followed and the
viral titers used in their study might have been different. Retroviral transduction of
goat BMSC with xenotropic pseudotyped vector would provide the ultimate method
to evaluate whether the results of our experiment would demonstrate the same. 
For future studies, a labeled cell percentage close to 100% is preferred to allow
quantitative interpretations of the contribution of host and donor cells to colonization
of the scaffold and bone formation. We showed this may be accomplished by
immunomagnetic sorting and expect even better results from FACS sorting, based
on current investigations. 
The results from the in-vitro culture study did not indicate a long-term effect of the
marker gene on proliferation, because in the co-culture experiment the expected
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percentage of labeled cells was matched. After an initial drop in the percentage of
labeled cells during the first week from 60% to 35%, the percentage gene-marked
cells stabilized at this level. Most likely, the untransduced cells have a slight growth
advantage the first week after transduction. 
We did not attempt to investigate the effect of the marker gene on in-vitro
differentiation because the frequently used alkaline phosphatase assay has shown
to be inadequate for goat and sheep BMSC’s,[122,278] Furthermore, the most
reliable information on differentiation potential is not provided by the in-vitro
phenotype but by in-vivo behavior of the transduced cells.[7] The results from the in-
vivo study indicated persistent gene expression following in-vivo growth and
differentiation. The presence within osteocyte lacunae illustrated the bone forming
capacity of the transduced cells. The presence in the osteoblast linings after 6
weeks suggests that transduced goat BMSC’s cells were still actively forming bone.
The observations related to in-vivo tissue engineered bone formation that we made
in this study, correlated well with previous findings of CM-Dil labeled goat
BMSC’s.[121] In that study, we concluded that the CM-Dil label was not applicable
for long-term investigation of the process of TE bone formation. With the retroviral
NGFR label investigated in this study, long-term investigation of the process of bone
TE in the goat model is now feasible.
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Chapter 8
OPTIMIZATION OF BONE TISSUE ENGINEERING IN GOATS: 
THE INFLUENCE OF SCAFFOLD TYPE AND CULTURE OF THE 
CONSTRUCTS
Summary
Introduction: Successful bone tissue engineering (TE) has been reported for
various strategies to combine cells with a porous scaffold. Particularly the period
after seeding until implantation of the constructs may vary between hours until
several weeks. Differences between these strategies can be reduced to: (a) the
presence of extracellular matrix; (b) the differentiation status of the cells; and (c) the
presence of residual immunogenic serum proteins. We investigated these
parameters in two types of scaffolds in a goat model of ectopic bone formation.
Methods: Culture expanded bone marrow stromal cells from eight goats were
seeded onto two types of hydroxyapatite granules: HA60/400 (60% porosity, 400µm
average pore size) and HA70/800. Scaffolds seeded with cells and control scaffolds
were cultured for six days in medium containing autologous or semi-synthetic
serum, in the presence or absence of dexamethasone. Other scaffolds were seeded
with cells just before implantation in medium with or without serum. All conditions
were implanted autologously in the paraspinal muscles for twelve weeks.
Results: Bone had formed in 87% of all TE constructs. Histomorphometry
indicated significantly more bone in the HA70/800 scaffolds. Furthermore, a
significant advantage in bone formation was found when the constructs had been
cultured for 6 days. 
Conclusion: Both scaffold characteristics (porosity) and TE strategy (culturing of
the constructs) was demonstrated to be important for bone TE. 
Proefschrift_Moyo_Kruyt.book  Page 93  Wednesday, September 10, 2003  1:03 PM
Chapter 8
94
Introduction 
Tissue engineering of autologous bone is a promising alternative for the surgically
derived autologous bone graft. Since the early nineties, many investigators
demonstrated the concept of combining osteoprogenitor cells with an appropriate
scaffold to be osteogenic ectopically in rodents and larger mammals.[114,128,130,224]
Recently, we demonstrated ectopic tissue engineered bone formation in a goat
model.[131] The advantage of an ectopic model is that it allows fundamental
research without the disturbing influence of host bone as present orthotopically.
Furthermore, many experimental conditions can be evaluated in one animal for
comparative studies. 
The scaffolds most frequently used for bone TE are porous ceramics, pure
hydroxyapatite (HA), or a composite with β-tricalcium phosphate (TCP).[68,128] The
osteoconductivity and biocompatibility of these materials are advantageous for
orthotopic application. The cells mostly used are Bone Marrow Stromal Cells
(BMSC’s).[63,76,128] These BMSC’s can be administered by soaking the scaffold in
fresh bone marrow,[228,234] or after culture expansion,[75,76,113] which was shown to
be superior.[105,123,130,131] 
Although many scaffold characteristics and the selection and expansion of BMSC’s
are quite similar between various studies, the strategy for building the final construct
is remarkably different. For instance, some investigators seed undifferentiated
“stem” cells under serum free conditions on the scaffold, followed by implantation
within several hours.[118,123,130] Others culture the cells in the constructs one or
more weeks prior to implantation, to allow extracellular matrix formation and to
stimulate osteogenic differentiation by addition of specific differentiation factors
such as dexamethasone.[103-105,131,224] Differences between these strategies may
be reduced to the following parameters: (a) the presence of extracellular matrix in
the scaffolds at time of implantation; (b) the differentiation status of the cells at time
of implantation; and (c) the presence of potentially immunogenic serum proteins
after seeding and culturing the constructs in the presence of commercial sera. In
order to optimize our bone tissue engineering approach, we investigated these
parameters in two different calcium phosphate scaffolds in a goat model of ectopic
bone formation.
Proefschrift_Moyo_Kruyt.book  Page 94  Wednesday, September 10, 2003  1:03 PM
Optimization of bone tissue engineering: Scaffold type and construct culture
95
8
Materials and Methods
Experimental design
A total of eight adult goats were used for the experiment, for which approval was
given by the local animal care committee. Forty-eight (8x6) units consisting of
granules of each scaffold type (HA70/800 and HA60/400), were prepared and
treated as single samples for all further treatment group related procedures
(Table 1). One week before implantation, four treatment groups were created by
seeding cultured BMSC’s on the units under conditions mentioned in the paragraph
Culturing and seeding conditions. These constructs were cultured for another 6
days in specific media. The night before implantation, another two treatment groups
were created. Because these constructs were not subsequently cultured, a higher
cell load was seeded to compensate for the cell increase on the cultured constructs.
The units were implanted randomly in the paraspinal muscles of the goat from
which the BMSC’s were derived from (autologous implantation). This resulted in a
sample-size of eight for each treatment group. To monitor bone formation in time,
fluorochrome labels were administered after 5, 7, and 9 weeks and the animals
were killed after 12 weeks. Bone formation in the scaffolds was investigated by
histology and histomorphometry of non-decalcified sections.
Scaffolds
Two different scaffolds were used in the current experiment: (1) HA70/800, a 70%
porous hydroxyapatite with an average pore size of 800µm (CAM Implants, The
Netherlands). This scaffold was produced with spray dried HA powder and the
interconnected pores were created using a H2O2 foaming method. According to the
manufacturer the ceramic was sintered at a temperature above 1100°C. This
resulted in a marked microporosity as shown in Fig.1. (2) HA60/400, a 60% porous
hydroxyapatite with an average pore size of 400µm (IsoTis NV, The Netherlands).
This scaffold was produced with commercial HA powder (Merck, The Netherlands)
using a wax incorporation method to create an interconnected porous structure.[296]
The sintering temperature was 1200ºC. Microporosity was less prominent in this
scaffold (Fig.1). The chemical composition of the materials was analyzed by X-ray
diffraction (XRD) and Fourier Transformed Infrared (FTIR) spectroscopy and
indicated HA without additional phases or impurities. Granules of 30-50mm3 of both
scaffold types were selected by sieving, cleaned in an ultrasonic bath and then
autoclaved. Two granules of each scaffold type (total 4 granules) were combined in
a 10ml tube and processed as one unit for all further treatments. Eight units were
impregnated with 100µg/ml fibronectin (Micronic, The Netherlands) to provide the
units for the serum free seeding condition.[68]
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Figure 1 Scaffolds 
1a) Two granules (Ø=3-4mm) of both scaffold types that were combined in the treatment
units. Macroscopically little difference can be seen.
1b) Scanning electron microscopy image of the HA70/800 surface. The material is composed
of small HA beads resulting in high microporosity between the individual beads; (bar=20µm).
1c) SEM image of the HA60/400 surface. The material is more smooth resulting in less
microporosity; (bar=20µm). 
Culturing and seeding conditions (Table 1)
BMSC’s were derived from both iliac wings and culture expanded as described in
detail previously.[103] In brief, 30ml aspirates were plated in culture flasks (5x105
nucleated cells per cm2) and cultured in a standard culture medium containing 15
vol% fetal bovine serum (FBS, Gibco, Scotland, lot# 3030960S). When colonies of
adherent cells had formed, these were replated at 5000 cells/cm2. At the 3rd
passage, one week before surgery, the cells were partially replated for culturing
another week, or seeded on scaffold units. For seeding dynamically (on a roller
bank) the cells were resuspended in different culture media at 5x105 cells/ml and
3.2ml of this cell suspension was added to a tube containing one unit (= 107 cells
per cm3 scaffold). This procedure constituted the first four conditions: 
(1) US-: The BMSC’s were resuspended in medium containing 2 vol% Ultroser G
(US. Invitrogen, The Netherlands) as a replacement of the 15 vol% FBS in the
standard culture medium. US was expected to be less immunogenic as it is mainly
synthetic. The exact constituents would not be given by the manufacturer but they
did not exclude the presence of human and animal derived components.
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(2) US+: as (1), with the addition of 10nM dexamethasone and 10mM
β-glycerophosphate (DEX and BGP, Sigma, the Netherlands) to stimulate
osteogenic differentiation.[106] This was the standard condition published
before,[131] of which the other groups were deduced.
(3) AS+: the medium contained 15 vol% autologous serum (AS) instead of FBS plus
DEX and BGP. AS was obtained from 200ml venous blood that was allowed to clot
in a sterile glass jar overnight. Before application, the serum was heat inactivated
for 30 minutes at 56-58ºC and filtered through a 0.2µm filter.
(4) Control: Units were maintained in US+ medium without cells seeded.
After seeding the units were taken to bacteriological 25-wells plates and the
medium was refreshed with the same medium type as used for seeding. Then the
units were cultured statically for another six days before implantation. This allowed
cell expansion and extra cellular matrix formation.[131]
The cells that were not seeded were replated and maintained in the US- culture
medium for another six days. Then the cells were resuspended at 5x105 cells/ml
and 17.6ml of this cell suspension was added to the units (55x106 cells per cm3
scaffold) 14-16 hours before implantation according two protocols:
(5) USS-: Cells were resuspended and seeded in US- medium. 
(6) SF-: Cells were resuspended in serum free medium and seeded on fibronectin-
coated scaffolds.
In a previous study scanning electron microscopy (SEM) showed the 6-day culture
period resulted in abundant ECM formation covering all of the scaffold surface.[131]
Table 1 Treatment groups
Cells were loaded on units of four granules (2*HA60/400 + 2*HA70/800). The constructs
were cultured six days before implantation in media with Ultroser G (US) or autologous serum
(AS) with or without DEX and BGP administration. Other constructs were seeded short before
implantation with Ultroser medium or serum free (USS, SF). Controls were maintained in the
US+ condition without cells. 
Condition
Seeding load
(cells/cm3 scaffold)
Cultured DEX and BGP
Serum
type
1) US-  107 yes no Ultroser G
2) US+  107 yes yes Ultroser G
3) AS+  107 yes yes Autologous
4) Control  0 yes (no cells) yes Ultroser G
5) USS-  5.5x107 no no Ultroser G
6) SF-  5.5x107 no no no
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Determination of cell seeding load for non-cultured constructs.
To standardize the cell number for all groups at implantation, we studied the
required seeding load to normalize the cell number on the non-cultured constructs
(USS- and SF-) in a separate study, prior to seeding of the in-vivo constructs. First
cell numbers on 6 days cultured US- Constructs (HA60/400, n=6) were quantified
by a tetrazolium salt assay, which measures mitochondrial metabolic activity (MTT,
sigma).[332] The constructs were incubated in 200µl MTT solution for two hours and
then lysed with 200µl DMSO. The light absorbance of the formazan product in the
lysate was read at 570nm. Subsequently, constructs seeded with similar, 4, 5 and 7
times higher cell loads than the 6 days cultured constructs were analyzed (n=6) 14
hours after seeding in US- medium or serum free medium. The seeding load for an
intensity equal to the cultured US- constructs was calculated from the function of the
curve as shown in Fig. 2a.
Cell quantification 
To determine the seeding efficiency and subsequent cell increase for the different
scaffold materials and different medium conditions including the FBS medium,
another cell quantification method that was described in detail before was applied in
a separate in-vitro study (CyQUANT® kit Molecular Probes, Eugene, US).[131,297]
Our experience was that absolute numbers (for seeding efficiency) can be
calculated more accurately with this method as compared to the MTT assay. The
constructs (n=5) were digested in a collagenase solution overnight on a shaking
platform to retrieve all DNA. The cell number was calculated from a standard curve
of identical cells.
Figure 2 In-vitro measurements (error bars indicate the SD)
2a) Relative cell quantities (by MTT assay) in HA60/40 constructs 14 hours after seeding with
increasing cell loads compared to constructs seeded with 4x105 cells and cultured for another
6 days. The open circle represents the cultured construct. Higher cell loads seeded in
Ultroser medium (USS-) or in serum free medium (SF-) resulted in higher cell numbers in the
non-cultured constructs. A seeding cell load of 2.2x106 cells per granule was calculated from
the USS- curve to normalize the cell number in the non-cultured constructs to the cultured
construct. SF- could not be normalized.
2b) Estimated cell numbers in different combinations of scaffold and culture conditions by
DNA quantification. The 6-day culture resulted in an average doubling of the DNA quantity.
Culture of HA60/400 constructs in autologous serum (AS+) resulted in 35% less DNA as
compared to identical constructs cultured in Ultroser medium (US+) (p<0.02).
2c) Relative alkaline phosphatase activity of goat cells cultured for 6 days in media containing
FBS, Ultroser (US), autologous serum (AS) or allogenic goat serum. The response to DEX
and BGP admission was ambiguous. No conditions were significantly different when all
conditions were compared.
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Figure 2
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Alkaline phosphatase measurement
The alkaline phosphatase activity (ALP) in relation to the cell number (ALP/DNA)
was measured to analyze cell response to DEX and BGP and to identify differences
between the media. The standard culture medium with FBS, the US medium, the
AS medium and medium containing 15% allogeneic goat serum were studied. Cells
of one batch were plated in six-well plates (5x104 cells per well) and cultured for 6
days to allow formation of confluent sheets.[106] The cell sheet was resuspended in
1ml 0.05% Triton solution and homogenized by sonification. 500µl was used for the
CyQUANT assay. Another 100µl was transferred to 100µl p-nitrohenyl phosphate
(PNP, 104R Sigma) in alkaline phosphatase buffer and incubated for 15 minutes to
determine the rate of conversion into p-nitrophenol. The reaction was stopped with
500µl 0.1N NaOH. Absorbance was read at 405nm. 
Animals and Implantation
Adult Dutch milk goats (19-26 months) were obtained at least four weeks prior to
surgery. The surgical procedures were performed under general inhalation
anesthesia, preceded by i.v. detomidine sedation (Pfizer, The Netherlands) and
maintained by a halothane gas mixture (Sanofi, The Netherlands). After shaving
and desinfection of the lumbar area, six separate skin incisions were made. By
using blunt dissection, intramuscular pockets were created and filled with one unit
according to a randomized scheme. Subsequently, the fascia was closed with a
non-resorbable suture and the skin was closed in two layers. Postoperatively pain
relief was given by buprenorphine (Shering-Plough, The Netherlands). In addition to
the intramuscular implantations, the goats were subjected to a femur defect
operation that will not be discussed in this paper.
Fluorochromes (all Sigma) were administered intravenously. At 5 weeks, Alizarin
red (30mg/kg), at 7 weeks Calceine green (10mg/kg) and at 9 weeks Xylenol
orange (100mg/kg).[300] After 12 weeks, the animals were killed by an overdose of
pentobarbital (Organon, The Netherlands). As a control for osteogenicity, per goat,
two HA70/800 granules of each condition and two granules of HA60/400 of the US+
condition were implanted subcutaneously for four weeks in nude mice (two mice per
goat).[103] These implants were scored as bone or no bone in the 16 (8x2) granules
that were implanted of each condition. 
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Post-mortem sample acquisition, histology and histomorphometry
After explantation, the units were fixated in 1.5% glutaraldehyde, dehydrated by
graded ethanol series and embedded in polymethylmethacrylate. Semi-thin
sections (10µm) were made with a Leica sawing microtome, stained with methylene
blue and basic fuchsin for routine histology[302] and histomorphometry, or left
unstained for epifluorescence microscopy. Per unit 4-10 sections were made to
provide sections through the center of each individual granule. The sections were
evaluated for general tissue response, bone formation and the fluorochrome labels
using a fluorescence/light microscope (E600 Nikon, Japan) with a double filter block
(dichroic mirror 505nm and 600nm). The mid-section through the single granules
was chosen for histomorphometry. The percentage of bone occupying available
space within the granules was measured using a VIDAS image analysis system
(KS400, Zeiss, Munich, Germany), coupled to a light microscope. First, the area of
interest was defined by outlining the specific granule. Pores that interrupted the
exterior scaffold contour were crossed with straight lines. Then, after blinding the
samples, the pore area and the bone area were identified and measured. Bone
formation was expressed as percent bone in available space (bone area/pore area
x100%).
Statistics
To analyze quantitative DNA and ALP/DNA data, ANOVA’s with Bonferroni
corrected post-hoc tests were performed. Histomorphometric results were analyzed
by Friedman paired rank test and post-hoc Wilcoxon signed rank tests. All tests
were performed with SPSS10 for Macintosh (significance level: p<0.05).
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Results
In-vitro results (Fig. 2) 
To normalize the cell numbers in the constructs that had not been cultured after
seeding to cultured constructs, a 5.5 times higher seeding load was calculated for
the USS- condition. The SF- condition could not be normalized as can be seen in
Fig. 2a. The average seeding efficiency according the CyQUANT® assay was about
60%, without significant difference between the sera or scaffold materials. After the
6-day culture period, the total DNA reflecting cell numbers had doubled once on
average, with about 35% less DNA in AS+ condition as compared to the US+
condition (p=0.018). This indicated a relatively low proliferation of the cells that,
when cultured in flasks, have a doubling time of only one day.[131] Other
comparisons did not show significant differences. (Fig. 2b). The ALP/DNA analysis
as a reflection of cell differentiation demonstrated a comparable alkaline
phosphatase activity for all study conditions. The effect of dexamethasone and BGP
admission was ambiguous and not significant as can be seen in Fig. 2c. 
In-vivo results
Although there were no surgical complications, two goats developed a painful nail
disease for which they were terminated after 10 weeks instead of 12 weeks.
Autopsy and cultures of blood and tissue did not indicate a cause related to the
procedure. The data of these two goats were applied for qualitative analysis and
paired comparisons within the animal. Histology showed that all granules were
embedded in well vascularized soft tissue without signs of inflammation. Bone
formation was found in all but the control conditions in amounts varying in and
between the goats (Fig. 3). The bone was typically present on the HA surface of the
smaller pores with an obvious preference for the HA70/800. In 35 of all 40 tissue
engineered units (87%), bone had formed, and in 33 cases the HA70/800 implants
yielded more bone than the HA60/400 implants (p<0.01). Fig.4 shows the result of
histomorphometry on the 12-weeks implants. Although the standard deviation
(between goats) was high, paired comparisons (within goats) revealed that the
condition/material combination significantly influenced the percentage of bone area
(p<0.01), also when considering only HA70/800 (p=0.01). The three conditions that
were cultured for 6 days (US-, US+, AS+) had comparable bone percentages (9-
13%) that were higher than the two conditions that were implanted directly after
seeding (3-5%). Post-hoc analysis of the US- condition (no DEX and BGP
admission) versus the USS- condition demonstrated a significant difference
(p=0.02) in bone formation. Fluorochrome analysis showed the fluorochrome labels
as distinct lines within the newly formed bone. The occasional presence of the 5
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weeks label and the line pattern were comparable for all conditions. The
fluorochrome line order indicated bone formation had started on the HA surface and
was directed towards the pore center. The line shape often indicated bone was
budding from the surface towards to opposite surface to bridge the pore (Fig.3).
Since the distances between the different labels was very variable, no attempt was
made to calculate the bone formation rate.
Figure 3 Bone formation after 12 weeks implantation in goats (☞ p. 184)
3a) HA70/800 scaffold of AS+ condition. Bone (red) is present in all pores in close contact to
the scaffold surface; (bar=500µm).
1b) HA70/800 granule of USS- condition. Only little bone had formed (triangle); (bar=800µm).
1c) HA70/800 of SF- condition, detail of bone. Note scaffold composition of small beads;
(bar=100µm).
1d) HA70/800 of US- condition. Fluorescent microscopy shows the budding of bone from the
scaffold surface to the pore center where two buds united, C = Calcein label (7 weeks) X =
Xylenol orange label (9 weeks); (bar=50µm).
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In the control granules implanted in mice, bone was also present in all cell
containing groups ranging from 62.5% (10/16) in the US- constructs to 100%
(16/16) in the SF- constructs. Remarkably HA60/400 and HA70/800 (both US+)
showed similar bone formation, both 90%.
Figure 4 Area % bone after 12 weeks implantation in goats (error bars indicate SD) 
HA70/800 yielded more bone than the HA60/400 (p< 0.01) Post-hoc paired comparisons
indicated US- (cultured) had more bone than USS- (non-cultured) (p=0.02).
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Discussion and conclusions
In the present study, the effect of five different TE strategies was investigated
ectopically in a goat model. Bone was found in all cell-based TE conditions with an
obvious preference for the HA70/800 scaffolds and for constructs that were cultured
before implantation. Neither the serum type nor dexamethasone admission
influenced bone formation. An explanation for these findings could be that only the
scaffold type and the presence of extracellular matrix is relevant for bone formation
without any role for the cells in-vivo. This hypothesis can be supported by literature
that reports a potential bone inductive capacity of porous ceramics and extracellular
matrix.[152,294,333,334] However, the scaffolds without cells failed to show bone
induction, and a previous study showed that identically cultured TE constructs that
contained extracellular matrix and were devitalized before implantation, also failed
to show any bone.[131] Therefore, the hypothesis of an osteoinductive mechanism
without a contribution of the cells is not plausible. Different parameters for this cell-
dependent bone TE were investigated: The presence of extra cellular matrix; the
differentiation status of the cells; and the presence of potential immunogenic serum
proteins.
The effect of extracellular matrix was investigated by comparing constructs cultured
for 6 days to constructs that were not cultured after seeding that do not contain
ECM.[131] In agreement with earlier observations in rats,[104,105] we found
significantly more bone in the cultured constructs indicating an advantage for this
situation. A remark that should be made is that the high cell load that was seeded
on the non-cultured constructs resulted in a cell distribution that was less
homogeneous (more clotting) as on the cultured constructs. 
To analyze the effect of cell differentiation, we attempted to stimulate differentiation
into the osteogenic lineage by adding DEX and BGP to the culture medium.[106] The
in-vitro results of the ALP/DNA assay, however, showed a very moderate alkaline
phosphatase activity in goat cells, with an ambiguous response to DEX and BGP
admission. This is contrary to human or rodent cells frequently analyzed by the
same method in our laboratory in which ALP/DNA is 10-20 times higher. This
phenomenon was also observed by others with sheep BMSC’s.[122] The absence of
an ALP/DNA increase in-vitro might explain why there was no significant effect in-
vivo. 
The presence of serum proteins in US and especially in FBS that could elicit an
immune reaction was a major concern. Therefore, the FBS-cultured constructs were
not implanted. However, a sensitization test (on guinea pigs) of Ultroser G that was
performed in a separate experiment, indicated an immune response against US that
was even stronger than the response to FBS. Despite this finding, bone formation in
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all cultured groups (US-, US+ and AS+) appeared similar and no advantage of
serum free seeding was found in the non-cultured groups (USS- and SF-). This
implies the absence of a profound inhibitory immune reaction and also shows the
feasibility of using autologous serum.
The type of scaffold appeared to affect the outcome more than any of the other
parameters. This was discussed earlier,[131] where we emphasized that a prominent
feature of the HA70/800 was the higher microporosity. The larger surface area
might result in increased dissolution and subsequent precipitation with the possible
integration of inducing factors in the scaffold surface.[98,105] This phenomenon
might be relevant only after prolonged implantation periods, which could explain the
absence of a material related difference in the frequently applied nude mice
model[121] (implanted for 4 weeks).
The MTT assay that we used for standardization of the cell numbers was not ideal
because of conflicting data. The measured cell increase during the 6 days culture
time was ten fold, whereas this quantity could be achieved with a 5.5 times higher
seeding load (Fig. 2). Others reported a selective adherence of the MTT to
plastics[335] which could have caused a relative under-estimation of low cell
numbers. The cell loads applied for normalization were more likely too high than too
low as, according to the DNA quantification method, the 6 day cell increase was
only two fold. Another reason to assume that the cell numbers on the non-cultured
constructs were sufficient, is by comparing our seeding load of 55x106 cells/cm3 to
literature where only 10-30x107 cells per cm3 scaffold are seeded.[119,122,123] 
Finally, it should be realized that the area% bone we found in goats (on average
12% in the cultured constructs) is low when compared to rodents where 25% was
reported,[336,337] This could be the result of a delayed vascularization related to an
increased implant volume and lower rate of metabolism.[173,338] Further research on
this topic will be necessary to upscale the technique for future clinical applications.
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Chapter 9
OPTIMIZATION OF BONE TISSUE ENGINEERING IN GOATS: 
A PEROPERATIVE SEEDING METHOD USING CRYOPRESERVED 
CELLS AND LOCALIZED BONE FORMATION IN CALCIUM 
PHOSPHATE SCAFFOLDS
Summary
Introduction: Bone tissue engineering by combining cultured bone marrow
stromal cells (BMSC’s) with a porous scaffold, is a promising alternative for the
autologous bone graft. Drawbacks of the technique include the delay necessary for
cell culture and the complicated logistics. We investigated methods to bypass these
drawbacks. Furthermore, we investigated the localization of bone formation inside
the scaffold. 
Methods: Goat BMSC’s were culture expanded and cryopreserved. Prior to
surgery, part of the cells were thawed, cultured and seeded on porous calcium
phosphate scaffolds. The constructs were cultured for another week until
implantation. The remaining cryopreserved cells were thawed just before
implantation and peroperatively resuspended in plasma before combining with the
scaffold. Scaffolds impregnated with fresh bone marrow, devitalized cultured
constructs and empty scaffolds, served as controls. All samples were implanted in
the back muscles of the goats (n=7) for nine weeks. 
Results: Histology showed little (<1%) bone in the empty and devitalized scaffolds,
4.2±5.1 area% bone in the bone marrow samples and significantly more bone in
both the cultured and peroperatively seeded constructs (11.7±2.5 and 14.0±2.0%).
The peripheral 350µm of the implants contained significantly less bone.
Conclusion: Peroperative preparation of osteogenic constructs with
cryopreserved cells is feasible. These constructs yield substantially more bone than
the scaffolds alone or scaffolds impregnated with fresh bone marrow. Bone
deposition is much less on the scaffold periphery.
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Introduction
At present, the autologous bone graft is the golden standard to reinforce or replace
bone in many orthopaedic interventions. Unfortunately, harvesting is inherent to
donor side complications and increased costs.[45] For that reason, a competent
alternative is highly demanded. Tissue engineering (TE) of bone could be a solution.
A concept of tissue engineering is to combine bone-forming cells with a porous
scaffold to obtain a hybrid construct. Friedenstein and colleagues discovered and
extensively investigated such cells in adult bone marrow and referred to these as
colony forming unit fibroblasts (CFU-F’s) or bone marrow derived stromal cells
(BMSC’s).[61] Since, the technique has been optimized, especially by applying
porous ceramics as a scaffold material.[68,128] The proof of the concept of bone TE
was shown with gene-marked cells in mice and rat.[128,191] Reports showing the
feasibility in larger animals are fewer, but both ectopic osteogenicity of the
constructs[130,131,278] and the successful application orthotopically was
shown.[119,123]
Although the technique is promising, there are some important drawbacks. At first,
there is a delay of at least 2 weeks necessary to culture expand the cells; secondly,
because the cells are cultured before combination with the scaffold, the logistics are
complicated to ensure the patient and the construct are prepared at the same time;
thirdly, when the construct is cultured before implantation, animal serum is often
required of which remnants in the final construct cannot be excluded. To overcome
these drawbacks, methods have been developed to concentrate the osteogenic
cells in fresh bone marrow by selective adhesion to the scaffold peroperatively.[6,47]
The fraction of osteogenic cells in bone marrow however, is only 1-10 per 105
cells.[5,61] Therefore, expansion of the BMSC’s is preferable when elective surgery
is an option, especially in the case of large graft volumes (which need many
progenitor cells). Cryopreservation allows long-term preservation of the expanded
cells and can simplify planning considerably.[339] The main concern in planning then
remains to thaw and replate the cells and, if applicable, culture the construct before
application. When for some reason the operation cannot proceed after (construct)
preparation, labor and cells are spilled. To overcome this drawback, we investigated
the feasibility of combining cryopreserved cells and the scaffold peroperatively by
using autologous plasma as a delivery vehicle. A potential advantage of this ex-vivo
prepared clot, as compared to the haematoma that will normally occur after
implantation, is the absence of erythrocytes, which are responsible for a detrimental
increase in potassium concentration.[143] The peroperative method was compared
to constructs that were cultured one week before implantation and to scaffolds
seeded with and without fresh bone marrow.[233] 
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A more fundamental question that we investigated, concerned the distribution of
newly formed bone. Although one would expect that new bone formation will
preferably be close to the outside of the scaffolds, where cells can survive by
diffusion and enhanced revascularization,[137,140,172] previous observations showed
a preference for bone formation away from the scaffold periphery.[121,131,278] With
regard to larger graft volumes consisting of separate granules, as for example used
in posterior spinal fusions, peripheral bone formation will be a prerequisite for
continuous bone bridging. Therefore, we separately analyzed bone formation in the
outer 350µm of the constructs and compared this to the bone formation in the whole
7x7x7mm construct.
Materials and methods
Experimental design
A total of 7 adult goats were used after approval by the institutional animal care
committee. Bone marrow aspirates were culture expanded and the BMSC’s were
cryopreserved. Ten days before the operation, aliquots of cryopreserved BMSC’s
were replated. After 3 days (one week before the operation), a proportion of these
cells was seeded on ceramic scaffolds and the constructs were subsequently
cultured, with or without the presence of dexamethasone. Cells that had not been
seeded on scaffolds were maintained in culture to be detached just before the
operation. At that time, also remaining aliquots of cryopreserved BMSC’s were
thawed. Peroperatively the cells were resuspended in autologous plasma and
combined with the scaffolds. Fresh bone marrow was combined with the scaffold at
the start of the operation. A total of eight conditions were created as discussed in
more detail in the section BMSC’s culture and seeding conditions and Table 1.
Scaffolds
Cubes of 7x7x7mm with rounded edges were prepared from OsSatura (IsoTis,
Bilthoven, The Netherlands) cleaned in ultrasonic baths, steam autoclaved and
dried before application. The ceramic consists of 80±5% hydroxyapatite (HA) and
20±5% tricalcium phosphate (TCP) as confirmed by X-ray diffraction (XRD) and
Fourier Transformed Infrared (FTIR), no additional phases or impurities where
detected. The 50% interconnected macroporosity was created by H2O2 foaming
resulting in a 100-1000µm poresize. The material was sintered at 1200ºC allowing
15±5% microporosity (1-10µm). Previously, this ceramic showed to be
osteoinductive ectopically in goats.[97]
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Table 1 Conditions
Control ceramic cubes (7x7x7mm) were kept in autologous serum (AS) medium with DEX
and BGP, but without cells, for one week (AS+NC). Others were impregnated with autologous
plasma peroperatively (PlmNC). A third control was created by devitalizing cultured AS+
constructs before implantation. Scaffolds that were impregnated for 1 hour with fresh bone
marrow (BM) provided a fourth control condition. Experimental conditions were obtained by
1-week culture of BMSC seeded scaffolds in AS medium with or without DEX and BGP (AS+
and AS-). Others were prepared peroperatively by using cultured or cryopreserved BMSC’s
resuspended in plasma (POcult. and POCP). Upon implantation the estimated cell load was
identical for all groups. 
BMSC’s culture and seeding conditions
Autologous serum (AS) was derived from venous blood that was taken during the
BM aspiration.[131] After the iliac wing BM aspirate, the nucleated cells were
counted and plated in culture flasks, to obtain the BMSC’s according to previously
described methods.[131] When sufficient, cells were cryopreserved in medium
containing 30% fetal bovine serum (FBS, Gibco, Paisly, Scotland, lot# 3030960S)
and 10% dimethylsulfoxide (DMSO, Sigma, Zwijndrecht, The Netherlands). Ten
days before the operation, aliquots of the cryopreserved cells were thawed with iced
FBS, centrifuged for 10 minutes at 100G and replated in 30% FBS medium for 3
days. One week before operation, cells were detached, centrifuged and partially
replated for another week in 15% AS medium. The remaining cell pellets were
resuspended in AS medium at a concentration of 1x107 cells/ml. Scaffolds were
seeded with 275µl of droplets of this suspension (8x106 cells per cm3 scaffold) and
incubated at 37ºC. After two hours, AS medium was added with or without 10nM
dexamethasone and 10mM β-glycerophosphate (DEX and BGP, both Sigma) which
Condition
Seeded cell load
(x106)/cm3 scaf.
Handling
Implanted cell load 
(x106)/cm3 scaf.
1) AS+NC  none 7-day cult. none
2) PlmNC  none Peroperative plasma none
3) AS+dev.  8 7-day cult. then frozen 8.7 (dead)
4) BM  3.5ml 1h attachment n.a.
5) AS-  8 7-day cult.-DEX 8.7
6) AS+  8 7-day cult.+DEX 8.7
7) POcult.  8.7 Peroperative 8.7
8) POCP  8.7 Peroperative 8.7
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have shown to stimulate osteogenic differentiation.[106] The constructs were
cultured for one more week to generate an extracellular matrix.[131,278] One extra
construct cultured in DEX and BGP medium was made and devitalized before
implantation by repeated freezing in liquid nitrogen, to provide a control with
extracellular matrix without viable cells.[131] Other control scaffolds were not seeded
with cells but were maintained in medium containing DEX and BGP.
The day of surgery, cultured cells were detached, resuspended at 106 cells/ml in AS
medium and 3.1ml was transported to the operation room. Cryopreserved cell
aliquots were thawed with iced AS and resuspended like the cultured cells. During
surgery, plasma was obtained by centrifuging 10ml venous blood at 1200G in a
plastic tube. The transported cell suspensions were centrifuged at 300G, medium
was decanted and the pellets were resuspended in 300µl plasma. Plasma with or
without cells was combined with the dry scaffold and allowed to clot. The plasma
penetrated the scaffold and the clot containing all cells (8.7x106 cells/cm3 scaffold)
was implanted. Bone marrow seeded scaffolds were prepared as previously
described[131] by adding 3.5ml fresh bone marrow without anti-coagulant to a dry
scaffold (10ml/cm3 scaffold) at least one hour before implantation. The above
procedures created the following groups (see also Table 1):
1 (AS+NC): scaffold without cells, maintained one week in AS+ medium;
2 (PlmNC): scaffold peroperatively impregnated with autologous plasma;
3 (AS+dev.): devitalized AS+ constructs (with extra cellular matrix);
4 (BM): scaffold impregnated with fresh bone marrow;
5 (AS-): constructs of scaffold and BMSC’s cultured one week in AS medium
without DEX and BGP;
6 (AS+): constructs cultured one week with DEX and BGP; 
7 (POcult.): construct prepared peroperatively with the number of cultured
BMSC’s adjusted to the AS+ condition;
8 (POCP): peroperatively prepared with adjusted numbers of cryopreserved
BMSC’s.
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Cell quantification
To determine seeding efficiency and cell increase after culture of the constructs in
the AS+ condition, which was expected to be comparable to the AS- condition,[278]
the DNA content of in-vitro constructs (n=6) was quantified with a CyQUANT® kit
(Molecular Probes, Eugene, US).[131] In order to implant all conditions with equal
cell numbers, the peroperatively seeded samples contained the amount of cells that
was calculated for the 1 week cultured constructs (=8.7x106 cells/cm3 scaffold).
Animals and Implantation
Adult female Dutch milk goats (24-36 months) were obtained at least four weeks
prior to surgery. The surgical procedures were performed under general inhalation
anesthesia, preceded by detomidine sedation (Pfizer, The Netherlands) and
maintained by a halothane gas mixture (Sanofi, The Netherlands). After shaving
and desinfection of the thoracolumbar area, a central skin section T8-L5 was made
to expose the muscle fascia. Separate fascia incisions were made and by using
blunt dissection, intramuscular pockets were created that were filled with one of the
implants, according to a randomized scheme. The fascia was closed with a non-
resorbable suture and the skin was closed in two layers. Postoperatively pain relief
was given by buprenorphine (Shering-Plough, The Netherlands). In addition to the
intramuscular implantations, the goats were subjected to a critical sized iliac defect
that will not be discussed in the present paper. Sequential fluorochrome markers
were administered; after 3 weeks Calcein Green (10mg/kg intravenously, Sigma);
after 5 weeks Oxytetracyclin (32mg/kg intramuscular, Engemycine, Mycofarm,
The Netherlands) and after 7 weeks Xylenol Orange (80mg/kg i.v. Sigma).[131] After
9 weeks, the animals were killed by an overdose of pentobarbital (Organon,
The Netherlands). 
Post-mortem sample acquisition, histology and histomorphometry
After explantation, the samples were fixated in 4%glutaraldehyde/5%
paraformaldehyde, dehydrated by ethanol series and embedded in
polymethylmethacrylate. Semi-thin sections (10µm) were made with a sawing
microtome (Leica, Nussloch, Germany) through the center of the cubes. Sections
were stained with methylene blue and basic fuchsin for routine histology and
histomorphometry, or left unstained for epifluorescence microscopy. General tissue
response, bone formation and the fluorochrome labels were evaluated by
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fluorescence/light microscope (E600 Nikon, Japan) with a quatriple filter block
(XF57, dichroic mirror 400, 485, 558 and 640nm, Omega filters, The Netherlands). 
For histomorphometry, high resolution, low magnification (10x) digital micrographs
(300dpi) were made of blinded sections (Fig. 1a). With Adobe Photoshop 5.5, bone
and scaffold were pseudocoloured red and green respectively. The area of interest
was defined by outlining the scaffold, pores that interrupted the exterior contour
were crossed with straight lines (Fig. 1b). Image analysis was carried out using a
PC-based system equipped with the KS400 version 3.0 software (Zeiss,
Oberkochen, Germany). A special program was developed, measuring the
percentage of bone occupying available space (bone area%) and the percentage of
available scaffold outline (which is the surface of the scaffold) in contact with bone
(contact%). The contact% was expected to be more sensitive for newly formed
bone, because previous work indicating this was strongly associated with the
scaffold surface.[131] A peripheral area of interest was defined by drawing a line 40
pixels central from the outer contour (corresponded with approximately 350µm)
(Fig.1b). Bone area% and contact% were also measured in the area between this
artificial line and the outer contour.
Figure 1 Image analysis procedures  (☞ p. 185)
1a): 10x magnification, high-resolution digital image of central section through a sample
peroperatively seeded with cryopreserved cells (POCP). 
1b): Pseudocoloured image of 1a, bone = red and scaffold = green. The area of interest was
outlined with straight lines. After measurement of the whole sample, an imaginary line was
drawn 40 pixels central to the outline, this corresponded with approximately 350µm. The area
between this line and the outline was analyzed separately as the peripheral zone.
ba
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Statistics
To analyze quantitative DNA data, two-sided student t-tests were performed.
Histomorphometrical data was analyzed with ANOVA according to a randomized
block design. Bonferroni corrected post-hoc test were done to analyze differences
between the groups. Differences between the peripheral and the total area were
determined by repeated measurements. All tests were performed with SPSS10 for
Macintosh (significance level p=0.05).
Results
In-vitro results 
The BM aspirates contained 9.1±2.3x106 (mean±SD) nucleated cells/ml. Colonies
formed after 5-7 days culture and the BMSC’s were harvested when confluent, after
10-13 days. After the 2nd passage, 0.8-1.1x108 BMSC’s were cryopreserved.
Thawed cells showed minimal dead cells (<5% according trypan blue exclusion)
and proliferated well before seeding on the scaffolds. Methylene blue staining of in-
vitro constructs after seeding for two hours, indicated a homogeneous distribution of
the cells in the scaffolds. The average seeding efficiency according the CyQUANT®
assay was 49.1±14.7% (mean±SD) (Fig. 2a). After the 1-week culture, the DNA
quantity had significantly increased (p=0.011), corresponding with 3.1±1.3x106
cells/scaffold (=8.7±3.7x106cells/cm3). By then, scaffolds were fully covered with an
extracellular matrix (Fig. 2b). After resuspension of cells in plasma peroperatively,
the plasma remained in a liquid state, which allowed good penetration of the
scaffolds. The plasma clotted within 10-20 minutes. SEM imaging of POCP
constructs, showed deposition of aggregates of spherical cells throughout the
scaffold (Fig. 2c). 
Figure 2 Analysis of in-vitro constructs
 2a): Histogram of the calculated cell numbers derived from the CyQUANT“ assay, error bars
indicate the standard deviation. After seeding 2.75*106 cells (=8*106 cells/cm3), 1.4±0.4*106
adhered. After one week culture, the cell number significantly increased (p<0.01) to
3.1±1.3x106 (=8.7*106 cells/cm3). 
2b): SEM image of 7-days cultured construct (AS+) Flattened cells with extra cellular matrix
deposited around a pore orifice (bar = 50µm).
2c): SEM image of construct after seeding with cryopreserved cells in plasma (POCP).
Aggregates of spherical cells adhered to the BCP ceramic of which the microporous structure
is well visible (bar = 50µm).
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In-vivo results
There were no surgical complications and all samples were retrieved. No
macroscopic or microscopic signs of infection were found. 
Histology showed consistent bone formation in all samples of the experimental
conditions (AS+, AS-, POcult and POCP), occasionally with bone marrow inclusion.
Less regularly (6/7 =86%), bone formation was found in the fresh BM condition. The
conditions without viable cells occasionally showed spots of new bone (see Table 2
and Fig. 3). Bone was never present on the scaffold exterior and at first sight, bone
formation in the peripheral zone (Fig. 1) seemed less. Fluorescence microscopy
showed a line pattern and the presence of the first (3-week) label that was
comparable for all conditions seeded with cells, including the BM group. No delayed
bone formation was recognized in any of these groups, the 3-week label was
always very close to the ceramic surface. In general, when bone had been formed
in the conditions without viable cells, only the 7-week label was visible, except for
one occasion (PlmNC), where the 5 week label was present. The fluorochrome
label order indicated bone formation started from the scaffold surface and was
directed centripetal, towards the pore center (Fig. 3).
Histomorphometry indicated a scaffold macroporosity of 49.9±4.2%. Bone formation
was comparable for all experimental (BMSC’s seeded) conditions (Table 2 and
Fig. 4). In these conditions, the area% bone was 11.2-14.0% and the contact%
25.8-27.3%. The BM group showed significantly less bone than the experimental
conditions (area% 4.2%, contact% 8.8%, p<0.01). The conditions without viable
cells showed minimal bone formation (<1%). Measurement of both the bone area%
and the contact% in the peripheral 350µm of the experimental conditions indicated
5 to 6 fold lower values respectively as compared to the whole implant (p=<0.001). 
Table 2 Histomorphometry data of intramuscular samples in goat
The percentage bone in available space (Bone area%) and the percentage scaffold-outline in
contact with bone (Contact%). Both measurements where done for the whole sample and the
peripheral 350µm. The bone-containing fraction of the samples is shown in the right column.
Condition Bone area% (mean±SD) Contact% (mean±SD) % Positive
samplesWhole sample Periphery Whole sample Periphery
1) AS+NC 0.2±0.2 0.1+0.1 0.4+0.5 0.1+0.3 71%(5/7)
2) PlmNC 0.7±1.1 0.0±0.1 1.2±1.7 0.1±0.2 57%(4/7)
3) AS+dev 0.2±0.3 0.0±0.1 0.5±1.1 0.1±0.1 57%(4/7)
4) BM 4.2±5.1 0.5±0.7 8.8±10.5 0.9±1.3 86%(6/7)
5) AS- 11.2±2.8 2.7±2.2 26.2±10.2 5.2±4.6 100%(7/7)
6) AS+ 11.7±2.5 1.9±1.2 22.8±9.1 3.9±2.5 100%(7/7)
7) POcult. 11.5±4.7 3.1±4.5 25.7±10.5 4.7±4.5 100%(7/7)
8) POCP 14.0±2.0 1.6±1.1 27.3±5.4 3.1±2.6 100%(7/7)
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Figure 3 Histology of 9 weeks intramuscularly implanted samples  (☞ p. 185)
3a): Undecalcified histology of 7-days cultured construct (AS+). Representative impression of
bone formation, occasionally bone marrow (M) was seen (bar=1mm).
3b): Fluorescence microscopy of 7-days cultured construct (AS+). All labels are present: C =
Calcein green 3-weeks; OTC = Oxytetracycline 5-weeks (yellow); X= Xylenol orange 7-
weeks. Growth dynamics can be deduced from the line pattern showing growth from the BCP
surface towards the pore (P) center (bar=400µm).
3c): Undecalcified histology of scaffold with plasma without cells (PlmNC). Discrete spots of
bone formation (▼) in close relation to the scaffold surface can be observed (bar=400µm).
3d): Fluorescence microscopy detail of bone in scaffold without cells (PlmNC). Only the
orange 7-weeks label was found in the spots of bone (bar=400µm).  
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Discussion
In the current study we demonstrated the feasibility of bone tissue engineering for
several different methods that ranged from peroperative preparation of the construct
with cryopreserved cells, to one week culture of constructs to stimulate osteogenic
differentiation and matrix production. Furthermore we observed a remarkable
decreased bone formation at the scaffold periphery. We did not observe differences
between the experimental groups where BMSC’s were used. Given the results of
this study, to obtain a relevant difference of 25% with the AS+ condition with a
power of 80%, the sample size of 7 was sufficient. Therefore, relevant differences
between the BMSC’s seeded conditions are unlikely. The peroperative seeding
method with cryopreserved cells overcomes complicated logistics as is the case
with cells and/or constructs that are prepared preoperatively. Furthermore, the need
for culture medium containing (animal) serum is minimized, which may reduce the
risk on residual animal serum proteins. Therefore, this peroperative method seems
more appropriate.
The alternative of using fresh bone marrow showed to be successful as well,
although this yielded only about a third as much bone, and not all samples showed
bone (86%). Apparently, the very low number of osteoprogenitor cells in the bone
marrow proliferated extensively in the 2-3 weeks after implantation, to generate
sufficient cells for consistent bone formation.[6] Interestingly, a delay in bone
formation, as can be expected to allow for this enormous cell expansion, was not
found in the BM group, when compared to the BMSC’s seeded groups. In both
these conditions, the early 3-week fluorochrome label was found always very near
to the ceramic surface. This may be explained by recent observations with labeled
cells in mice concerning the cellular processes in 7-days cultured constructs.[121]
After implantation, the BMSC’s detached from the ceramic surface to loosely fill the
pores for about 10 days, then part of the transplanted (labeled) cells condensed on
the scaffold surface, where a morphological and functional differentiation towards
an osteoblast phenotype occurred. If cell development would be similar in the goats,
the situation after about two weeks implantation may have been quite comparable
for all cell-seeded conditions including the BM condition: the pores occupied with a
certain (reachable) amount of progenitor cells that condense on the scaffold surface
where differentiation towards the osteogenic lineage starts. This implicates the
importance of the scaffold surface in the success or failure of bone tissue
engineering as was also shown in this and previous studies.[131,278]
The advantage of culturing the constructs before implantation, which we observed
in the previous studies,[104,278] but not in this study, may be related to the scaffold
used. Contrary to those studies, in the current study the scaffold itself showed to be
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osteoinductive. It is conceivable that the osteoinductive capacity influenced the
BMSC’s. In that case, the more advanced osteogenic differentiation that existed in
the cultured constructs may have become irrelevant. This could also explain the
absence of the frequently observed stimulating effect of dexamethasone,[106,128]
although this also can be explained by a possible resistance of goat BMSC’s to
dexamethasone.[122,278] 
Figure 4 Bone formation after 9 weeks intramuscular implantation in goats
Black bars reflect the whole sample; white bars the peripheral 350µm. Error bars indicate the
standard deviation.
4a): The percentage of the available space occupied by bone (Bone area%). BMSC's seeded
samples (AS+, AS-, POcult, POCP) yielded significantly more bone than control samples with
or without bone marrow (p<0.01). The peripheral zone contained far less bone (p<0.01).
4b): The percentage of available scaffold outline occupied by bone (Contact%). Black bars
reflect the whole sample; white bars the peripheral 350µm. Error bars indicate the standard
deviation.
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The extracellular matrix, in combination with the osteoinductive scaffold was not
sufficient for increased ectopic bone formation in the devitalized constructs. This
supports the assumption that under normal circumstances, the cells survive
implantation and are in some way responsible for new bone formation.[131] This
assumption however, contrasts to the finding that there was far less bone formation
in the scaffold periphery. Cell survival in this area can be expected to be much
higher as a result of to revascularization and nutrient diffusion.[140] Actually, many
studies suggest that cell survival is only possible up to 300µm inside grafts.[137,172]
Therefore, another mechanism is likely to play an important role. As mentioned
before, the osteoinductive scaffold could have stimulated osteogenic differentiation
of the cells. Although the exact mechanism of this phenomenon remains a
speculation,[152,340] osteoinduction is generally known to occur in well-confined
cavities,[152] as was the case more central in our scaffolds. For example Ripamonti
found bone induction only in block-shaped porous ceramics with cavities and not in
granules. He referred to this morphological prerequisite as geometric induction.[152]
It is conceivable that in such cavities the accumulation of factors that are needed for
induction/differentiation of the cells is enabled.[341] Furthermore, such a
microenvironment may favor calcium phosphate dissolution and reprecipitation,
potentially together with important factors, a mechanism postulated before to be
responsible for bone induction.[98,131] This induction theory may even be supported
by the finding that osteogenesis inside arterosclerotic plaques only occurred as a
final stage, inside calcified (hydroxyapatite) plaques.[342] It also implies an
advantage of scaffolds with improved dissolution/reprecipitation potential, as is the
case with an increased microporosity, shown before to be advantageous.[131,278]
With regard to clinical application of the technique, the tendency for bone formation
to occur only in confined areas remains a concern, because this will impede
continuous bone formation that is for example obligatory for spinal fusion.[156]
Further research to gain a more fundamental understanding of these phenomena
will be needed.
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Chapter 10
THE FEASIBILITY OF BONE TISSUE ENGINEERING IN A CRITICAL 
SIZE DEFECT IN THE GOAT
Summary
Introduction: Since the application of the autologous bone graft, the need for an
alternative has been recognized. Tissue engineering (TE) of bone by combining
bone marrow stromal cells (BMSC’s) with a porous scaffold, is considered a
promising technique. In this study we investigated the potential of tissue engineered
bone to heal a critical sized defect in the goat. Orthotopic bone formation was
compared to ectopic bone formation.
Methods: TE constructs were prepared from goat BMSC’s and porous biphasic
calcium phosphate ceramic scaffolds. These constructs and scaffolds without cells
were implanted paired in critical sized iliac wing defects. Comparable samples were
implanted intramuscularly. After 9 (n=7) and 12 (n=8) weeks implantation, the
samples were analyzed histomorphometrically. 
Results: After 9 weeks implantation in the iliac wing defect, significantly more bone
apposition was found in the TE condition. After 12 weeks, the defects were almost
completely filled with bone, but no significant advantage of tissue engineering was
determined anymore. This contrasted with the intramuscular samples where TE
implants showed significantly more bone at both time points. 
Conclusion: Bone tissue engineering is feasible in critical sized defects. However,
when appropriate osteoconductive/inductive materials are applied the effect of cell
seeding may be temporary.
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Introduction
Since the application of the autologous bone graft in orthopedic surgery, the need
for an alternative has been recognized. Besides the well-known complications of the
harvesting procedure,[45,46] other important disadvantages of the autologous bone
graft include the extended surgical procedure and limited availability. Therefore,
many substitutes have been developed, all of which have specific disadvantages
and generally do not perform as well as the autologous graft. In order to be more
successful, it is conceivable that substitutes will need one or more of the features
that result in the superior functioning of the autologous bone graft. Although little is
known about the exact mechanisms involved in the use of autologous bone
grafts,[43] the osteoconductive and osteoinductive properties, in addition to a pool of
viable osteoprogenitor cells, are likely to be such features.[42,232] Therefore, tissue-
engineering (TE) of bone by combining osteoprogenitor cells (usually bone marrow
derived stromal cells, BMSC’s) with an appropriate synthetic scaffold, to create a
so-called hybrid construct, is an interesting technique. The proof of the concept has
been shown with genetically labeled cells in rodent studies both ectopically[66,116]
and orthotopically.[118,191,213] Despite these successes in rodents, in larger animals
only few studies have shown the feasibility of the technique orthotopically,[119,123]
and even less studies address the question whether clinically sized constructs are
osteogenic ectopically.[130,131,278] A comparison between ectopic and orthotopic
functioning in larger animals has never been reported. It is conceivable that
functioning of the technique in clinically sized grafts with a delayed vascularization
will be more challenging due to the difficulties that can be anticipated for cell
survival. Therefore, insight regarding the influence of the surrounding tissue will
improve the knowledge on how and when bone tissue engineering will function. In
the present study, we investigated tissue-engineered grafts in an established
critically sized defect model that allows paired comparisons.[36] In the same
animals, comparable constructs were evaluated ectopically in a model previously
shown to be successful for bone tissue engineering.[131] To investigate the growth
dynamics, sequential fluorochrome labels were administered. The samples were
analyzed after 9 and 12 weeks implantation with different parameters focusing on
the apposition and the amount of newly formed bone.
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Materials and Methods 
Scaffolds
Scaffolds were made of 50-60% macroporous, biphasic calcium phosphate (BCP,
OsSatura, IsoTis, The Netherlands). The ceramic consisted of 80±5%
hydroxyapatite (HA) and 20±5% tricalcium phosphate (TCP) as confirmed by X-ray
diffraction (XRD) and Fourier Transformed Infrared spectroscopy (FTIR), no
additional phases or impurities where detected. The material was sintered at
1200ºC resulting in 15±5% microporosity (pores<10µm). Previously, this ceramic
has been shown to be osteoinductive ectopically in goats.[97] Discs of Ø17x6mm
(orthotopic implantation) and 7x7x7mm cubes (ectopic implantation) were cut,
cleaned in ultrasonic baths and steam sterilized. 
BMSC’s culture and seeding conditions
Autologous serum (AS) was derived from 100ml venous blood that was taken at the
time of BM aspiration.[131] The BMSC’s were derived from 30ml iliac wing aspirates
that were counted before plating in tissue culture flasks. The adherent cells were
culture expanded according to previously described methods.[131] When sufficient
numbers were achieved, the cells were cryopreserved in medium containing 30%
fetal bovine serum (FBS, Gibco, Paisly, Scotland, lot# 3030960S) and 10%
dimethylsulfoxide (DMSO, Sigma, The Netherlands). Ten days before surgery, the
cells were thawed in pure FBS, centrifuged for 10 minutes at 100G and replated in
medium containing 30% FBS. After 3 days, cells were detached, centrifuged and
resuspended at a concentration of 1x107 cells/ml in medium containing 15% AS.
The discs were statically seeded by dropping 500µl of cell suspension on each side
of the discs (=8x106 cells per cm3 scaffold). The cubes were similarly seeded with
275µl of cell suspension per cube (=8x106 cells per cm3). The constructs were
incubated at 37ºC for two hours to allow cell attachment. Constructs and control
scaffolds without cells were cultured for seven days in AS medium with 10nM
dexamethasone and 10mM β-glycerophosphate (DEX and BGP, Sigma) that has
been shown to stimulate osteogenic differentiation of rat and human
BMSC’s.[106,159] Seeding efficiency and cell proliferation during culture were
determined on the 7x7x7 cubes (n=6) by a DNA quantification assay (CyQUANT®
kit Molecular Probes, Eugene, US) as described before.[131] A Methylene blue
staining was done on TE cubes and discs before and after the 7-day culture period
to evaluate cell attachment and the distribution of cells and matrix after seeding. 
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Animals and Implantation
Adult female Dutch milk goats (24-36 months) were obtained at least four weeks
prior to surgery. The surgical procedures were performed under standard
conditions.[131] After shaving and disinfection of the dorsal thoracolumbar area, a
central skin incision T8-L5 was made to expose the muscle fascia. Both iliac crests
were identified and cleared of muscle tissue. Under constant saline cooling, central
guide holes were drilled before Ø17mm trephine holes were made.[36] The implants
were press fit placed into the defects according to a randomized scheme. The
muscles were then sutured tight to the remaining fascia on the crests.
Intramuscular pockets were created by blunt dissection after separate fascia
incisions in the paraspinal muscles (L1-3). After inserting the implant, the fascia was
closed with a non-resorbable suture. The skin was closed in two layers.
Postoperatively, pain relief was given by buprenorphine (Shering-Plough,
The Netherlands). The goats received sequential fluorochrome labels at 3 weeks
(Calceine green, 10mg/kg intravenously, Sigma), 5 weeks (Oxyteracycline, 32 mg/
kg intramuscular, Engemycine, Mycofarm, The Netherlands) and 7 weeks (Xylenol
orange, 80mg/kg i.v. Sigma).[131,300] Animals were killed by an overdose of
pentobarbital (Organon, the Netherlands) after 9 weeks (n=7) and after 12 weeks
(n=8).
Post-mortem sample acquisition, histology and histomorphometry
Explanted samples were fixated in 4%glutaraldehyde/5%paraformaldehyde,
dehydrated by graded ethanol series, and embedded in polymethylmethacrylate.
Semi-thin sections (10µm) were made with a sawing microtome (Leica, Nussloch,
Germany). The mid-section through the samples was used for histomorphometry.
To obtain the mid-section, the explanted iliac wing was ground in the plane parallel
to the cortex, until the outer (circular) margin of the implant appeared. A central
section, 3mm below the ground surface, was then cut from the 6mm thick discs.
After cutting 3-4 central slides, additional sections were made perpendicular to the
plane of the central section, to evaluate bone formation on the axial faces of the disc
that had been exposed to the soft tissue. A similar method was used to obtain
central sections from the ectopically implanted samples. Slides were cut 3.5mm
below the outside of the 7x7x7mm cubes. Sections were either stained with
methylene blue and basic fuchsin for routine histology and histomorphometry or left
unstained for epifluorescence microscopy with a light microscope (E600 Nikon,
Japan) equipped with a quadruple filter block (XF57, dichroic mirror 400, 485, 558
and 640nm, Omega filters, The Netherlands). 
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For histomorphometry, high resolution (300dpi), low magnification (10x) digital
micrographs were made of blinded sections. Using Adobe Photoshop 5.5, bone and
scaffold were pseudocoloured red and green respectively. The area of interest was
defined by adjusting the radius of a circle to exactly fit the perimeter of the iliac
implant. The area of interest of the cubic ectopic samples was outlined with straight
lines bridging the pores that interrupted the exterior contour. Image analysis was
performed using a PC-based system equipped with the KS400 version 3.0 software
(Zeiss, Oberkochen, Germany). A special program was developed to measure the
following parameters of bone: 1) the percentage bone in the entire region of interest
(fill%); 2) the percentage bone in the available (pore) space (B/Parea% = bone area/
pore area x 100%); 3) the area of bone related to the area of scaffold (B/Sarea% =
bone area/scaffold area x 100%) and 4) the percentage of available scaffold
perimeter in contact to bone (contact% = scaffold perimeter length/bone-scaffold
contact length x 100%). Fill% was measured to allow comparison with previous
studies. This also accounts for the frequently used B/Parea% that is more
informative on the filling of the available space.[131] In addition, the B/Sarea% was
measured based on previous work indicating that tissue engineered bone formation
is strongly associated with the scaffold surface.[131] It therefore seems more
appropriate to relate the quantity of TE bone formation to available scaffold rather
than available pore space. Similarly, contact% is more sensitive for early bone
apposition which always occurs on the ceramic surface and has relatively little
volume. Developmental differences between the above parameters indicate the
growth dynamics of newly formed bone. 
Statistics
Data are shown as mean±standard deviation. Two-sided, student t-tests were
performed to analyze differences between tissue engineered and control implants at
each time point (paired) and between the time points (unpaired). The level of
significance was set at p=0.05.
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Results
In-vitro 
The BM aspirates contained 9.7±2.6x106 (mean±SD) nucleated cells/ml. Colonies
formed after 6-8 days culture and the BMSC’s were harvested when confluent, after
10-14 days. After the 2nd passage, 0.8-1.5x108 BMSC’s were cryopreserved.
Thawed cells showed minimal dead cells (<5% according trypan blue exclusion)
and proliferated well before seeding onto the scaffolds. The seeding efficiency of
8x106 cells/cm3 cube, determined by DNA quantification, was 49.1±14.7% and,
after 1-week of culture, cells doubled to 8.7±3.7x106 cells/cm3. Stereomicroscopy
after seeding showed homogeneous cell attachment throughout the entire scaffolds.
The 1-week cultured constructs showed the cells were spread on the ceramic
surface (Fig. 1a) with dense multilayers on the outside of the constructs. This was
confirmed by SEM imaging that showed the scaffolds were covered with cells and
extracellular matrix (Fig. 1b). 
Figure 1 In-vitro imaging of cultured constructs
1a): Stereomicroscopy of central part of a 7-days cultured disc as used for iliac defect
implantation. Methylene blue stained cells are spread and cover the concavity of the pores.
The small orifices are the interconnections between the pores (bar = 500µm).
1b): SEM image of 7-days cultured cube. Flattened cells with extra cellular matrix positioned
around an external pore interconnection orifice (bar = 100µm).
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In-vivo results of orthotopic implants 
There were no surgical complications and no macroscopic or microscopic signs of
infection. The iliac wing implants were overgrown by tissue and could not be
detected visually or manually (no motion). 
Plain histology of the iliac wing implants revealed two cases (one for each condition
in the 9-week group) of partial resorption of the inferior iliac wing border, resulting in
only 80-90% of these implants being surrounded by bone. Besides these two
implants, the scaffolds were totally integrated by the surrounding cancellous bone
without interposition of fibrous tissue. No signs of scaffold resorption were present
at both implantation periods. In the 9-week implants, bone formation appeared
advanced in the TE group, although neither of the conditions showed bone
formation in the center of the implanted discs. At the disc surfaces that were
exposed to soft tissue, a similar distribution of new bone in close association with
the surrounding bone was seen, while it was absent in the center. In the 12-week
implants, considerable bone had formed and some defects were almost completely
filled with bone in both conditions (Fig. 2 and 3a). 
Fluorescent microscopy indicated bone was growing away from the scaffold surface
and confirmed that no bone had formed in the middle of the defect in the first 9
weeks. No obvious differences in the presence or pattern of the labels was
observed between TE and control samples (Fig. 3b,c).
Histomorphometry of the explanted samples indicated a porosity of 53.7±10.9% for
the 9 week implants and 65.0±5.2% for the 12-week implants (mean±SD). After 9
weeks, the bone fill%, the B/Parea% (in available space) and the B/Sarea% (bone
area related to scaffold area) were not significantly different between the TE and
control samples (Table 1). However, at this follow-up, the contact% was significantly
higher in the TE group as compared to the controls (24.7±9.3 vs. 17.9±8.4, p<0.01)
(Fig. 4a). Because of the observed differences in porosity between the 9 and 12
weeks implanted samples, comparisons for the fill% and B/Parea% in time were
considered not applicable and only the parameters that related bone directly to the
scaffold were addressed. After 12-weeks, the B/Sarea% had increased significantly
for both the TE and control condition when compared to the 9-week group. The
contact% had increased less and did not show significantly more bone in the TE
condition. Comparing the TE condition to the controls after 12 weeks did not reveal
significant differences.
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Figure 2 Pseudocoloured images of the ∅17mm iliac wing implants
2a): Control scaffold implanted for 9 weeks. Surrounding bone (dark grey) covers the
periphery of the entire scaffold (light grey). 
2b): TE sample implanted for 9 weeks in the same goat as 2a. No bone formation was
observed in the middle of the 9-weeks implants.
2c): Control scaffold implanted for 12 weeks. The entire scaffold is covered with bone. 
2d): TE sample implanted for 12 weeks contralateral to sample 2c. The scaffold is completely
integrated in the surrounding cancellous bone.
Proefschrift_Moyo_Kruyt.book  Page 128  Wednesday, September 10, 2003  1:03 PM
The feasibility of bone tissue engineering in a critical size defect in goat
129
10
Figure 3 Histology  (☞ p. 186)
3a): Low magnification micrograph of the ∅17mm iliac implant as shown in figure 2d (12
weeks TE). Squares indicate the source for the fluorescence microscopy images (3b, c).
3b): High magnification fluorescence microscopy of a peripheral area of the implant in 3a.
Bone formation originated before 3 weeks on the outer side and inner side of the ceramic, as
indicated by the Calcein green (C, 3-week) label. Fusion between surrounding bone and the
scaffold was accomplished around 5 weeks as indicated by the yellow OTC label (bar =
50µm).
3c): High magnification fluorescence microscopy of a more central part. Only the Xylenol
orange (X, 7-weeks) was present close to the BCP scaffold (bar = 50µm).
3d): Low magnification micrograph of 7x7x7mm TE construct implanted ectopically for 9
weeks. Bone formation was in close association with the scaffold surface, but never occurred
on the exterior. 
3e): Fluorescence microscopy of bone formed in the middle of 9 weeks implanted TE
scaffold. All three fluorochrome labels were present. Growth dynamics can be deduced from
the line pattern showing growth started from the BCP surface towards the pore (P) center
(bar = 100µm).
3f): High magnification micrograph of TE construct implanted ectopically for 12 weeks.
Typical trabecular bone formation lined with osteoblast zones (bar = 50µm).   
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Table 1 Histomorphometry of orthotopic and ectopic implants
For both the orthotopic and ectopic locations, the area% bone in the whole sample (Total
fill%); the area% bone in available pore space (B/Parea%); the area% bone related to
scaffold area (B/Sarea%); and the percentage of the scaffold perimeter in contact to
bone(Contact%) are shown. The effect of tissue engineering (TE) vs. the control with no cells
(NC) and the effect of implantation time was analyzed. NA = Not Applicable (see text) and NS
= Not Significant 
Orthotopically an effect of TE existed only after 9 weeks for the contact% (*1) In time, the  
B/Sarea% increased in both TE and NC condition, the contact% increased only for the NC
condition(*2). Ectopically the effect of TE was obvious for all parameters. In time, the 
B/Sarea% increased (*3) whereas the contact% slightly decreased in the TE condition(*4).
In-vivo results of ectopic implants 
All samples were retrieved without macroscopic or microscopic signs of infection.
Plain histology showed small foci of bone, lined by osteoblasts, in 5/7 controls
(=71%) after 9 weeks, and in 6/8 (=75%) after 12 weeks. In all tissue engineered
samples, ample bone was present. In these samples, bone lined by osteoblasts was
closely related to the scaffold surface after 9 weeks and had a more trabecular
appearance after 12 weeks. Bone was never found on the exterior of the scaffolds
and seemed more abundant centrally in the scaffolds (Fig. 3d-f).
Fluorescence microscopy indicated that bone formation was always directed away
from the scaffold surface and had started before 3 weeks implantation in the TE
group (Fig. 3e) and only after 5 weeks implantation in the controls, which
occasionally showed the 7-week label. 
Histomorphometry of all slides indicated a scaffold porosity of 48.9±4.1 for the 9-
week samples and 61.8±4.4 for the 12-week samples. After 9 weeks, all parameters
indicated an about 50 times higher yield of bone inside the TE scaffolds (p<0.01)
(Table 1 and Fig. 4b). To analyze an effect of time, again the fill% and B/Parea%
where not considered. After 12 weeks, the B/Sarea% had significantly increased for
Location Parameter 9 weeks 12 weeks Level of significance
NC TE NC TE NCvs.TE 9vs.12W
Orthotopic
(mean±SD)
Total fill% 10.1±4.3 11.6±3.9 16.7±5.4 19.5±5.5 NS NA
B/Parea% 18.9±9.3 22.1±8.3 25.1±7.1 29.0±10.0 NS NA
B/Sarea% 23.3±12.1 26.5±11.8 51.1.±20.5 54.4±16.2 NS <0.01
Contact% 17.9±8.4*1,2 24.7±9.4*1 30.3±8.8*2 34.5±16.9 <0.01*1 0.016*2
Ectopic
(mean±SD)
Total fill% 0.1±0.1 5.6±0.9 0.3±0.5 6.1±1.6 <0.01 NA
B/Parea% 0.2±0.2 11.7±2.5 0.6±0.8 10.2±2.9 <0.01 NA
B/Sarea% 0.2±0.2 10.7±1.8*3 0.9±1.4 15.3±4.6*3 <0.01 0.025*3
Contact% 0.4±0.5 25.8±2.4*4 2.1±3.0 21.4±3.6*4 <0.01 0.019*4
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the TE condition, while the contact% had slightly decreased from 25.8 to 21.4%,
which was significant (p=0.019). The substantial difference between TE and control
groups remained for all parameters.
Figure 4 Orthotopic and ectopic bone formation after 9 weeks (n=7) and 12 weeks (n=8) 
4a): Orthotopic implants in the iliac wing defect. The percentage of the total defect filled with
bone (Fill%); the area of bone related to the scaffold area (B/Sarea%) and the percent bone
apposition on available scaffold outline (Contact%) were measured. White bars reflect the
controls; black bars the tissue engineered constructs. Error bars indicate the standard
deviation. At 9 weeks, the contact% was significantly higher in the TE samples (*1p<0.01).
4b): In the ectopic samples the same parameters were measured. Always significantly more
bone was found in the tissue engineered samples.
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4a)  Bone formation in 9 and 12 week orthotopic implants
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Discussion
In the current study in goats, we investigated bone formation in tissue engineered
constructs both ectopically and orthotopically. Ectopically, the scaffolds without cells
were shown to be osteoinductive in the majority of the goats for both implantation
periods, as was expected based upon previous observations.[97] It is conceivable
that this inductive capacity stimulated (part of) the seeded BMSC’s because the
BMSC population contains both determined and inducible osteoprogenitor cells
(DOPC’s and IOPC’s).[78,170] Because of this inductive stimulus, the one-week
predifferentiation of the cells as was done in this study may be irrelevant.
Furthermore it appeared that at the moment of implantation only slightly more cells
were present than the number of cells that was originally seeded (8.7 compared to
8x106/cm3) which also supports the frequently used alternative of combining the
cells and scaffold just prior to surgery.[119,122,191] Ectopically the effect of tissue
engineering was obvious, however, orthotopically the effect was less pronounced.
Only at the early explantation period of 9 weeks, the tissue engineered samples
demonstrated significantly more bone apposition on the available scaffold surface.
This effect could not be detected after 12 weeks implantation, at which time the TE
group showed only about 10% higher values for all parameters. It should be
mentioned, that due to the unexpectedly large standard deviation, despite paired
comparisons, the effect needed to be in the order of 40-50% to be detectable with a
power of 80%. 
Compared to other reports on orthotopic implantation for up to 5 months in large
animal models,[119,123-125] the impact of TE in our study was modest. The most
rational explanation for this lies in the use of different hybrid constructs. Both the
osteogenicity of the TE constructs and the scaffold material itself must be
considered. A lack of osteogenicity of the constructs at the orthotopic location is
unlikely because the osteogenicity was shown clearly in the ectopic model. In
previous studies with this model, it was demonstrated that viable cells were crucial
to accomplish bone formation, indicating the osteogenic role of the cells.[131]
Unfortunately, the osteogenicity of the constructs (ectopically) used by other
researchers was not reported in their animal model. Another explanation concerns
the scaffold material itself, which was shown to be osteoinductive. It is possible that
bone conduction in combination with this inductive capacity, resulted in so much
bone apposition, that the TE-related osteogenesis was overruled. This hypothesis is
supported by the finding that bone formation was only found at the early (9 weeks)
evaluation, and after 12 weeks bone was present also throughout the control
implant with bone filling 16.7% of the entire defect area. For comparison, in previous
studies with this model after the same time period, empty controls contained 13.5%
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bone, a porous osteoconductive copolymer only 1.5%, allograft 13% and autograft
36%.[36] In that study also the grafted chips of the allo and autograft were counted
as bone, whereas in the current study only new bone was counted.
A more discouraging explanation for the modest effect of TE may be proposed by
the absence of early osteogenesis in the center of the iliac defects. This is not that
surprising, considering the literature on cell survival in large unvascularized bone
grafts, as cell survival is expected to be limited and not to exceed a distance of
300µm from a nutrient supply.[22,169,172] However, if this were true, ectopic bone
formation should also be limited, since the diffusion depth in these samples was
also much larger, up to 3.5mm. This appeared not to be the case, and on the
contrary, bone seemed to be more abundant in the middle of the constructs.
Although (micro)movement on the scaffold outside may account for absence of
bone at the very exterior, the observation of extensive bone centrally does indicate
that cells probably survived at relatively large diffusion depths, although this needs
to be confirmed with techniques that can reliably identify the transplanted
cells.[116,213] Cell survival in the orthotopic location, however, will be different from
the ectopic location. The greater trauma with a subsequently larger heamatoma,
results in more wound excudate and delayed revascularization. Another difference
is the fracture healing response, which may interfere with the implanted cells.
Typically, fracture healing does not rely on cells present inside the defect, but
recruits the cells from the surrounding mesenchymal tissue.[147,148] It is possible
that cells inside the defect were subject to phagocytosis during the immediate injury
response.
The measured porosity of the 9 and 12 week implants were different (approximately
50 and 60%, respectively), resulting in different available spaces for bone formation.
Although material degradation cannot be ruled out completely, this difference in
porosity is likely the result of fluctuations in the normal production process. This
complicated the investigation of growth dynamics by comparisons between the 9
and 12 week implants. Therefore, the fill% and the bone per available pore space
(B/Parea%), which are directly related to the available pore space, were not
statistically compared between this time points. By relating bone to the available
scaffold material (B/Sarea%) and to the available scaffold perimeter (contact%),
relevant comparisons could be made because bone apposition was always on the
scaffold surface. Together with the fluorochrome markers, these parameters
indicated bone formation was associated with the ceramic surface and grew
cenripetally after initiation. In the ectopic samples, the percent scaffold outline
occupied by bone decreased between 9 and 12 weeks, suggesting no new bone
formed on the scaffold surface after 9 weeks. However, based on the increasing 
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B/Sarea% and the presence of osteoblast zones, bone formation itself continued
(Fig.  3f).
In conclusion, we have shown the relative contribution of tissue engineering to bone
formation ectopically and orthotopically. Although the constructs where osteogenic
ectopically, orthotopic functioning was modest in comparison to the osteoconductive
and osteoinductive capacity of the scaffold. In situations that may be considered to
have and ectopic constituent or where the inherent conductive and inductive nature
of the scaffold is likely to be limited, e.g. posterior spinal fusions, bone tissue
engineering may be helpful.
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Chapter 11
GENERAL DISCUSSION
In this chapter, a brief overview of the findings that have been discussed in detail in
the chapters 3-10 will be given.
In Chapter 3, the review article on spinal fusion models for bone tissue engineering,
we discussed the most likely mechanism and the potential of bone tissue
engineering. Although we could not elucidate the exact mechanism, we assumed
that bone formation would be intramembranous. Furthermore we emphasized on
the fact that little is known about the feasibility of the technique, which demands for
a humble research attitude to primarily gain insight in the technique. The
achievements of our research will be attended in the order of the specific aims of
this thesis:
1) To investigate the role of cell viability in autologous bone grafts;
2) To investigate the role of cell viability in TE constructs;
3) To develop a labeling technique to trace cells used for TE;
4) To investigate methods to optimize bone tissue engineering;
5) To investigate the applicability of TE in clinically relevant models.
Ad. 1: To investigate the role of cell viability in autologous bone grafts
In Chapter 4 we investigated the role of cell viability in autologous bone grafts. We
observed that osteogenesis was far more advanced in viable transplanted grafts,
especially in the ectopically implanted grafts. Furthermore, when viable bone chips
were implanted, these were bridged with new bone forming a solid mass.
Orthotopically, a less pronounced advantage of cell viability was determined after
one month implantation in the condyle defect. This was not a critical size model and
Proefschrift_Moyo_Kruyt.book  Page 135  Wednesday, September 10, 2003  1:03 PM
Chapter 11
136
host bone formation probably shaded the osteogenic activity of the grafted cells.
Although it is tempting to conclude that cells do survive and make bone after
transplantation, this study only permits the conclusion that viability at the moment of
transplantation has an obvious effect on subsequent bone formation. What exactly
happens to the cells after transplantation could not be determined with the current
design. Therefore, several alternative explanations for the role of viability in
autologous grafts should be kept in mind and further investigated. These include the
following three:
1) Grafted cells do not participate in bone formation, but the extracellular matrix
itself is osteoinductive (does not depend on viable cells) and is responsible for bone
formation. We devitalized the control samples by freezing in liquid nitrogen. This
procedure may have destroyed the extracellular osteoinductivity of the graft. 
• This seems indeed a comprehensible explanation. However, literature indicated 
that freezing minimally effects bone induction,[48,292] as discussed in Chapter 4.
2) Grafted cells do not participate in bone formation, but prior to death, or in a
senescent state, release a bone inducing substance that activates invading
mesenchymal cells, a mechanism proposed by many authors.[42,57,170,172] 
• Unfortunately, there is no literature available that directly investigates this possi-
bility. 
3) Donor cells do not participate in bone formation, but release prior to death or in a
senescent state, factors which are responsible for increased vascularization. Since
vascularization is closely related to bone formation,[343] as source of oxygen and
nutrients, an orienting factor for bone apposition[344,345] and a potential source of
stem cells which may be pericytes,[7] subsequent bone formation will be increased.
• Although the direct coupling remains to be proven, it was shown recently that 
increased neo-angiogenesis was present in constructs with viable BMSC’s 
implanted in rats.[140] Furthermore, it was determined that BMSC’s release stim-
ulating levels of vascular endothelial growth factor (VEGF).[346,347]
Based on the studies we performed, as well as upon the available literature, these
alternative explanations cannot be rejected. However, if viability of the autologous
grafts would not have had any influence on bone formation and new bone would not
be formed in either situation, it would have been unlikely that the cells play any role.
Therefore, we conclude that with respect to the first aim of this thesis cells do play a
role in autologous bone grafts. This provides a rationale for cell-based bone tissue
engineering. 
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Ad. 2: To investigate the role of cell viability in TE constructs
In Chapter 5 the rationale for cell-based bone tissue engineering was confirmed in
the goat model of ectopic bone formation. The presence of extracellular matrix
alone appeared to be insufficient for bone formation, provided that freezing did not
affect bone induction negatively. To investigate the alternative hypothesis that cells
do not participate in bone formation, but only release substances which promote
bone formation, we conducted a simple test: Prior to ectopic implantation, TE
constructs (n=4) were irradiated sub-lethally with 10 and 40 Gray.[75,226,230] The
subsequent chromosomal damage prevented further proliferation (verified by in-
vitro analysis). Despite the damage, the cells remained viable and metabolically
active (possibly capable to release a substance that stimulates bone formation), as
confirmed with an alamarBlue™ assay.[348] If the alternative hypothesis of
substance release would have been true, bone formation should be present in these
samples. However, we did not find any bone in those samples after 9 weeks
implantation, whereas all non-irradiated constructs consistently showed bone as
was described in Chapter 9. We realize that irradiation may have influenced the
release of substances negatively and therefore cannot totally reject the alternative
hypothesis. However, with respect to the second aim of this thesis, this finding
increased the burden of indirect proof that cells do survive and are responsible for
tissue engineered bone formation ectopically in the goat.
Ad. 3: To develop a labeling technique to trace cells used for TE
The only direct proof of cell osteogenicity and an ideal tool for further research of
cell development would be the ability to identify these cells in the histological
samples. In Chapter 6 we investigated the “off the shelf” intramembranous CM-Dil
label and unfortunately had to conclude this label was only applicable for evaluation
of cells after short implantation periods (up to 10 days). Despite that many research
groups did use the label for long-term evaluation,[120,186,316] in our experiment,
transfer of the label was obvious. The consequence of that finding was that the label
was inappropriate to determine the fate of the cells after longer implantation
periods. As a next step, other fluorescent labels were investigated. When using
intracellular labels instead of the intramembranous CM-Dil, again transfer was
found and therefore these labels were also considered inappropriate to reliably
show the cell fate after transplantation. 
In collaboration with the department of Haematology of the UMC Utrecht, we
developed a retroviral labeling method as described in Chapter 7. The membrane
surface marker NGFR that we investigated, appeared to be stable and no influence
on the bone forming capacity of the labeled cells was observed. We could proof the
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direct coupling between the goat BMSC’s and bone formation in our tissue
engineered constructs (=osteogenicity) in the nude mice model. Furthermore,
analyses of the sequential implantation times provided more insight in the process
of bone formation. The cell layer on the constructs that were cultured for one week
appeared not to continue after implantation with appositional bone formation.
Instead, cells seemed to become detached and loosely filled the pores. Ten days
after implantation, part of the cells condensed on the ceramic surfaces, were bone
formation started. This observation is indicative of a local stimulus that probably is
needed either to direct the relatively undifferentiated/dedifferentiated cells towards
the osteogenic lineage or to provide a substrate for (bonding) osteogenesis. It is
conceivable that this stimulus greatly depends upon the scaffold that is used as was
discussed in more detail in chapters 8, 9 and 10. Additionally to the development of
the retroviral cell surface marker (NGFR), we also transduced goat BMSC’s with the
luciferase gene. This gene encodes for the fire fly enzyme responsible for light
emission. Cells that were labeled with this gene could be monitored in constructs for
up to 6 weeks in mice, indicating their survival and maintenance. This pilot study
has however, not yet been published. With respect to the third aim of this thesis, the
most important merit of these studies is that we now have a tool to investigate cell
behavior in clinically relevant goat models. 
Ad. 4: To investigate methods to optimize bone tissue engineering
To optimize bone tissue engineering, the following issues are relevant: 
The yield of bone;
Because this allows quantitative data it is most often applied. However, the optimal
amount of bone is unknown, therefore the relevance of this parameter decreases
with higher quantities, as it does not address other important aspects like
distribution and remodelling.
The ease of the procedure;
An important optimization would be to overcome current disadvantages of the TE
technique such as the delay necessary for cell culture and the complicated logistics
to ensure the patient and the construct are prepared at the same time.
The functionality of the newly formed bone.
The ability of tissue engineered bone to generate a structural (fusion)mass and to
participate in the physiologic (host) bone turnover would be an important issue to
optimize.
11_chapter_11.fm  Page 138  Friday, September 12, 2003  10:10 AM
General discussion
139
11
In Chapter 8 we found an advantage (in terms of in-vivo bone yield) for constructs
that were cultured for one week after seeding of the cells. When the constructs were
not cultured, which makes the procedure considerably less complicated, bone
formation appeared to be feasible as well. Another important finding of that study
was the feasibility of using autologous serum instead of FBS for cell culture.
Because several granules were implanted together, we could investigate the
tendency for bone bridging between these granules. This was observed to occur
between ectopically transplanted autologous bone chips of comparable size, that
fused to solid masses (Chapter 4). However, bone bridging was almost never
observed between the tissue engineered granules, which is a concern for future
clinical application that relies on the ability to form continuous masses.
In Chapter 9 we further optimized the technique both with respect to the yield of
bone and the ease of the procedure. We used another type of ceramic scaffold
(biphasic calcium phosphate BCP). This ceramic was chosen because in a
separate study on ectopic bone formation, it yielded about twice as much bone as
the HA70/800 that we used before (n=8, p<0.01, not published). The ectopic bone
yield of 14% of the available space after 9 weeks in the 7x7x7mm cubes (=0.35cm3)
is relatively high when compared to the limited literature that is available[130,131] and
may be sufficient for functional application (as mentioned before, the optimal
amount of bone is speculative). More importantly, compared to the study in Chapter
8, the bone yield was more predictable as reflected by the relatively low coefficient
of variance and the Gaussian distribution of the data, which allowed for parametric
statistical analysis. By using these scaffolds, culture of the constructs appeared not
to be advantageous anymore in terms of bone yield. It was not investigated whether
the enhancement of bone formation in time, as shown previously,[104] was (still)
present. The method of peroperatively combining cryopreserved cells with the
ceramic scaffold considerably reduced the logistics to the level of a standard
elective procedure, and the labor of culturing cells and constructs was reduced. The
functionality of the newly formed bone however remains a concern. The total
absence of bone on the exterior of the implants and the dramatic decrease (>5
times less) of bone in the scaffold periphery indicated that bone formation is limited
to a confined environment and may not participate in continuous mass formation.
Besides this worrisome consequence of the typical distribution of newly formed
bone, the similarity with the distribution of ectopically induced
bone[11,101,157,333,349,350] also gave new insight in the potential mechanism of bone
formation. Likely were the processes responsible for the scaffold to be
osteoinductive, also essential for tissue engineered bone formation, either by
inducing the cells to become osteoblast or by providing a suitable substrate for
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osteogenesis. It is conceivable that this process starts with the formation of a
biological carbonated apatite layer on the ceramic surface, with potentially the
incorporation of inducing- or specific binding proteins, like
integrins.[97,99,100,293,294,350-355] The hypothesis that an in-vivo ceramic surface
modification preceded the actual osteogenesis was also strongly supported by the
observations from the labeling studies (Chapter 6 and 7), which indicated that after
implantation of cultured constructs (with cell multilayers on the scaffold surface), the
cells detached and about a week later condensed again on the scaffold surface,
where they started bone formation. Finally, the hypothesis is supported even more
by the finding that the cells and the scaffold did not had to be linked at the moment
of implantation in order to give bone, actually culturing the cells for a week in-vitro
on the ceramic did not show more bone formation at all. With respect to the fourth
aim of this thesis, we can conclude that the procedure can be optimized
substantially, however, functionality of the bone remains a concern. 
Ad. 5: To investigate the applicability of TE in clinically relevant
models
This was first addressed in a critical size segmental femur defect that was
developed for bone induction studies.[301] This pilot study, not further addressed in
this thesis, with six different TE constructs of the HA70/800 scaffold (n=2 per
condition) demonstrated a lack of relevant bone formation or fusion in these
constructs, although all constructs showed to be osteogenic ectopically. We
hypothesized this model was too challenging, due to the impossibility of rigid
stabilization. Therefore, this model was discarded and replaced by the critical size
defect model in the goat iliac wing, which is more stable and allows for paired
comparisons. With this model, a moderate effect of tissue engineering could be
observed as described in Chapter 10. This effect was only found at the early
evaluation time of 9 weeks, for the parameter that is most sensitive for tissue
engineered bone formation, namely, the percent of available scaffold surface where
bone apposition was found. After 12 weeks implantation, no effect was observed
any more. As mentioned in the discussion of this chapter, the effect of tissue
engineering had to be over 40% to be determined with a power of 80%. Although
we did not observe such an effect, it is unlikely this was related to a lack in
osteogenicity. Namely, the ectopic implants showed perpetual bone formation as
reflected by the increased bone yield between 9 and 12 weeks and the presence of
osteoblast zones at 12 weeks. It is plausible that the scaffold itself was responsible
for the absence of an obvious effect of tissue engineering. Not because the scaffold
is unsuitable, but on the contrary, is that potent that the majority of bone is by
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conduction/induction. This potency was reflected by the high bone yield in the
control ceramics that where almost totally covered by bone after 12 weeks
implantation.
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Chapter 12
GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES
To draw conclusions on the applicability of cell-based strategies for bone tissue
engineering, the most important tool is the available literature. For the work of this
thesis, this was always the point of reference. Regarding the literature, efforts to
back-up the feasibility of the concept of tissue engineering, or at least to provide
indirect proof that cells play any role in clinically sized autologous bone grafts failed.
The concept appeared unrealistic, because fundamental knowledge predicts cell
death in constructs exceeding several mm3 (chapter 2). Furthermore, there were no
studies that showed cell survival and function in large animals. Based on the
literature itself, but also on the failure of other well established research groups to
report on relevant progress in terms of clinical successes, one should be skeptical.
For comparison, numerous successful studies in large animals were reported for
BMP-based tissue engineering and by now clinical successes of this technique are
piling up. This skeptical viewpoint was the basis for the studies that were performed
in this thesis. Despite the expectation of the principal author that making progress
would be very challenging, many results of the studies were promising and can be
summarized in the following list of conclusions supporting the feasibility of the
technique.
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Conclusions supporting the feasibility of tissue engineering
• Viability is an important factor for bone formation in autologous bone grafts of 
clinical relevant size;
• Viable cells are crucial for bone formation in tissue engineered constructs;
• Cells are directly involved in bone formation in small sized implants;
• Cell-based tissue engineering enhances bone formation orthotopically;
• The procedure of bone tissue engineering can be simplified considerably.
These conclusions are encouraging and provide a strong rationale to further
develop the technique. However, this does not support clinical application of the
technique at this moment. On the contrary, the list of worrisome conclusions
indicates that both the applicability and the functioning of the technique needs
further investigation.
Worrisome conclusions
• There is no necessity for viable cells in orthotopic grafting;
• Bridging between individual tissue engineered granules is exceptional;
• Transplanted cells are capable of fibrous tissue formation;
• Bone formation is restricted to confined areas;
• Orthotopically, the effect of tissue engineering is moderate and may be irrelevant 
at long-term implantation intervals.
Irrespective of the type of conclusion, the studies improved our knowledge on bone
tissue engineering. Scientifically, the technique is intriguing and provides the
opportunity to drastically improve our knowledge on many aspects of bone
formation. Not only the role of putative stem cells and their differentiation is
accessible for research, but also the role of the (micro) environment necessary for
bone formation. This environmental aspect has merely been investigated in this
thesis, but most likely plays a crucial role in providing a substrate for the adhesion of
specific cells and their subsequent differentiation. The ultimate example of the
power of this aspect is the ability of some scaffolds to induce bone formation without
the addition of pre-selected cells or factors. We hypothesize that the processes
involved in this phenomenon, more specifically, the dissolution of the ceramic
surface and reprecipitation of a biological carbonated apatite layer are essential for
the tissue engineered bone formation that we observed. With the current
possibilities in biotechnology, these and many other aspects can be thoroughly
investigated further.
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If this thesis would be a departure for such studies, as a first step the role of the
cells can be investigated in more detail. The retroviral labeling technique that we
developed allows for histological identification, both in the ectopic and the orthotopic
model. Luciferase labeling enables real time in-vivo evaluation of the cells, which is
particularly interesting to determine a difference between orthotopic and ectopic
implantation. Furthermore, strategies that improve the vascularization of the
construct in-vivo can be accurately investigated by this method. Another opportunity
lies in the finding that cryopreserved cells and scaffolds can be mixed
peroperatively, which opens possibilities for less complicated elective procedures
and the preparation of compositions that can be used as cement (e.g. CaP bone
cement). Of course, scaffold induced bone formation should be investigated further
as it is most likely that this phenomenon is enhanced by cell admission. The answer
to improvement of functionality of the tissue engineered bone may be derived from
such investigations or, as often is the case in medicine, found by serendipity. The
final and most important conclusion that can be drawn at the end of this thesis is:
Cell-based bone tissue engineering has the potential to 
become an ideal autologous bone graft substitute
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Samenvatting in het Nederlands 
Introductie
Binnen de orthopaedie wordt op grote schaal gebruik gemaakt van lichaamseigen
bot. Dit wordt gebruikt om het genezingsproces van vaak gecompliceerde
reparaties aan het bot te stimuleren. Een goed voorbeeld is de zogenaamde
posterolaterale wervelfusie: hierbij wordt het lichaamseigen bot naast de
wervellichamen gelegd. Nieuw bot dat vanuit de wervellichamen groeit kan het
getransplanteerde bot als model/voorbeeld gebruiken en het in de loop van de tijd
volledig vervangen. Zo kunnen de twee wervellichamen met nieuw bot aan elkaar
vast groeien.
Door evolutionaire selectie heeft het menselijk lichaam zich gedurende minstens
een miljoen jaar uiterst efficiënt ontwikkeld. Daarbij is geen rekening gehouden met
de orthopaedische mogelijkheden van de laatste honderd jaar. Helaas is er dus
geen (grote) voorraad reservebot aangemaakt. Het wegnemen van lichaamseigen
bot (meestal uit de bekkenkam) is dus in principe een verminking die niet straffeloos
kan plaats vinden. De nadelige gevolgen zijn veelomvattend en betreffen met name
pijnklachten. Het is daarom een grote uitdaging een alternatief te ontwikkelen voor
het lichaamseigen bot met wel alle voordelen, maar niet de nadelen. Daarvoor is
het belangrijk de voordelen van het lichaamseigen bot te kennen en mee te nemen
in de ontwikkeling van een alternatief: in de eerste plaats wordt het lichaamseigen
bot per definitie niet als lichaamsvreemd ervaren en kan het probleemloos worden
geïmplanteerd zonder afstotingsverschijnselen. Bij bot van andere (menselijke)
donoren, dat veelvuldig als een alternatief wordt gebruikt, is acceptatie van het
weefsel wel een probleem, naast het risico dat ziektekiemen kunnen worden
overgebracht. In de tweede plaats is een belangrijk voordeel van met name het
trabeculaire bot (uit de bekkenkam) dat dit een uitstekend voorbeeldmateriaal is
voor het nieuwe reparatiebot. Ten derde, een omstreden maar zeer opvallend
verschil tussen het lichaamseigen bot en de huidige alternatieven is dat het
lichaamseigen bot vol met levende cellen zit op het moment van transplantatie. In
hoeverre dit ook echt een voordeel is, is echter tot op heden onbekend. De
belangrijkste reden om hieraan te twijfelen is dat de cellen gedurende de eerste
periode na transplantatie afgesloten zijn van bloedvoorziening en daardoor moeilijk
kunnen overleven. Vele fundamentele onderzoekers stellen daarom dat alleen in
het allerbuitenste deel (zo’n 300µm), of in zeer kleine transplantaten (enige kubieke
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millimeters) cellen kunnen overleven, terwijl de gangbare grootte van een klinisch
toegepast transplantaat al gauw enige kubieke centimeters is (1000x zo groot).
Desalniettemin wordt door vele (meer klinisch georiënteerde) onderzoekers
verondersteld dat een aanzienlijk aantal van de cellen overleeft en bijdraagt aan
nieuwe botvorming. 
Op basis van de (omstreden) voordelen die het lichaamseigen bot heeft ten
opzichte van de huidige alternatieven wordt daarom verondersteld dat een optimaal
alternatief moet beschikken over de volgende drie eigenschappen:
1 Volledige acceptatie door de ontvanger; 
2 Optimale voorbeeldsfunctie voor nieuw bot;
3 Voorzien van levende cellen die nieuw bot kunnen vormen.
Wanneer verschillende wetenschappelijke disciplines gaan samenwerken om
vervangingsweefsel zoals een alternatief voor het lichaamseigen bot te
ontwikkelen, noemen we dit tissue engineering. Een veelbelovende vorm van tissue
engineering is ontstaan uit de combinatie van vindingen in de jaren zeventig van de
vorige eeuw, door twee zeer verschillende disciplines.
Vanuit de technische chemie werd ontdekt dat het mogelijk is calciumfosfaten zo te
mengen en te bakken dat een poreus keramiek ontstaat. Dit materiaal bleek
volledig door het lichaam te worden geaccepteerd en, beter nog, een uitstekende
geleider voor nieuwe botvorming. Eigenlijk is dat ook niet zo verwonderlijk omdat
het mineraal waaruit bot voor het grootste deel bestaat, chemisch gezien, van
dezelfde compositie is. Vanuit de haematologie (geneeskunde) was ontdekt dat om
bloed-stamcellen, die werden gebruikt voor beenmergtransplantaties, buiten het
lichaam te laten groeien, deze cellen op een matras van ondersteunende cellen
gekweekt moesten worden. Deze cellen bleken in het beenmerg aanwezig en
werden stromale cellen (= Latijn voor matrascellen) genoemd. Lang bleven deze
cellen alleen verdienstelijk voor het kweken van de haematologische cellen, tot
werd ontdekt dat deze stromale cellen zich in allerlei richtingen konden ontwikkelen.
De celsoorten die zo ontstaan bevonden zich allemaal binnen een bepaalde
embryonale kiemlaag, de zogenaamde mesodermale laag, waaruit het steun en
bewegingsapparaat ontstaat, met onder andere bot en kraakbeencellen. Een
andere naam voor deze cellen is ook wel mesenchymale stamcellen. 
Het onderzoek kwam in een stroomversnelling toen bleek dat de combinatie van
poreus keramiek als een dragermateriaal met deze cellen osteogeen was, dit wil
zeggen uit zichzelf bot kon maken op plaatsen waar bot normaal niet voorkomt
(bijvoorbeeld in de spieren). Sindsdien is er veel onderzoek gedaan naar tissue
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engineered bot. Ook in een botomgeving (waar het uiteindelijk zal moeten
functioneren) bleek het in staat de genezing te versnellen. Hoewel in het begin snel
vooruitgang werd geboekt, met name in kleine proefdieren met relatief kleine
implantaten, is de doorbraak naar de kliniek nog niet gekomen. Dit komt met name
doordat grotere implantaten (met een veel slechtere overlevingskans) het een stuk
minder goed blijken te doen. Zoals zo vaak bij nieuwe ontwikkelingen blijkt ook
tissue engineering veel gecompliceerder dan gehoopt. 
Het doel van ons onderzoek was verschillende aspecten van bot tissue
engineering met betrekking tot de haalbaarheid in de klinisch situatie te
onderzoeken:
1 Onderzoeken wat de rol is van levende cellen in lichaamseigen bot;
2 Onderzoeken wat de rol is van levende cellen in tissue engineered bot;
3 Ontwikkelen van een techniek om cellen te markeren en vervolgen;
4 Optimaliseren van de tissue engineering techniek;
5 Onderzoeken van de haalbaarheid van tissue engineering voor klinische
toepassingen.
Daarvoor hebben we vooral gebruik gemaakt van een model waarbij we de werking
onderzochten van relatief grote implantaten in de spieren van de geit. Het voordeel
van dit model (in de spieromgeving) is dat veel verschillende condities tegelijkertijd
kunnen worden onderzocht en dat het gevonden bot met zekerheid afkomstig is van
het implantaat en niet deels van omringend bot, zoals in een botomgeving. 
Bevindingen
Ad. 1: De rol van levende cellen in lichaamseigen bot hebben we onderzocht door
bot zowel levend als dood te transplanteren in de spieren van geiten. Immers, als
levende cellen een rol spelen, zou een verschil meetbaar moeten zijn. Na 12 weken
implantatie was inderdaad een groot verschil zichtbaar. Een deel van de dode
transplantaten was na 12 weken totaal verdwenen terwijl de levende transplantaten
als stevige massa’s van (nieuw) bot werden teruggevonden. In tegenstelling tot het
dode bot had het levend getransplanteerde bot veel nieuw bot gevormd. 
Ad. 2: De rol van levende cellen in tissue engineered bot hebben we op een
vergelijkbare manier onderzocht. Ook hier bleek nieuwe botvorming in de spier
alleen mogelijk met levend getransplanteerde cellen.
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Ad. 3: Een andere methode om te onderzoeken wat de rol is van de cellen, is deze
voordat ze worden getransplanteerd te markeren en later in het histologisch beeld
te identificeren. Eerst hebben we een markering onderzocht met een
fluorescerende stof. Deze kon de cellen goed markeren maar bleek helaas door
niet-gemarkeerde gastheercellen cellen te kunnen worden overgenomen. Hierdoor
kon de afkomst van gemarkeerde cellen niet meer met zekerheid worden
vastgesteld. Een andere methode die we hebben ontwikkeld was met een
zogenaamde retrovirale marker. Dit is een methode die met behulp van een virus
een markering aanbrengt in het DNA van de cellen en daardoor zeer specifiek is en
blijft. Deze methode bleek succesvol en in een studie naar tissue engineered bot in
muizen konden we via een directe weg aantonen dat deze cellen inderdaad het
nieuwe bot maakten.
Ad. 4: Voor het optimaliseren van de techniek hebben we verschillende
dragermaterialen en procedures onderzocht. Wat betreft het dragermateriaal bleek
dat naast de gewone (macro)porositeit ook de microporositeit van groot belang is.
De door IsoTis ontwikkelde drager van biphasisch calciumphosphaat (BCP) met
een hoge microporositeit bleek uiteindelijk optimaal. Daarnaast bleek het goed
mogelijk om tijdens de operatie cellen die bewaard waren in vloeibare stikstof direct
te gebruiken. Dit maakt de procedure een stuk eenvoudiger in vergelijking met de
procedure die daarvoor werd gebruikt. Daarbij werd de combinatie van cellen en
drager eerst nog een week doorgekweekt en werden de cellen door bepaalde
stoffen toe te voegen gestimuleerd om botcel te worden. De operatie moest daarom
al een week van te voren vast staan. Wanneer de operatie op het laatst toch niet
door zou kunnen gaan (wat in een ziekenhuis niet ondenkbaar is) zou alle moeite
voor niets zijn geweest.
Ad. 5: Om te onderzoeken of de tissue engineering techniek ook werkte in een
klinisch relevant model, hebben we deze onderzocht in een groot botdefect in de
geit. Het grote verschil met de andere studies in de spieren was: 1) de grootte van
de transplantaten, waardoor overleven van cellen nog moeilijker was en 2) de
omgeving. De botomgeving is toch heel anders dan in de spier. Het zou zelfs zo
kunnen zijn dat het normale reparatieproces in bot, als reactie op een door ons
aangebracht defect, helemaal niet gediend is van de grote hoeveelheid cellen die
worden geïmplanteerd. Hoewel er op de korte termijn (9 weken) wel een positief
effect van de cellen meetbaar was, bleek dit op de langere termijn (12 weken) niet
meer aanwezig. Mogelijk komt dit doordat het reparatiemechanisme van het bot zo
sterk is dat het effect van de cellen wordt overschaduwd.
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Conclusie
De resultaten zijn tot nu toe zeer bemoedigend. Het levend zijn van zowel
lichaamseigen bot als van tissue engineered bot bleek een absolute voorwaarde
voor nieuwe botvorming in de spieren van de geit. Dit betekent dat het uitgangspunt
van de noodzaak van levende cellen voor tissue engineering kan worden
onderbouwd. Het onderzoek naar de gemarkeerde cellen heeft ook laten zien dat
die cellen inderdaad in het nieuw gevormde bot aanwezig zijn. De manier waarop
het nieuw gevormde bot zich gedraagt is echter nog onduidelijk, en met name of het
echt een bijdrage levert in klinisch relevante situaties is nog niet aangetoond. De
techniek staat dus nog in de kinderschoenen en van een volwaardig alternatief voor
het lichaamseigen bot is nog geen sprake. Toch kunnen we op basis van het
onderzoek concluderen dat tissue engineering de potentie heeft een ideaal
alternatief voor het lichaamseigen bot te worden.
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zonder de hulp en toewijding van velen. Om het mezelf gemakkelijk te maken, is de
volgorde waarin ik iedereen zou willen bedanken gebaseerd op de academische
pikorde en heb ik een tutoyerende stijl gekozen.
De promotoren: 
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Wouter, je toewijding en betrokkenheid, gecombineerd met de vrijheid die je me
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Joost, hoewel we op een aantal punten verschillende meningen hadden, was dit
juist een bron van inspiratie en wat mij betreft zeer welkom. Ik waardeer enorm hoe
je mij, met mijn soms recalcitrante houding op IsoTis, in mijn waarde hebt gelaten.
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Color Figures
COLOR MICROGRAPHS OF RELEVANT FIGURES FROM CHAPTERS 3 THROUGH 10.
FIGURE CAPTIONS MAY BE FOUND IN THEIR RESPECTIVE CHAPTERS.
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Chapter 3
Figure 2 Micrographs of constructs implanted 9 weeks intramuscularly in goats
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Chapter 4
Figure 1 Low magnification micrographs of etopic autologous implants in goats
Figure 2 Histology and fluoroscopy of ectopic autologous implants in goats
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Chapter 5
Figure 4 Histology of vital tissue engineered constructs implanted for 12 weeks
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Chapter 6
Figure 5 Micrographs of samples with CM-Dil labeled cells implanted in mice
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Chapter 7
Figure 4 Samples of in-vivo hybrid constructs with NGFR labeled cells
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Chapter 8
Figure 3 Bone formation after 12 weeks implantation in goats
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Chapter 9
Figure 1 Image analysis procedure of ectopic samples
Figure 3 Histology of 9 weeks intramuscularly implanted samples
ba
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Chapter 10
Figure 3 Histology of tissue engineered samples orthotopically and ectopically
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